prtk-10q_20190930.htm

0001564590-19-042902.txt : 20191112 0001564590-19-042902.hdr.sgml : 20191112 20191112160656 ACCESSION NUMBER: 0001564590-19-042902 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36066 FILM NUMBER: 191209339 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 10-Q 1 prtk-10q_20190930.htm 10-Q prtk-10q_20190930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended: September 30, 2019 or

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission file number: 001-36066

PARATEK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

33-0960223

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

75 Park Plaza

Boston, MA 02116

(617) 807-6600

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive office)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	PRTK	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of October 31, 2019, there were 33,287,946 shares of the registrant's common stock, par value $0.001 per share, outstanding.

TABLE OF CONTENTS

		Page
PART I FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	2

	Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018	2

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2019 and 2018	3

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2019 and 2018	4

	Condensed Consolidated Statement of Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2019 and 2018	5

	Notes to Unaudited Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39

Item 4.	Controls and Procedures	39

PART II OTHER INFORMATION

Item 1.	Legal Proceedings	39

Item 1A.	Risk Factors	39

Item 6.	Exhibits	40

	SIGNATURES	41

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except for share and par value amounts)

(unaudited)

	September 30,			December 31,
	2019			2018
Assets
Current assets
Cash and cash equivalents	$	104,907		$	46,987
Marketable securities		120,730			203,364
Restricted cash		788			266
Accounts receivable, net		3,976			41
Inventories, net		8,826			598
Other receivables		854			208
Prepaid and other current assets		5,095			3,779
Total current assets		245,176			255,243
Long-term restricted cash		2,947			249
Long-term marketable securities		—			42,487
Fixed assets, net		967			1,173
Goodwill		829			829
Right-of-use asset		2,701			—
Other long-term assets		154			211
Total assets	$	252,774		$	300,192
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities
Accounts payable	$	3,956		$	2,090
Other accrued expenses		20,042			15,619
Other current liabilities		1,020			—
Total current liabilities		25,018			17,709
Long-term debt		260,410			228,959
Long-term lease liabilities		2,344			—
Other liabilities		5,608			5,946
Total liabilities		293,380			252,614
Commitments and contingencies (Note 16)
Stockholders’ equity (deficit)
Preferred stock:
Undesignated preferred stock: $0.001 par value; 5,000,000 authorized; no shares issued and outstanding		—			—
Common stock, $0.001 par value, 100,000,000 shares authorized, 32,901,446 and 32,259,363 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively		33			32
Additional paid-in capital		643,106			630,142
Accumulated other comprehensive income (loss)		148			(128	)
Accumulated deficit		(683,893	)		(582,468	)
Total stockholders’ equity (deficit)		(40,606	)		47,578
Total liabilities and stockholders’ equity (deficit)	$	252,774		$	300,192

See accompanying notes to unaudited condensed consolidated financial statements.

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Product revenue, net	$	3,053		$	—		$	6,102		$	—
Collaboration and royalty revenue		881			50			1,475			101
Net revenue	$	3,934		$	50		$	7,577		$	101
Expenses:
Cost of product revenue		958			—			1,731			—
Research and development		8,350			16,040			30,421			45,706
Selling, general and administrative		23,636			13,610			67,874			38,395
Impairment of intangible asset		—			21			—			107
Changes in fair value of contingent consideration		—			(11	)		—			(57	)
Total operating expenses		32,944			29,660			100,026			84,151
Loss from operations		(29,010	)		(29,610	)		(92,449	)		(84,050	)
Other income and expenses:
Interest income		992			922			2,873			2,292
Interest expense		(4,560	)		(3,383	)		(11,777	)		(7,793	)
Other gains (losses), net		(36	)		(12	)		(72	)		(14	)
Net loss before provision for income taxes	$	(32,614	)	$	(32,083	)	$	(101,425	)	$	(89,565	)
Provision for income taxes		—			—			—			—
Net loss		(32,614	)		(32,083	)		(101,425	)		(89,565	)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net of tax		(68	)		(103	)		276			(170	)
Comprehensive loss	$	(32,682	)	$	(32,186	)	$	(101,149	)	$	(89,735	)
Basic and diluted net loss per share	$	(1.00	)	$	(1.01	)	$	(3.12	)	$	(2.86	)
Weighted average common stock outstanding
Basic and diluted		32,590,454			31,742,854			32,458,010			31,301,249

See accompanying notes to unaudited condensed consolidated financial statements.

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	For the Nine Months Ended September 30,
	2019			2018
Net loss	$	(101,425	)	$	(89,565	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accretion		(1,124	)		(530	)
Stock-based compensation expense		10,742			12,955
Noncash interest expense		5,097			4,608
Impairment of intangible asset		—			107
Change in fair value of contingent consideration		—			(57	)
Changes in operating assets and liabilities
Accounts receivable and other current assets		(6,052	)		4,966
Purchase of prepaid interest - marketable securities		153			(548	)
Inventories		(7,555	)		—
Operating lease right-of-use asset		534			—
Accounts payable and accrued expenses		1,843			5,164
Operating lease liability		(1,468	)		—
Other liabilities and other assets		740			706
Net cash used in operating activities		(98,515	)		(62,194	)
Investing activities
Purchase of fixed assets		(45	)		(54	)
Purchase of marketable securities		(77,077	)		(220,732	)
Proceeds from maturities of marketable securities		204,000			116,058
Net cash provided by (used in) investing activities		126,878			(104,728	)
Financing activities
Proceeds from the issuance of long-term convertible debt, net of costs		—			158,974
Proceeds from the issuance of long-term debt, net of costs		—			9,950
Proceeds from the issuance of long-term royalty-backed loan agreement, net of costs		30,554			—
Proceeds from the employee stock purchase plan		294			—
Proceeds from exercise of stock options		—			287
Proceeds from sale of common stock, net of costs		1,929			51,516
Net cash provided by financing activities		32,777			220,727
Net increase in cash, cash equivalents and restricted cash		61,140			53,805
Cash, cash equivalents and restricted cash at beginning of period		47,502			35,828
Cash, cash equivalents and restricted cash at end of period	$	108,642		$	89,633
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	$	9,579		$	3,751
Purchases of equipment included in accounts payable and accrued expenses	$	151			—

See accompanying notes to unaudited condensed consolidated financial statements.

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

(unaudited)

	Common Stock				Additional Paid-in		Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Deficit
Balances at December 31, 2018		32,259,363	$	32	$	630,142	$	(128	)	$	(582,468	)	$	47,578
Vesting of restricted stock unit awards		156,614		—		—		—			—			—
Employee stock purchase plan expense		—		—		24		—			—			24
Unrealized gain on available-for-sale securities, net of tax		—		—		—		200			—			200
Stock-based compensation expense		—		—		3,839		—			—			3,839
Net loss		—		—		—		—			(35,610	)		(35,610	)
Balances at March 31, 2019		32,415,977	$	32	$	634,005	$	72		$	(618,078	)	$	16,031
Vesting of restricted stock unit awards		5,000		—		—		—			—			—
Employee stock purchase plan expense		—		—		24		—			—			24
Issuance of stock under the employee stock purchase plan		95,212		—		294		—			—			294
Unrealized gain on available-for-sale securities, net of tax		—		—		—		144			—			144
Stock-based compensation expense		—		—		3,031		—			—			3,031
Net loss		—		—		—		—			(33,201	)		(33,201	)
Balances at June 30, 2019		32,516,189	$	32	$	637,354	$	216		$	(651,279	)	$	(13,677	)
Issuance of common stock, net of expenses		360,575		1		1,928		—			—			1,929
Vesting of restricted stock unit awards		24,682		—		—		—			—			—
Employee stock purchase plan expense		—		—		25		—			—			25
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(68	)		—			(68	)
Stock-based compensation expense		—		—		3,799		—			—			3,799
Net loss		—		—		—		—			(32,614	)		(32,614	)
Balances at September 30, 2019		32,901,446	$	33	$	643,106	$	148		$	(683,893	)	$	(40,606	)

	Common Stock				Additional Paid-in		Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Equity
Balances at December 31, 2017		27,941,015	$	28	$	552,720	$	(158	)	$	(470,112	)	$	82,478
Issuance of common stock, net of expenses		3,301,436		3		51,512		—			—			51,515
Vesting of restricted stock unit awards		171,999		—		—		—			—			—
Issuance of common stock under stock option plan		28,699		—		177		—			—			177
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(21	)		—			(21	)
Stock-based compensation expense		—		—		4,367		—			—			4,367
Net loss		—		—		—		—			(27,750	)		(27,750	)
Balances at March 31, 2018		31,443,149	$	31	$	608,776	$	(179	)	$	(497,862	)	$	110,766
Vesting of restricted stock unit awards		271,500		1		—		—			—			1
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(47	)		—			(47	)
Stock-based compensation expense				—		4,503		—			—			4,503
Net loss		—		—		—		—			(29,733	)		(29,733	)
Balances at June 30, 2018		31,714,649	$	32	$	613,279	$	(226	)	$	(527,595	)	$	85,490
Vesting of restricted stock unit awards		41,600		—		—		—			—			—
Issuance of warrants for common stock		—		—		130								130
Issuance of common stock under stock option plan		25,239		—		110		—			—			110
Unrealized loss on available-for-sale securities, net of tax		—		—		—		(103	)		—			(103	)
Stock-based compensation expense		—		—		4,085		—			—			4,085
Net loss		—		—		—		—			(32,083	)		(32,083	)
Balances at September 30, 2018		31,781,488	$	32	$	617,604	$	(329	)	$	(559,678	)	$	57,629

Paratek Pharmaceuticals, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(unaudited)

1. Description of the business

Paratek Pharmaceuticals, Inc., or the Company or Paratek, is a Delaware corporation with its corporate office in Boston, Massachusetts and an office in King of Prussia, Pennsylvania.

The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The Company’s United States Food and Drug Administration, or FDA, approved commercial product, NUZYRA^® (omadacycline) is a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, and acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible pathogens. The Company launched NUZYRA in the United States in February 2019. SEYSARA^® (sarecycline) is an FDA-approved product, with respect to which the Company has exclusively licensed development and commercialization rights in the United States to Almirall, LLC, or Almirall. SEYSARA was launched by Almirall in the United States in January 2019 as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Company retains development and commercialization rights with respect to sarecycline in the rest of the world.

The Company has incurred significant losses since inception in 1996. The Company has generated an accumulated deficit of $683.9 million through September 30, 2019 and will require substantial additional funding in connection with the Company’s continuing operations to support development and commercial activities associated with NUZYRA. Based upon the Company’s current operating plan, it anticipates that its cash, cash equivalents and available for sale marketable securities of $225.6 million as of September 30, 2019 will enable the Company to fund operating expenses and capital expenditure requirements through at least the next twelve months from the issuance of the financial statements included in this Quarterly Report on Form 10-Q. The Company expects to finance future cash needs primarily through a combination of product sales, royalties, public or private equity offerings, debt or other structured financings, strategic collaborations and grant funding. The Company is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain additional financing to fund the future development of the Company’s product candidates, the need to obtain compliant product from third party manufacturers, the need to obtain marketing approval for the Company’s product candidates, the need to successfully commercialize and gain market acceptance of product candidates, the risks of manufacturing product with an external supply chain, dependence on key personnel, and compliance with government regulations as well as the risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission, or the SEC, on March 6, 2019, and in the Company’s other filings with the SEC.

2. Summary of Significant Accounting Policies and Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America, or U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB, and pursuant to the rules and regulations of the SEC.

The accompanying condensed consolidated financial statements are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2018, except as described below related to Note 10, Other Accrued Expenses, and the adoption of ASU No. 2018-07 and ASC 842, and, in the opinion of management, reflect all normal recurring adjustments necessary for the fair presentation of the Company’s financial position as of September 30, 2019, results of operations for the three month and nine month periods ended September 30, 2019, cash flows for the nine month period ended September 30, 2019 and changes in stockholders’ equity (deficit) for the three month and nine month periods ended September 30, 2019. Beginning on April 1, 2019, the Company presented “accrued interest” as a separate line item in Note 10, Other Accrued Expenses. The Company reclassified accrued interest of $1.8 million as of December 31, 2018, previously presented as part of “accrued professional fees” into “accrued interest” in Note 10, Other Accrued Expenses. On December 31, 2018, the Company presented “accrued contract manufacturing costs” as a separate line item on its consolidated balance sheet. Beginning on January 1, 2019, the Company reclassified the December 31, 2018 accrued contract manufacturing costs balance of $2.8 million, into “other accrued expenses”. Also, beginning on January 1, 2019, the Company reclassified inventories of $0.6 million as of December 31, 2018 previously presented as part of “prepaid and other current assets” into “inventories” on the condensed consolidated balance sheet.

The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2018, and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 6, 2019.

Summary of Significant Accounting Policies

As of September 30, 2019, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 6, 2019, have not changed except as discussed below.

Accounts Receivable, Net

Accounts receivable as of September 30, 2019 represents trade accounts receivable of $3.2 million consisting of payments to be received from customers for sales of NUZYRA, net of prompt payment discounts, chargebacks, rebates and certain fees. An additional $0.7 million in accounts receivable consists of royalty revenue earned, but not yet received, during the three months ended September 30, 2019 in connection with SEYSARA sales under the Company’s collaboration agreement with Almirall. Refer to Note 8, License and Collaboration Agreements, for further details.

Leases

Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases, or ASC 842, using the required modified retrospective approach and utilizing the effective date as its date of initial application. Results and disclosure requirements for reporting periods after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under Topic 840. The adoption of ASC 842 resulted in changes to the Company’s accounting policies for leases previously recognized under ASC 840, as detailed below.

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of a distinct identified asset(s) and the Company’s control over the use of that identified asset. Most leases are recognized on the balance sheet as right-of-use assets and lease liabilities, current and non-current, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. These lease costs will be expensed as incurred. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plans to renew its material leases on a quarterly basis.

Right-of-use assets and lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received or initial direct costs. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.

In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.

Although separation of lease and non-lease components is otherwise required, certain expedients are available. Entities may elect to not separate lease and non-lease components by class of underlying asset and account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for each lease component and related non-lease component as a single lease component and allocate all of the contract consideration to the lease component only.

Product Revenue

The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the United States. These customers subsequently resell the Company’s product to health care providers or dispense the product to patients. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of our product.

Revenues from product sales are recognized when the customer obtains control of the Company’s product, which typically occurs once the company has transferred physical possession of the good to the customer. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration based on the Company’s estimates of channel mix. The types of variable consideration in our product revenue are as follows:

•

Trade discounts and allowances

•

Product returns

•

Chargebacks and rebates

•

Government rebates

•

Commercial payer and other rebates

•

Voluntary patient assistance programs

In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration.

The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled:

The “expected value” is the sum of probability-weighted amounts in a range of possible consideration amounts. Under ASC Topic 606, Revenue from Contracts with Customers, or Topic 606, an expected value may be an appropriate estimate of the amount of variable consideration if the Company has many contracts with similar characteristics.

The “most likely amount” is the single most likely amount in a range of possible consideration amounts (i.e., the single most likely outcome of the contract). Under Topic 606, the most likely amount may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes (i.e., either achieve or do not achieve a threshold specified in a contract).

The method selected is applied consistently throughout the contract when estimating the effect of an uncertainty on an amount of variable consideration. In addition, the Company considers all the information (historical, current, and forecasted) that is reasonably available to the Company and shall identify a reasonable number of possible consideration amounts. The relevant factors used in this determination include, but are not limited to, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns.

In assessing whether a constraint is necessary, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows:

Trade Discounts and Allowances - The Company generally provides customers with discounts that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain customers. To the extent the services received are distinct from the Company’s sale of products to the customer, these payments are classified in selling, general and administrative expenses in the condensed consolidated statements of operation and comprehensive loss of the Company.

Product Returns – Generally, the Company’s customers have the right to return any unopened/unused product supply during the 18-month period beginning six months prior to the labeled expiration date and ending 12 months after the labeled expiration date. Since the Company currently does not have history of NUZYRA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establish historical sales over a longer period of time (i.e., two years), the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns.

At the end of each reporting period for any of our products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products.

Chargebacks – Although the Company primarily sells products to specialty distributors in the United States, the Company also enters into agreements with hospitals and outpatient infusion centers, either directly or through group purchasing organizations acting on behalf of their members, in connection with the purchase of product. Based on these agreements, some of the Company’s customers have the right to receive a discounted price on product purchases. In the case of discounted pricing, the Company typically provides a credit to our specialty distributors customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price.

Government Rebates –We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of an estimate of claims for the current quarter and estimated future claims that will be made for product sales that have been recognized as revenue but remain in distribution channel inventory at period end.

Commercial Payer and Other Rebates – The Company plans to contract with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of NUZYRA and contracted formulary status. The Company estimates these rebates and records reserves for such estimates in the same period the related revenue is recognized. Currently, the reserve for customer payer rebates considers future utilization based on third party studies of payer prescription data; the utilization is applied to product that remains in the distribution and retail pharmacy channel inventories at the end of each reporting period. As the Company distributes its product and establishes historical sales over a longer period of time (i.e., two years), the Company will be able to place more reliance on historical data related to commercial payer rebates (i.e., actual utilization units) while continuing to rely on third party data related to payer prescriptions and utilization.

Patient Assistance – The Company offers certain voluntary patient assistance programs for prescriptions, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product sale that has been recognized as revenue but remains in the distribution and pharmacy channel inventories at the end of each reporting period.

At the end of each reporting period, the Company adjusts its allowances for cash discounts, product returns, chargebacks, and other rebates and discounts when the Company believes actual experience may differ from current estimates.

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:

	Chargebacks, discounts and fees			Government and other rebates			Returns		Patient assistance			Total
Balance at December 31, 2018	$	—		$	—		$	—	$	—		$	—
Provision related to current period sales		514			995			149		249			1,907
Adjustment related to prior period sales		—			—			—		—			—
Credit or payments made during the period		(272	)		(309	)		—		(16	)		(597	)
Balance at September 30, 2019	$	242		$	686		$	149	$	233		$	1,310

Contract costs

The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any significant incremental costs of obtaining a contract with a customer.

Cost of Revenue

Cost of revenue consists primarily of the manufacturing costs for NUZYRA. All manufacturing costs incurred prior to NUZYRA’s approval in the United States on October 2, 2018 were expensed in research and development and were not included in cost of revenue.

Stock-Based Compensation

Prior to the adoption of ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”, or ASU No. 2018-07, as discussed in Note 17, Recent Accounting Pronouncements, the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After the adoption of ASU No. 2018-07, the measurement date for non-employee awards is the later of the adoption date of ASU No. 2018-07 or the date of grant, without changes in the fair value of the award. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the results of operations of Paratek Pharmaceuticals, Inc. and its wholly-owned subsidiaries, Paratek Pharma, LLC, Paratek Securities Corporation, Transcept Pharma, Inc., Paratek UK, Limited, Paratek Royalty Corporation, Paratek Bermuda Ltd. and Paratek Ireland Limited. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the accompanying unaudited condensed consolidated financial statements, in conformity with U.S. GAAP, requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent liabilities in the Company’s financial statements. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to, among other items, accounts receivable and related reserves, inventory, intangible assets, goodwill, leases, stock-based compensation arrangements, manufacturing and clinical accruals, net product revenue, useful lives for depreciation and amortization of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known by the Company’s management.

Segment and Geographic Information

Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.

3. Cash and Cash Equivalents and Marketable Securities

The following is a summary of available-for-sale securities as of September 30, 2019 and December 31, 2018 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
September 30, 2019
U.S. treasury securities	$	120,582	$	155	$	(7	)	$	120,730
Total	$	120,582	$	155	$	(7	)	$	120,730
December 31, 2018
U.S. treasury securities	$	245,979	$	65	$	(193	)	$	245,851
Total	$	245,979	$	65	$	(193	)	$	245,851

No available-for-sale securities held as of September 30, 2019 and December 31, 2018 had remaining maturities greater than twelve months and fifteen months, respectively.

4. Restricted Cash

	September 30, 2019		September 30, 2018
Cash and cash equivalents	$	104,907	$	89,117
Short-term restricted cash		788		266
Long-term restricted cash		2,947		250
Total cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$	108,642	$	89,633

Short-term restricted cash

As of December 31, 2018, restricted cash of $0.3 million primarily represented royalty income received but not yet paid to former stockholders of Transcept Pharmaceuticals, Inc., or Transcept, as part of the royalty sharing agreement, or the Royalty Sharing Agreement, executed by the Company in October 2016 with the Special Committee of the Company’s Board of Directors, which was established in connection with the business combination between privately-held Paratek Pharmaceuticals, Inc. and Transcept in October 2014, or the Merger. This amount was paid to former stockholders of Transcept in the first quarter of 2019.

On May 1, 2019, the Company deposited $4.0 million into an interest reserve account in conjunction with the funding of a royalty-backed loan agreement, or the Royalty-Backed Loan Agreement, executed with Healthcare Royalty Partners III, L.P. Payments of interest under the Royalty-Backed Loan Agreement are made quarterly using royalty payments received since the immediately preceding payment date under the Almirall Collaboration Agreement. On each interest payment date, if the royalty payments received do not equal the total interest due for the respective quarter, the Company will cover the balance of the interest payment due from the interest reserve account. Refer to Note 13, Long-Term Debt, for further details. As of September 30, 2019, restricted cash of $0.8 million represents the estimated amount that is expected to be paid to Healthcare Royalty Partners III, L.P. out of the interest reserve account within the next twelve months.

Long-term restricted cash

The Company leases its Boston, Massachusetts office space under a non-cancelable operating lease. Refer to Note 14, Leases, for further details. In accordance with the lease, the Company has a cash-collateralized irrevocable standby letter of credit in the amount of $0.3 million as of both September 30, 2019 and December 31, 2018, naming the landlord as beneficiary.

As of September 30, 2019, long term restricted cash of $2.6 million represents the remaining balance in the interest reserve account that is expected to be paid to Healthcare Royalty Partners III, L.P. after September 30, 2020.

5. Inventories, Net

The following table presents inventories (in thousands):

	September 30, 2019		December 31, 2018
Work in process	$	8,705	$	598
Finished goods		121		—
Total inventories	$	8,826	$	598

When recorded, inventory reserves reduce the carrying value of inventories to their net realizable value. The Company reviews inventories on hand at least quarterly and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value.

6. Fixed Assets, Net

Fixed assets, net, consists of the following (in thousands):

	September 30, 2019			December 31, 2018
Office equipment	$	866		$	866
Computer equipment		412			412
Computer software		798			798
Leasehold improvements		920			909
Construction in progress		184			—
Gross fixed assets		3,180			2,985
Less: Accumulated depreciation and amortization		(2,213	)		(1,812	)
Net fixed assets	$	967		$	1,173

7. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method or the if-converted method, as applicable. For purposes of this calculation, shares of common stock issuable upon conversion of convertible debt, stock options, restricted stock units, warrants to purchase common stock, and shares issuable under the employee stock purchase plan are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following outstanding shares subject to stock options and restricted stock units, warrants to purchase shares of common stock, common stock issuable upon conversion of convertible debt and shares issuable under the employee stock purchase plan were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation as of the three and nine months ended September 30, 2019 and 2018 as indicated below:

	Nine Months Ended September 30,
	2019		2018
Excluded potentially dilutive securities ⁽¹⁾:
Common stock issuable under outstanding convertible notes		10,377,361		10,377,361
Shares subject to outstanding options to purchase common stock		3,293,102		3,762,912
Unvested restricted stock units		2,955,758		1,937,512
Shares subject to warrants to purchase common stock		104,455		104,455
Shares issuable under employee stock purchase plan		884,621		979,833
Totals		17,615,297		17,162,073

(1)

The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of September 30, 2019. Such amounts have not been adjusted for the treasury-stock method or weighted-average outstanding calculations as required if the securities were dilutive.

8. License and Collaboration Agreements

Tetraphase Pharmaceuticals, Inc.

On March 18, 2019, Paratek and Tetraphase Pharmaceuticals, Inc., or Tetraphase, entered into a License Agreement, or the Tetraphase License Agreement. Under the terms of the Tetraphase License Agreement, Paratek granted to Tetraphase a non-exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain Paratek patents, to develop, make, have, use, import, offer for sale and sell the licensed product, or XERAVA^TM (Eravacycline), which is a drug for the treatment of complicated, intra-abdominal infections caused by bacteria, which was approved by the FDA in August 2018.

The terms of the Tetraphase License Agreement provide for Tetraphase to pay Paratek royalties at a low single digit percent on net product revenues of the licensed product sold in the United States. Tetraphase’s obligation to pay royalties with respect to the licensed product shall be retroactive to the date of the first commercial sale of the licensed product in the United States, which occurred in February 2019. Tetraphase is currently selling XERAVA^TM (Eravacycline) in the United States.

The Tetraphase License Agreement will continue until the expiration of and payment by Tetraphase of all Tetraphase’s payment obligations, which is when there are no longer any valid claims of the licensed Paratek patents that would be infringed, in the absence of a license, by a manufacture, use, or sales of the licensed product. The principal licensed patent under the Tetraphase License Agreement is expected to expire in October 2023.

The Company recognized $22,500 and $0.1 million of royalty revenue for the three and nine months ended September 30, 2019, respectively, under the Tetraphase License Agreement.

Zai Lab (Shanghai) Co., Ltd.

On April 21, 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of Paratek Pharmaceuticals, Inc., and Zai Lab (Shanghai) Co., Ltd., or Zai, entered into a License and Collaboration Agreement, or the Zai Collaboration Agreement. Under the terms of the Zai Collaboration Agreement, Paratek Bermuda Ltd. granted Zai an exclusive license to develop, manufacture and commercialize omadacycline, or the licensed product, in the People’s Republic of China, Hong Kong, Macau and Taiwan, or the Zai territory, for all human therapeutic and preventative uses other than biodefense. Zai is responsible for the development, manufacturing and commercialization of the licensed product in the Zai territory, at its sole cost with certain assistance from Paratek Bermuda Ltd.

Under the terms of the Zai Collaboration Agreement, Paratek Bermuda Ltd. earned an upfront cash payment of $7.5 million in April 2017 and $5.0 million upon approval by the FDA of a New Drug Application, or NDA, submission in the CABP indication, which occurred on October 2, 2018. Paratek Bermuda Ltd. is eligible to receive up to $9.0 million in potential future regulatory milestone payments and $40.5 million in potential future commercial milestone payments, the next being $3.0 million upon submission of the first regulatory approval application for a licensed product in the People’s Republic of China. The terms of the Zai Collaboration Agreement also provide for Zai to pay Paratek Bermuda Ltd. tiered royalties at a low double digit to mid-teen percent on net sales of the licensed product in the Zai territory.

The Zai Collaboration Agreement will continue, on a region-by-region basis, until the expiration of and payment by Zai of all Zai’s payment obligations, which is until the later of: (i) the abandonment, expiry or final determination of invalidity of the last valid claim within the Paratek patents that covers the licensed product in the region in the Zai territory in the manner that Zai or its affiliates or sublicensees exploit the licensed product or intend for the licensed product to be exploited; or (ii) the eleventh anniversary of the first commercial sale of such licensed product in such region.

The Company evaluated the Zai Collaboration Agreement under Topic 606. The Company determined that there were six material promises under the Zai Collaboration Agreement: (i) an exclusive license to develop, manufacture and commercialize omadacycline in the Zai territory, (ii) the initial technology transfer, (iii) a transfer of certain materials and materials know-how, (iv) optional manufacturing services, (v) optional regulatory support and (vi) optional commercialization support. The Company determined that the exclusive license and initial technology transfer were not distinct from one another, as the license has limited value without the transfer of the Company’s technology; which will allow Zai to develop the manufacturing process and commercialize omadacycline in the Zai territory in the timeline anticipated under the agreement. Without the technology transfer, Zai would incur additional costs to recreate the Company’s know-how. Therefore, the license and initial technology transfer are combined as a single performance obligation. The transfer of materials is a single distinct performance obligation. The Company evaluated the option rights for manufacturing services, regulatory support and commercialization support to determine whether they represent or include material rights to Zai and concluded that the options were not issued at a discount, and therefore do not represent material rights. As such, they are not considered performance obligations at the outset of the arrangement.

Based on these assessments, the Company determined that two performance obligations existed at the outset of the Zai Collaboration Agreement: (i) the exclusive license combined with the initial technology transfer and (ii) the transfer of certain materials.

The Company determined that the upfront payment of $7.5 million constituted the entirety of the consideration to be included in the transaction price as of the outset of the Zai Collaboration Agreement. Future potential milestone payments were excluded from the transaction price as they are fully constrained as the risk of significant reversal has not yet been resolved. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success or regulatory approvals and therefore carry significant uncertainty. The Company will reevaluate the likelihood of achieving future milestones at the end of each reporting period. As all performance obligations have been satisfied, if the risk of significant reversal is resolved, any future milestone revenue from the arrangement will be recognized as revenue in the period the risk is relieved.

The Company satisfied both performance obligations and recognized the upfront payment of $7.5 million as revenue in the year ended December 31, 2017. As FDA approval was not within the control of the Company and was not obtained until October 2, 2018, the achievement of the milestone was not deemed probable and the risk of significant reversal of revenue was not resolved until that time. Upon the FDA approval, the uncertainty related to this milestone was resolved and a significant reversal of revenue would not occur in future periods. As such, the $5.0 million milestone payment was recognized as revenue at the time of FDA approval in the fourth quarter of 2018.

As regulatory approval in the People’s Republic of China is not within the control of the Company, the achievement of the milestone was not deemed probable and the risk of significant reversal of revenue was not resolved as of September 30, 2019. As such, the next milestone payment was not recognized as revenue in the year ended December 31, 2018 or the nine months ended September 30, 2019.

The Company recognized an insignificant amount of collaboration revenue for the three and nine months ended September 30, 2019 under the Zai Collaboration Agreement.

Almirall, LLC

In July 2007, the Company and Warner Chilcott Company, Inc. (which became a part of Allergan plc, or Allergan), entered into a collaborative research and license agreement under which the Company granted Allergan an exclusive license to research, develop and commercialize tetracycline products for use in the United States for the treatment of acne and rosacea. In August 2018, Allergan assigned to Almirall, its rights under the collaboration agreement, or the Almirall Collaboration Agreement. Since Allergan did not exercise its development option with respect to the treatment of rosacea prior to initiation of a Phase 3 trial for the product, the license grant to Allergan, which was assigned to Almirall, converted to a non-exclusive license for the treatment of rosacea as of December 2014. Under the terms of the Almirall Collaboration Agreement, the Company and Almirall are responsible for, and are obligated to use, commercially reasonable efforts to conduct specified development activities for the treatment of acne and, if requested by Almirall, the Company may conduct certain additional development activities to the extent the Company determines in good faith that the Company has the necessary resources available for such activities. Almirall has agreed to reimburse the Company for its costs and expenses, including third-party costs, incurred in conducting any such development activities.

Under the terms of the Almirall Collaboration Agreement, Almirall is responsible for and is obligated to use commercially reasonable efforts to develop and commercialize tetracycline compounds that are specified in the agreement for the treatment of acne. The Company has agreed during the term of the Almirall Collaboration Agreement not to directly or indirectly develop or commercialize any tetracycline compounds in the United States for the treatment of acne, and Almirall has agreed during the term of the Almirall Collaboration Agreement not to directly or indirectly develop or commercialize any tetracycline compound included as part of the agreement for any use other than as provided in the Almirall Collaboration Agreement.

The Almirall Collaboration Agreement contains two performance obligations: (i) an exclusive license to research, develop and commercialize tetracycline products for use in the United States for the treatment of acne and rosacea and (ii) research and development services. The performance obligation to deliver the license was satisfied upon execution of the Almirall Collaboration Agreement in July 2007. All research and development services were completed by December 2010. The options provided to Almirall for additional development services do not provide Almirall with a material right as these services will not be provided at a significant or incremental discount. As such, the option services are not performance obligations. As the performance obligation to deliver the license was satisfied in 2007 and research and development services were completed by December 2010, all subsequent milestone payments are recognized as revenue when the risk of significant reversal is resolved, generally when the milestone event occurs.

The Company received an upfront fee in the amount of $4.0 million upon the execution of the Almirall Collaboration Agreement, $1.0 million upon filing of an Investigational New Drug Application in 2010, $2.5 million upon initiation of Phase 2 trials in 2012 and $4.0 million upon initiation of Phase 3 trials associated with the Almirall Collaboration Agreement in December 2014.

In December 2017, the FDA’s acceptance of the NDA for sarecycline was received, triggering a milestone payment of $5.0 million earned upon acceptance of an NDA for a product licensed under the Almirall Collaboration Agreement.

In October 2018, the FDA’s regulatory approval of sarecycline, under the tradename SEYSARA, triggered the last milestone payment under the Almirall Collaboration Agreement of $12.0 million. Since FDA approval of SEYSARA was outside of the Company’s control and not obtained until October 2, 2018, the achievement of the milestone was not deemed probable and the risk of significant reversal of revenue was not resolved until such time. Upon the FDA approval, the uncertainty related to this milestone was resolved and a significant reversal of revenue would not occur in future periods. As such, the $12.0 million milestone payment was recognized as revenue at the time of FDA approval in the fourth quarter of 2018.

Almirall is also obligated to pay the Company tiered royalties, ranging from the mid-single digits to the low double digits, based on net sales of tetracycline compounds developed under the Almirall Collaboration Agreement, with a standard royalty reduction post patent expiration for such product for the remainder of the royalty term. Almirall’s obligation to pay the Company royalties for each tetracycline compound it commercializes under the Almirall Collaboration Agreement expires on the later of the expiration of the last to expire patent that covers the tetracycline compound in the United States and the date on which generic drugs that compete with the tetracycline compound reach a certain threshold market share in the United States.

The Company recognized $0.8 million and $1.4 million of royalty revenue for the three and nine months ended September 30, 2019, respectively, under the Almirall Collaboration Agreement. Royalty revenue recognized for sales of SEYSARA in the United States was estimated using third party data and an approximation of discounts and allowances to calculate net product sales, to which the Company then applied the applicable royalty percentage specified in the Almirall Collaboration Agreement. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter. During the three months ended September 30, 2019, the Company recorded an adjustment of $0.1 million to increase the estimated royalty revenue to the actual royalty revenue payment received for sales that occurred during the three months ended June 30, 2019.

Tufts University

In February 1997, the Company and Tufts University, or Tufts, entered into a license agreement under which the Company acquired an exclusive license to certain patent applications and other intellectual property of Tufts related to the drug resistance field to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases or medical conditions in humans or animals or for agriculture. The Company subsequently entered into eleven amendments to that agreement, collectively the Tufts License Agreement, to include patent applications filed after the effective date of the original license agreement, to exclusively license additional technology from Tufts, to expand the field of the agreement to include disinfectant applications, and to change the royalty rate and percentage of sublicense income paid by the Company to Tufts under sublicense agreements with specified sublicensees. The Company is obligated under the Tufts License Agreement to provide Tufts with annual diligence reports and a business plan and to meet certain other diligence milestones. The Company has the right to grant sublicenses of the licensed rights to third parties, which will be subject to the prior approval of Tufts unless the proposed sublicensee meets a certain net worth or market capitalization threshold. The Company is primarily responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents covering the intellectual property licensed under the Tufts License Agreement at its sole expense. The Company has the first right, but not the obligation, to enforce the licensed intellectual property against infringement by third parties.

The Company issued Tufts 1,024 shares of the Company’s common stock on the date of execution of the original license agreement, and the Company was required to make certain payments of up to $0.3 million to Tufts upon the achievement by products developed under the Tufts License Agreement of specified development and regulatory approval milestones. The Company made a payment of $50,000 to Tufts for achieving the first milestone following commencement of the Phase 3 clinical trial for omadacycline and a payment of $100,000 to Tufts for achieving the second milestone following its first marketing application submitted in the United States. The third, and final, payment of $150,000 became due upon FDA approval of omadacycline in October 2018. The Company is also obligated to pay Tufts a minimum royalty payment in the amount of $25,000 per year. In addition, the Company is obligated to pay Tufts royalties based on gross sales of products, as defined in the agreement, ranging in the low single digits depending on the applicable field of use for such product sale. If the Company enters into a sublicense under the Tufts License Agreement, based on the applicable field of use for such product, the Company will be obligated to pay Tufts (i) a percentage, ranging from 10% to 14% (ten percent to fourteen percent) for compounds other than omadacycline, and a percentage in the single digits for the compound omadacycline, of that portion of any sublicense issue fees or maintenance fees received by the Company that are reasonably attributable to the sublicense of the rights granted to the Company under the Tufts License Agreement and (ii) the lesser of (a) a percentage, ranging from the low tens to the high twenties based on the applicable field of use for such product, of the royalty payments made to the Company by the sublicensee or (b) the amount of royalty payments that would have been paid by the Company to Tufts if the Company had sold the product.

Unless terminated earlier, the Tufts License Agreement will expire at the same time as the last-to-expire patent in the patent rights licensed to the Company under the agreement and after any such expiration the Company will continue to have an exclusive, fully-paid-up license to such intellectual property licensed from Tufts. Tufts has the right to terminate the agreement upon 30 days’ notice should the Company fail to make a material payment under the Tufts License Agreement or commit a material breach of the agreement and not cure such failure or breach within such 30-day period, or if, after the Company has started to commercialize a product under the Tufts License Agreement, the Company ceases to carry on its business for a period of 90 consecutive days. The Company has the right to terminate the Tufts License Agreement at any time upon 180 days’ notice. Tufts has the right to convert the Company’s exclusive license to a non-exclusive license if the Company does not commercialize a product licensed under the Tufts License Agreement within a specified time period.

The Company incurred $46,000 and $0.1 million of royalty expense for the three and nine months ended September 30, 2019, respectively, and did not incur any royalty expense under the Tufts License Agreement for the three and nine months ended September 30, 2018.

Past Collaborations

Novartis International Pharmaceutical Ltd.

In September 2009, the Company and Novartis International Pharmaceutical Ltd., or Novartis, entered into a Collaborative Development, Manufacture and Commercialization License Agreement, or the Novartis Agreement, which provided Novartis with a global, exclusive patent and technology license for the development, manufacturing and marketing of omadacycline. The Novartis Agreement was terminated by Novartis without cause in June 2011 and the termination was effective 60 days later. The Company and Novartis subsequently entered in a letter agreement in January 2012, or the Novartis Letter Agreement, as amended, pursuant to which we reconciled shared development costs and expenses and granted Novartis a right of first negotiation with respect to commercialization rights of omadacycline following approval of omadacycline from the FDA, European Medicines Agency, or any regulatory agency, but only to the extent the Company had not previously granted such commercialization rights related to omadacycline to another third party as of any such approval. The Company also agreed to pay Novartis a 0.25% royalty, to be paid from net sales received by the Company in any country following the launch of omadacycline in that country and continuing until the later of expiration of the last active valid patent claim covering such product in the country of sale and 10 years from the date of first commercial sale in such country. The first royalty payment became payable as of March 31, 2019. The amended Novartis Letter Agreement resulted in a long-term liability in the amount of $3.5 million and $3.6 million as of September 30, 2019 and December 31, 2018, respectively, included within “Other liabilities” on the Company’s consolidated balance sheet. In addition, a short-term liability of $0.1 million, included within “Other current liabilities” on the Company’s consolidated balance sheet, exists as of September 30, 2019 that represents the portion of royalty payments due to Novartis within twelve months. There are no other payment obligations to Novartis under the Novartis Agreement or the amended Novartis Letter Agreement.

9. Capital Stock

In October 2015 and February 2017, the Company entered into Controlled Equity Offering^SM Sales Agreements, or the 2015 Sales Agreement and 2017 Sales Agreement, respectively, and collectively, the Sales Agreements, with Cantor Fitzgerald & Co., or Cantor, under which the Company could, at its discretion, from time to time sell shares of its common stock, with a sales value of up to $50.0 million under each Sales Agreement through Cantor. The Company provided Cantor with customary indemnification rights, and Cantor was entitled to a commission at a fixed rate of 3% of the gross proceeds per share sold. Sales of the shares under the Sales Agreements were to be made in transactions deemed to be “at the market offerings”, as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has sold all $50.0 million of shares of its common stock under the 2015 Sales Agreement. The 2017 Sales Agreement was terminated effective on June 22, 2019. The Company has sold 2,102,315 shares of common stock pursuant to the 2017 Sales Agreement for $47.7 million in proceeds, after deducting commissions of $1.5 million. None of these sales occurred during the nine months ended September 30, 2019.

On July 2, 2019, the Company entered into an At the Market Sales Agreement, or the 2019 Sales Agreement, with Jefferies LLC, or Jefferies, and BTIG, LLC, or BTIG, under which it may offer and sell its common stock having aggregate sales proceeds of up to $50.0 million from time to time through Jefferies or BTIG as its sales agents. Sales of the Company’s common stock through Jefferies or BTIG, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Global Market or any other existing trading market for its common stock. Jefferies and BTIG will use commercially reasonable efforts to sell the Company’s common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions we may impose). The Company will pay Jefferies or BTIG, as applicable, a commission of 3% of the gross sales proceeds of any common stock sold through Jefferies and BTIG under the 2019 Sales Agreement. The Company has also provided Jefferies and BTIG with customary indemnification rights.

The Company is not obligated to make any sales of common stock under the 2019 Sales Agreement. The Company has sold 360,575 shares of common stock pursuant to the 2019 Sales Agreement for $1.9 million in proceeds, after deducting commissions of $0.1 million during the three and nine months ended September 30, 2019. As of October 31, 2019, $48.0 million remains available for sale under the 2019 Sales Agreement.

The offering of shares of the Company’s common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the 2019 Sales Agreement, or (ii) termination of the 2019 Sales Agreement in accordance with its terms.

Warrants to Purchase Common Stock

Warrants to purchase preferred stock with intrinsic value issued to HBM Healthcare Investments (Cayman) Ltd., Omega Fund III, L.P., and K/S Danish BioVenture, all beneficial owners of more than 5% of the Company’s common stock, were exchanged for 9,614 warrants to purchase common stock in connection with the Merger. These 9,614 warrants to purchase common stock have an exercise price of $0.15 per share and will, if not exercised, expire in 2021. A further 5,120 warrants to purchase common stock with an exercise price of $73.66 per share expired in April 2016.

In connection with the Loan and Security Agreement, dated September 30, 2015, as amended from time to time, or the Hercules Loan Agreement, into which the Company entered with Hercules Technology II, L.P. and Hercules Technology III, L.P., together, Hercules, and certain other lenders and Hercules Technology Growth Capital, Inc. (as agent), the Company issued to each of Hercules Technology II, L.P. and Hercules Technology III, L.P. a warrant to purchase 16,346 shares of its common stock (32,692 shares of common stock in total) at an exercise price of $24.47 per share, or the Hercules Warrants, on September 30, 2015, which expire five years from issuance or at the consummation of a Public Acquisition, as defined in each of the Hercules Warrant agreements.

In connection with the second amendment to the Hercules Loan Agreement on December 12, 2016, the Company issued to each of Hercules Technology II, L.P. and Hercules Technology III, L.P. a warrant to purchase 18,574 shares of its common stock (37,148 shares of common stock in total) at an exercise price of $13.46 per share, or the Second Amendment Warrants.

In connection with the borrowing under the Hercules Loan Agreement on June 27, 2017, the Company issued an additional warrant to Hercules Capital, Inc. to purchase 5,374 shares of its common stock at an exercise price of $23.26 per share, or the Additional Warrant.

In connection with the fifth amendment to the Hercules Loan Agreement, on August 1, 2018, the Company issued to Hercules Capital, Inc. a warrant to purchase up to 19,627 shares of its common stock at an exercise price of $10.19 per share, or the Fifth Amendment Warrant.

The Hercules Warrants, Second Amendment Warrants, Additional Warrant and the Fifth Amendment Warrant, collectively referred to as the Warrants, may be exercised on a cashless basis. The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years (or seven years, in the case of the Fifth Amendment Warrant) from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the various agreements for the Warrants.

10. Other Accrued Expenses

Other accrued expenses consist of the following (in thousands):

	September 30,		December 31,
	2019		2018
Accrued legal costs	$	271	$	366
Accrued other		54		809
Accrued professional fees		754		750
Accrued compensation		5,529		6,070
Accrued interest		4,199		1,813
Accrued contract research		3,514		1,747
Accrued commercial		2,330		1,280
Accrued manufacturing		1,408		2,784
Accrued sales allowances		1,310		—
Accrued inventory		673		—
Total	$	20,042	$	15,619

11. Fair Value Measurements

Financial instruments, including cash, cash equivalents, restricted cash, money market funds, U.S. treasury securities, accounts receivable, accounts payable, and accrued expenses are carried on the condensed consolidated financial statements at amounts that approximate fair value. The fair value of the Company’s long-term debt is determined using current applicable rates for similar instruments as of the balance sheet date. The fair value of the Company’s debt (including the Notes as defined in Note 13, Long-Term Debt), is $187.5 million as of September 30, 2019. The fair value of the Company’s debt was determined using Level 3 inputs. Fair values are based on assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.

The following table presents information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2019 and December 31, 2018 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities or other inputs that are observable market data. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability (in thousands):

Description	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
September 30, 2019
Assets:
U.S. treasury securities	$	120,730	$	—	$	—	$	120,730
Total Assets	$	120,730	$	—	$	—	$	120,730
December 31, 2018
Assets:
U.S. treasury securities	$	245,851	$	—	$	—	$	245,851
Total Assets	$	245,851	$	—	$	—	$	245,851

Marketable Securities

U.S. treasury securities fair values can be obtained through quoted market prices in active exchange markets and are therefore classified as Level 1.

12. Stock-Based and Incentive Compensation

Stock-based Compensation

The following table presents stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development expense	$	560	$	1,442	$	2,868	$	4,456
Selling, general and administrative expense		3,264		2,642		7,874		8,499
Total stock-based compensation expense	$	3,824	$	4,084	$	10,742	$	12,955

Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period. The Company estimates the fair value of its stock options using the Black-Scholes option-pricing model. The weighted-average assumptions used to determine the fair value of the stock option grants is as follows:

	Nine Months Ended September 30,
	2019			2018
Volatility		63.3	%		67.4	%
Weighted-average risk-free interest rate		2.0	%		2.7	%
Expected dividend yield		0.0	%		0.0	%
Expected life of options (in years)		5.9			5.9

Stock Option Plan Activity

The Company’s Board of Directors adopted the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, or the 2015 Plan, which was approved by Company stockholders at the annual meeting of shareholders held on June 9, 2015, reserving 1,200,000 shares of common stock for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards, performance cash awards and other stock awards to directors, officers, employees and consultants. The 2015 Plan is intended to be the successor to and continuation of the Paratek Pharmaceuticals, Inc., 2006 Incentive Award Plan and the Paratek Pharmaceuticals, Inc. 2014 Equity Incentive Plan, or collectively, the Prior Plans. When the 2015 Plan became effective, no additional stock awards were granted under the Prior Plans, although all outstanding stock awards granted under the Prior Plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the Prior Plans. On January 1, 2019, 1,612,969 shares of common stock were automatically added to the shares authorized for issuance under the 2015 Plan pursuant to a “Share Reserve” provision contained in the 2015 Plan. The Share Reserve automatically increases on January 1^st of each year, for the period commencing on (and including) January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to 5% of the total number of shares of common stock outstanding on December 31^st of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors of the Company may act prior to January 1^st of a given year to provide that there will be no January 1^st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise automatically occur. Total shares available for future issuance under the 2015 Plan are 501,818 shares as of September 30, 2019.

The Company recognizes the compensation cost of awards subject to performance-based vesting conditions over the requisite service period, to the extent achievement of the performance condition is deemed probable relative to targeted performance using the accelerated attribution method. If achievement of the performance condition is not probable, but the award will vest based on the service condition, the Company recognizes the expense over the requisite service period. A change in the requisite service period that does not change the estimate of the total compensation cost (i.e., it does not affect the grant-date fair value or quantity of awards to be recognized) is recognized prospectively over the remaining requisite service period.

During the nine months ended September 30, 2019, the Company’s Board of Directors granted 56,210 stock options and 2,211,740 RSUs to directors, executives and employees of the Company under the 2015 Plan. The stock option awards are subject to time-based vesting over a period of one to four years. The RSU awards made in February 2019 to executives are subject to time-based vesting, with 10/40 of the shares vesting on December 10, 2019, or the Initial Vest Date, with an additional 15/40 of the shares vesting on the succeeding two anniversaries of the Initial Vesting Date. The RSU awards made in February 2019 to non-executive employees of the Company are subject to time-based vesting and vest in three equal installments commencing on each of the one-year anniversaries of the grant date. The grants also included performance-based RSU, or PRSU, awards to certain executives and employees of the Company. The PRSU awards issued in February 2019 and July 2019 will vest as follows: (a) 25/60 and (b) 25/60, each, on certain net product revenue achievements and (c) the remaining 10/60 on certain other business achievements. Since the Company believes it is probable that milestones (a) and (b) above will be achieved, the Company recognized compensation cost for a total of $0.8 million for the performance condition during the nine months ended September 30, 2019 using the accelerated attribution method.

During the year ended December 31, 2018, the Company’s Board of Directors granted PRSU awards to certain executives and employees of the Company and have vested or will vest as follows: (a) 10/55 shall be earned and time vest on achievement of European Medicines Agency, or EMA, filing preliminary validation, which occurred in October 2018, (b) 20/55 shall be earned and time vest on achievement of EMA approval, and (c) 25/55 shall be earned on achievement of the launch of omadacycline in the United States and time vest on the date that is 15 months following such launch date. During the three months ended September 30, 2019, the Company’s Board of Directors modified the vesting terms related to the PRSU that were expected to time vest on achievement of EMA approval. The modification resulted in stock-based compensation expense of $0.5 million during the three months ended September 30, 2019.

The Company’s Board of Directors adopted the Paratek Pharmaceuticals, Inc. 2015 Inducement Plan, or the 2015 Inducement Plan, in accordance with Nasdaq Rule 5635(c)(4), reserving 360,000 shares of common stock solely for the grant of inducement stock options to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company. The Company has not made any grants under the 2015 Inducement Plan since December 31, 2015. Although the Company does not currently anticipate the issuance of additional grants under the 2015 Inducement Plan, as of September 30, 2019, 306,500 shares remain available for grant under that plan, as well as any shares underlying outstanding stock options that may become available for grant pursuant to the plan’s terms. It is therefore possible that the Company may, based on the business and recruiting needs of the Company, issue additional stock options under the 2015 Inducement Plan.

In June 2017, the Company’s Board of Directors adopted the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, or the 2017 Inducement Plan, in accordance with Nasdaq Rule 5635(c)(4), reserving 550,000 shares of common stock solely for the grant of inducement stock options and RSU awards to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company. In October 2018, the Company’s Board of Directors approved the reserve of an additional 500,000 shares for the 2017 Inducement Plan, for a total of 1,050,000 shares reserved for issuance under it. During the nine months ended September 30, 2019, the Company’s Board of Directors granted 130,500 stock options and 57,600 RSUs to employees of the Company under the 2017 Inducement Plan. The stock option awards are subject to time-based vesting over a period of one to four years. The RSU awards are generally subject to time-based vesting, with 100% of the shares of common stock subject to the RSU award vesting three years from the grant date. As of September 30, 2019, 403,624 shares remain available for grant under the 2017 Inducement Plan, as well as any shares underlying awards that may become available for grant pursuant to the plan’s terms.

Stock Options

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		3,777,162		$	16.65		7.10	$	506
Granted		186,710
Cancelled or forfeited		(670,770	)
Outstanding at September 30, 2019		3,293,102		$	15.57		6.53	$	126
Exercisable at September 30, 2019		2,768,725		$	16.13		6.16	$	12

Restricted Stock Units

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:

	Number of Shares			Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2018		1,470,237		$	15.28
Granted		2,269,340		$	6.01
Released		(186,296	)	$	14.06
Forfeited		(597,523	)	$	10.84
Unvested balance at September 30, 2019		2,955,758		$	9.14

Total unrecognized stock-based compensation expense for all stock-based awards was $16.8 million as of September 30, 2019. This amount will be recognized over a weighted-average period of 1.72 years.

2018 Employee Stock Purchase Plan

The Company’s Board of Directors adopted, and in June 2018 Company’s stockholders approved, the Paratek Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, or the 2018 ESPP. The 2018 ESPP was amended in October 2018 to change the commencement dates of the offering periods. The maximum aggregate number of shares of our common stock that may be purchased under the 2018 ESPP is 943,294 shares, or the ESPP Share Pool, subject to adjustment as provided for in the 2018 ESPP. The ESPP Share Pool represented 3% of the total number of shares of our common stock outstanding as of March 31, 2018. The 2018 ESPP allows eligible employees to purchase shares during certain offering periods, which will be six-month periods commencing June 1 and ending November 30 and commencing December 1 and ending May 31 of each year. The first offering under the 2018 ESPP occurred on December 1, 2018. As of September 30, 2019, 884,621 shares remained available for issuance. During the nine months ended September 30, 2019, the Company issued 95,212 shares of common stock and recognized approximately $0.3 million in related stock-based compensation expense.

Revenue Performance Incentive Plan

On October 4, 2018, the Company adopted the Revenue Performance Incentive Plan, or the Plan, to grant performance-based cash incentive awards to key employees and consultants of the Company. The Plan provides for an incentive pool of up to $50.0 million, plus accrued interest during the period between the awards’ vesting date and payment dates. Each participant will be allocated a percentage of the incentive pool.

The incentive pool will be divided into two equal tranches with the first tranche vesting upon the Company’s achievement of cumulative net product revenues over $300.0 million by December 31, 2025, or Tranche 1, and the second tranche vesting upon the Company’s achievement of cumulative product revenues over $600.0 million by December 31, 2026, or Tranche 2. Participants will vest annually in each tranche of their awards in four equal installments on December 31, 2019, December 31, 2020, December 31, 2021, and December 31, 2022, subject to their continued employment with the Company through the applicable vesting date. If a participant’s employment terminates prior to December 31, 2022 due to death or disability, the participant will automatically vest in an additional 25% of each tranche of his or her award. Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant who has remained in continuous employment with the Company through December 31, 2022 will be 100% vested in the applicable tranche. In the event of a change of control of the Company prior to December 31, 2026, participants whose employment has terminated prior to such date will be eligible for payouts under the Plan based on the then-vested portion of their awards, and participants who have remained employed through the change of control will be deemed to have time vested in full in each tranche of their awards.

Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant’s payout in respect of the applicable tranche of his or her award will equal (a) the participant’s then-vested percentage, multiplied by (b) $25 million, multiplied by (c) the participant’s individual percentage allocation of the incentive pool.

If a change of control occurs prior to December 31, 2026, and the Tranche 1 milestone was not achieved prior to the change of control, the Tranche 1 milestone will be deemed to be achieved at a percentage equal to the greater of (1) 50% and (2) the cumulative product revenues as of the change of control, divided by $300.0 million. If a change of control occurs prior to December 31, 2026, and the Tranche 2 milestone was not achieved prior to the change of control, the Tranche 2 milestone will be deemed to be achieved at a percentage equal to the greater of (1) 30% and (2) the cumulative product revenues as of the change of control, divided by $600.0 million. A participant’s payout in respect of each tranche of his or her award in a change of control will equal (1) the participant’s then-vested percentage of such tranche, multiplied by (2) the percentage of that tranche’s milestone that has been achieved or is deemed to have been achieved, multiplied by (3) $25.0 million, multiplied by (4) the participant’s individual percentage allocation of the incentive pool.

Amounts that become payable upon achievement of the Tranche 1 milestone will be paid in a lump-sum in the first quarter of 2026 and amounts that become payable upon achievement of the Tranche 2 milestone will be paid in a lump-sum in the first quarter of 2027. In the event of a change of control, any portion of the incentive pool that is earned, but unpaid, or deemed earned in connection with the change of control will be paid at the time of the change of control.

If a change of control occurs prior to the achievement of either or both of the Tranche 1 and Tranche 2 milestones, the awards will remain outstanding and the remaining unpaid portion of the incentive pool applicable to the Tranche 1 or Tranche 2 milestone, as applicable, will be paid following the achievement of either such milestone at the time or times the bonuses would otherwise be paid out. Any successor in interest to the Company upon or following a change of control will be required to assume all obligations under the Plan.

Awards may be paid out in cash or in a combination of cash and registered securities of equal value (based on the Company’s 20-day trailing average closing common stock price), with the portion paid in registered securities not to exceed 50% of the aggregate payment amount with respect to each tranche; provided, however, that any amounts payable with respect to an award in connection with a change in control will be paid in cash.

The Company will recognize the compensation cost over the requisite service period, to the extent achievement of the performance condition is deemed probable relative to targeted performance. The performance condition is not yet deemed probable; as such, no amounts were accrued under the Plan during the nine months ended September 30, 2019.

13. Long-Term Debt

Hercules Loan Agreement

On June 27, 2019, the Company entered into an Amended and Restated Loan and Security Agreement, or the Loan Agreement, with Hercules Technology III, L.P., certain other lenders, together, the Lenders, and Hercules Capital, Inc. (as agent), under which the Company may borrow up to $100.0 million in multiple tranches, each, a Term Loan Tranche. The Loan Agreement amends and restates in its entirety the Company’s prior Loan and Security Agreement with the Lenders dated as of September 30, 2015 to, among other things, provide for an extension of the scheduled maturity date of the $60.0 million Term Loan Tranche, or the First Tranche, from September 1, 2021 to September 1, 2023, upon certain events set forth in the Loan Agreement, and an extension of the scheduled maturity date of the $10.0 million Term Loan Tranche, or the Second Tranche, and additional Term Loan Tranches (if any), from August 1, 2022 to August 1, 2024, upon certain events set forth in the Loan Agreement. The Loan Agreement also provides for an additional $10.0 million of additional Term Loan Tranches (up to a total of $30.0 million of additional Term Loan Tranches) that may be available to the Company, subject to approval by Hercules, in its sole discretion, whether to provide such tranches. As such there can be no assurance as to whether or not the additional Term Loan Tranches shall be funded.

The interest rate with respect to the First Tranche is a floating per annum rate equal to the greater of (i) 8.50% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.75%, and (ii) 8.50%. The interest rate with respect to the Second Tranche is, and the interest rate with respect to additional Term Loan Tranches (if any) will be, a floating per annum rate equal to the greater of (i) 7.85% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.75%, and (ii) 7.85%. An end of term charge equal to 4.5% with respect to $50.0 million of the First Tranche and equal to 2.25% with respect to the remaining $10.0 million of the First Tranche, and an end of term charge equal to 6.95% of the Second Tranche, and the Additional Term Loan Tranches (if any), of the issued principal balance of the term loans is payable at maturity, including in the event of any prepayment, and is being accrued as interest expense over the term of the term loans using the effective interest method. Payments under the Loan Agreement with respect to the First Tranche are interest only until January 1, 2021, followed by equal monthly payments of principal and interest through the scheduled maturity date. Payments under the Loan Agreement with respect to the Second Tranche are, and with respect to additional Term Loan Tranches (if any) will be, interest only until January 1, 2021 (which can be extended to May 1, 2021 or September 1, 2021, upon certain events set forth in the Loan Agreement), followed by equal monthly payments of principal and interest through the scheduled maturity date. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its and Paratek Pharma, LLC’s assets, other than intellectual property.

If the Company prepays the loan prior to maturity, it will pay the Lenders a prepayment charge, based on a percentage of the then outstanding principal balance, equal to 1.75% if the prepayment occurs prior to January 1, 2020, or equal to 0% if the prepayment occurs on or after January 1, 2020.

The Loan Agreement includes customary affirmative and restrictive covenants, including a liquidity covenant and a covenant against suffering a “change of control,” and also includes customary events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of Lenders’ security interest or in the value of the collateral, cross acceleration to the debt and certain events relating to bankruptcy or insolvency. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the assets of the Company.

Upon an Event of Default, an additional 5.0% interest would be applied, and Hercules could, at its option, accelerate and demand payment of all or any part of the term loans together with the prepayment and end of term charges. An Event of Default is defined in the Hercules Loan Agreement as (i) failure to make required payments; (ii) failure to adhere to financial, operating and reporting loan covenants; (iii) an event or development occurs that would be reasonably expected to have a material adverse effect; (iv) false representations in the Hercules Loan Agreement; (v) insolvency, as described in the Hercules Loan Agreement; (vi) levy or attachments on any of the Company's assets; and (vii) default of any other agreement or subordinated debt greater than $1.0 million. In the event of insolvency, this acceleration and declaration would be automatic. In addition, in connection with the Hercules Loan Agreement, the Company agreed to provide Hercules with a contingent security interest in the Company's bank accounts. The Company's control of its bank accounts is not adversely affected unless Hercules elects to obtain unilateral control of the Company's bank accounts by declaring that an Event of Default has occurred. The principal of the term loans, which is not due within 12 months of September 30, 2019, has been classified as long-term debt.

The Company recognized interest expense of $1.7 and $5.1 million for the three and nine months ended September 30, 2019, respectively.

The following table summarizes the impact of the Hercules Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):

	September 30, 2019			December 31, 2018
Gross proceeds	$	70,000		$	70,000
Unamortized debt issuance costs		(423	)		(606	)
Carrying value	$	69,577		$	69,394

Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.

Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan Agreement as of September 30, 2019 are as follows (in thousands):

Fiscal Year
2019	$	—
2020		—
2021		65,835
2022		4,165
Total	$	70,000

Convertible Senior Subordinated Notes

On April 18, 2018, the Company entered into a Purchase Agreement, or the Purchase Agreement, with several initial purchasers, or the Initial Purchasers, for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Partners LLC acted as representatives, relating to the sale of $135.0 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2024, or the Notes, to the Initial Purchasers. The Company also granted the Initial Purchasers an option to purchase up to an additional $25.0 million aggregate principal amount of Notes, which was exercised in full on April 20, 2018.

The Purchase Agreement includes customary representations, warranties and covenants. Under the terms of the Purchase Agreement, the Company agreed to indemnify the Initial Purchasers against certain liabilities.

In addition, J. Wood Capital Advisors LLC, the Company’s financial advisor, purchased $5.0 million aggregate principal amount of Notes in a separate, concurrent private placement on the same terms as other investors.

The Notes were issued by the Company on April 23, 2018, pursuant to an Indenture, dated as of such date, or the Indenture, between the Company and U.S. Bank National Association, as trustee, or the Trustee. The Notes bear cash interest at the annual rate of 4.75%, payable on November 1 and May 1 of each year, beginning on November 1, 2018, and mature on May 1, 2024 unless earlier repurchased, redeemed or converted. The Company will settle conversions of the Notes through delivery of shares of common stock of the Company, in accordance with the terms of the Indenture. The initial conversion rate for the Notes is 62.8931 shares of common stock (subject to adjustment as provided for in the Indenture) per $1,000 principal amount of the Notes, which is equal to an initial conversion price of approximately $15.90 per share, representing a conversion premium of approximately 20% above the closing price of the common stock of $13.25 per share on April 18, 2018.

Holders of the Notes may convert all or any portion of their Notes, in multiples of $1,000 principal amount, at their option at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date.

The Company may not redeem the Notes prior to May 6, 2021. The Company may redeem for cash all or part of the Notes, at its option, on or after May 6, 2021 if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If the Company experiences a fundamental change, as described in the Indenture, prior to the maturity date of the Notes, holders of the Notes will, subject to specified conditions, have the right, at their option, to require the Company to repurchase for cash all or a portion of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date of the Notes and following a notice of redemption of the Notes, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event or redemption.

The Indenture provides for customary events of default. In the case of an event of default with respect to the Notes arising from specified events of bankruptcy or insolvency, all outstanding Notes will become due and payable immediately without further action or notice. If any other event of default with respect to the Notes under the Indenture occurs or is continuing, the Trustee or holders of at least 25% in aggregate principal amount of the then outstanding Notes may declare the principal amount of the Notes to be immediately due and payable.

After deducting costs incurred of $6.0 million, the Company raised net proceeds from the issuance of long-term convertible debt of $159.0 million in April 2018. All costs were deferred and are being amortized over the life of the Notes at an effective interest rate of 5.47% and recorded as additional interest expense.

The Company recognized coupon interest expense of $2.0 million and $5.9 million, and amortization expense on the debt issuance costs of $0.2 million and $0.6 million, for the three and nine months ended September 30, 2019, respectively.

The Company has evaluated the Indenture for derivatives pursuant to ASC 815, Derivatives and Hedging, or ASC 815, and identified an embedded derivative that requires bifurcation as the feature is not clearly and closely related to the host instrument. The embedded derivative is a default provision, which could require additional interest payments. The Company determined in the prior year that the fair value of this embedded derivative was nominal.

The Company evaluated the conversion feature and determined it was not within the scope of ASC 815 and therefore is not required to be accounted for separately. The Company concluded that the embedded conversion option is not subject to separate accounting pursuant to either the cash conversion guidance or the beneficial conversion feature guidance. Under the general conversion guidance in ASC 470, Debt, all of the proceeds received from the Notes was recorded as a liability on the condensed consolidated balance sheet.

The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Gross proceeds	$	165,000		$	165,000
Unamortized debt issuance costs		(4,762	)		(5,434	)
Carrying value	$	160,238		$	159,566

Royalty-Backed Loan Agreement

On February 25, 2019, the Company, through its wholly-owned subsidiary Paratek Royalty Corporation, or the Subsidiary, entered into a royalty-backed loan agreement, or the Royalty-Backed Loan Agreement, with Healthcare Royalty Partners III, L.P., or HCRP. Pursuant to the terms of the Royalty-Backed Loan Agreement, upon the satisfaction of the conditions precedent set forth therein, the Subsidiary borrowed a $32.5 million loan, which was secured by, and will be repaid based upon, royalties from the Almirall Collaboration Agreement. On May 1, 2019, the Company received $27.8 million, net of $0.5 million lender discount, $0.2 million in lender expenses incurred, and $4.0 million that was deposited into an interest reserve account. The Company also paid $1.2 million in other lender fees related to the Royalty-Backed Loan Agreement. During the three months ended September 30, 2019, the Company paid $1.0 million to HCRP based upon royalties earned from the Almirall Collaboration Agreement and outstanding interest payments due to HCRP.

Under the Royalty-Backed Loan Agreement, the outstanding principal balance will bear interest at an annual rate of 12.0%. Payments of interest under the Royalty-Backed Loan Agreement are made quarterly out of the Almirall Collaboration Agreement royalty payments received since the immediately preceding payment date. On each interest payment date, any royalty payments in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. In addition, the Subsidiary made up-front payments to HCRP of (i) a 1.5% fee and (ii) up to $300,000 for HCRP’s expenses. The Royalty-Backed Loan Agreement matures on May 1, 2029, at which time, if not earlier repaid in full, the outstanding principal amount of the loan, together with any accrued and unpaid interest, and all other obligations then outstanding, shall be due and payable in cash. The Company has entered into a Pledge and Security Agreement in favor of HCRP, pursuant to which the Subsidiary’s obligations under the Loan Agreement are secured by a pledge of all of the Company’s holdings of the Subsidiary’s capital stock.

The Royalty-Backed Loan Agreement contains certain customary affirmative covenants, including those relating to: use of proceeds; maintenance of books and records; financial reporting and notification; compliance with laws; and protection of Company intellectual property. The Royalty-Backed Loan Agreement also contains certain customary negative covenants, barring the Subsidiary from: certain fundamental transactions; issuing dividends and distributions; incurring additional indebtedness outside of the ordinary course of business; engaging in any business activity other than related to the Almirall Collaboration Agreement; and permitting any additional liens on the collateral provided to HCRP under the Royalty-Backed Loan Agreement.

The Royalty-Backed Loan Agreement contains customary defined events of default, upon which any outstanding principal and unpaid interest shall be immediately due and payable. These include: failure to pay any principal or interest when due; any uncured breach of a representation, warranty or covenant; any uncured failure to perform or observe covenants; any uncured cross default under a material contract; any uncured breach of the Company’s representations, warranties or covenants under its Contribution and Servicing Agreement with the Subsidiary; any termination of the Almirall Collaboration Agreement; and certain bankruptcy or insolvency events.

The Company recognized interest expense of $1.0 and $1.6 million for the three and nine months ended September 30, 2019, respectively.

The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):

	September 30, 2019			December 31, 2018
Gross proceeds	$	32,500		$	—
Unamortized debt issuance costs		(1,905	)		—
Carrying value	$	30,595		$	—

Long-term debt on the Company’s consolidated balance sheets at September 30, 2019 includes the carrying value of the Hercules Loan Agreement, the Notes and the Royalty-Backed Loan Agreement. Long-term debt on the Company’s consolidated balance sheet at December 31, 2018 includes the carrying value of the Hercules Loan Agreement and the Notes.

14. Leases

Operating Leases

The Company leases its Boston, Massachusetts and King of Prussia, Pennsylvania office spaces under non-cancelable operating leases expiring in 2021 and 2024, respectively.

The Company entered into the original King of Prussia and Boston leases in January 2015 and April 2015, respectively. The lease terms under the original agreements were for six and four years, respectively. Each agreement had one renewal option for an extended term, which are not included in the measurement of these leases as these options are not reasonably certain to be exercised. The King of Prussia and Boston lease terms under the original agreements began in June 2015 and July 2015, respectively.

The Company executed an amended lease agreement on its Boston office space in July 2016. The amended lease agreement added 4,153 rentable square feet of office space and extended the original lease term by two years. In accordance with the amended lease agreement, the Company paid a security deposit of $0.1 million. Subsequent to the amended lease agreement, the Company records monthly lease expense of approximately $49,000 for the Boston office space. In applying the ASC 842 transition guidance, the Company retained the classification of this lease to be operating and recorded a lease liability and a right-of-use asset on the ASC 842 effective date.

The Company executed an amended lease agreement on its King of Prussia office space in October 2016. The amended lease agreement is for 19,708 rentable square feet of office space and the Company took control of this office space during the first quarter of 2017. The amended lease agreement contains rent escalation and a partial rent abatement period, which is accounted for as rent expense under the straight-line method. In applying the ASC 842 transition guidance, the Company retained the classification of this lease to be operating and recorded a lease liability and a right-of-use asset on the ASC 842 effective date.

The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2019:

Operating leases	For the Three Months Ended September 30, 2019
Lease cost (in thousands)
Operating lease cost	$	255
Variable lease cost		43
Total lease cost	$	298
Cash paid for amounts included in the measurement of lease liabilities:		289

	For the Nine Months Ended September 30, 2019
Lease cost (in thousands)
Operating lease cost	$	765
Variable lease cost		87
Total lease cost	$	852
Cash paid for amounts included in the measurement of lease liabilities:	$	770

Other information
Weighted average remaining lease term (in years)		3.8
Weighted average discount rate		8.75	%

Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of September 30, 2019, are as follows:

Maturity of lease liabilities (in thousands)	As of September 30, 2019
2019	$	291
2020		1,178
2021		964
2022		508
2023		518
2024 and thereafter		396
Total lease payments	$	3,855
Less: imputed interest		(580	)
Total operating lease liabilities	$	3,275

The total operating liability is presented on the Company’s condensed consolidated balance sheet based on maturity dates. $0.9 million of the total operating liabilities is classified under “other current liabilities” for the portion due within twelve months, and $2.3 million is classified under “long-term lease liability”.

The Company is party to a manufacturing and services agreement for which space within the manufacturing facility will be leased. This lease has not yet commenced as of the reporting date and is not included in the maturity table above.

15. Income Taxes

The Company recorded no provision for income taxes for the three or nine months ended September 30, 2019 and September 30, 2018.

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax bases of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company’s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the Company’s otherwise recognizable net deferred tax assets.

16. Commitments and Contingencies

Other Legal Proceedings

In the ordinary course of business, the Company is from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements, employment and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, as of September 30, 2019, the Company was not party to any other legal or arbitration proceedings that may have, or have had in the recent past, significant effects on the Company’s financial position. No governmental proceedings are pending or, to the Company’s knowledge, contemplated against the Company. The Company is not a party to any material proceedings in which any director, member of executive management or affiliate of the Company is either a party adverse to the Company or the Company’s subsidiaries or has a material interest adverse to the Company or the Company’s subsidiaries.

17. Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The amendment requires a lessee to recognize assets and liabilities for leases with term of more than 12 months. A lessee would recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the leased asset (the underlying asset) for the lease term. The guidance is required to be adopted using a modified retrospective approach applied to leases existing at the date of initial application. The new standard was effective for the Company on January 1, 2019. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January 1, 2019 and used the effective date as its date of initial application. Consequently, financial information will not be restated, and the disclosures required under the new standard will not be provided for dates and periods prior to January 1, 2019.

The new standard provides a number of optional practical expedients in transition. The Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which did not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Further, the Company utilized the short-term lease exemption for all leases with a lease term of 12 months or less for purposes of applying the recognition and measurements requirements in the new standard. The Company’s analysis included, but is not limited to, assessing its existing lease and service contracts, determining the appropriate discount rates to apply to its leases in order to determine the impact that the new leasing. Further, the Company has established policies and procedures in order to adhere to the requirements of the new standard, which includes enhanced disclosure requirements.

The adoption of this standard resulted in the recognition of operating lease liabilities and right-of-use assets of $3.7 million and $3.2 million, respectively, on the Company’s balance sheet relating to its leases for its corporate headquarters in Boston, Massachusetts and for office space in King of Prussia, Pennsylvania. The adoption of the standard did not have a material effect on the Company’s condensed consolidated statements of operation and comprehensive loss, condensed consolidated statements of cash flows, or condensed consolidated statements of stockholders’ equity.

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment, or ASU 2017-04. The amendments in ASU 2017-04 eliminate the current two-step approach used to test goodwill for impairment and require an entity to apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. ASU 2017-04 is effective for fiscal years and interim periods beginning after December 15, 2019 (upon the first goodwill impairment test performed during that fiscal year). Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. A reporting entity must apply the amendments in ASU 2017-04 using a prospective approach. The Company does not expect the adoption of ASU 2017-04 to have a material impact to its consolidated financial position or results of operations.

In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, or ASU 2018-07. These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which previously only included share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU No. 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees. ASU No. 2018-07 is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted this guidance effective January 1, 2019. The adoption of ASU No. 2018-07 did not have a material impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q. All references to “Paratek,” “we,” “us,” “our” or the “Company” in this Quarterly Report on Form 10-Q mean Paratek Pharmaceuticals, Inc. and our subsidiaries.

This discussion contains certain forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are identified by words such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward- looking” information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2018 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and except as required by law, we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Company Overview

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. NUZYRA^® (omadacycline), our product, and SEYSARA^® (sarecycline), the product which we have exclusively licensed to Almirall, LLC, or Almirall, development and commercialization rights in the United States, both received U.S. Food and Drug Administration, or FDA, approval in October 2018. The FDA approved NUZYRA, a new once-daily oral and intravenous, or IV, broad-spectrum antibiotic, for the treatment of adults with community acquired bacterial pneumonia, or CABP, and acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible bacteria. We launched NUZYRA in the United States in February 2019. The FDA approved SEYSARA, a new once-daily oral therapy, for the treatment of inflammatory acne vulgaris in patients age nine or older. Almirall launched SEYSARA in the United States in January 2019.

To date, we have conducted more than 20 Phase 1 studies of omadacycline to characterize the effects of the drug on humans, including how it is absorbed, metabolized, and excreted. These Phase 1 studies also included evaluation in special populations like hepatic and renal failure patients. We have also conducted three successful Phase 3 clinical studies. Our first two Phase 3 clinical studies were for the treatment of ABSSSI (OASIS-1) and CABP (OPTIC). Both studies utilized initiation of IV therapy with transitions to oral-based treatment on clinical response. Our third Phase 3 clinical study (OASIS-2) was an oral-only administration of omadacycline in ABSSSI compared to oral-only linezolid. All three Phase 3 clinical studies resulted in omadacycline demonstrating positive efficacy results and a generally safe and well tolerated profile. These data formed the basis of approval for NUZYRA in the United States. We have also agreed on a path forward with the FDA to evaluate an oral-only dosing regimen for NUZYRA in CABP. The agreed-upon clinical study is designed to demonstrate that the pharmacokinetics, or PK, of NUZYRA’s oral-only dosing regimen will be comparable to the PK of NUZYRA’s approved IV-to-oral dosing regimen in patients with CABP. We have begun to initiate sites for this PK study during the fourth quarter of 2019. Based upon the modest size of the required study, we anticipate a submission and potential approval for this oral-only CABP posology in time for the 2020 pneumonia season in the United States.

Based on the body of pre-clinical and clinical data combined with the in vitro activity of omadacycline against urinary tract infection, or UTI, pathogens, we initiated two Phase 2 clinical studies evaluating omadacycline for the treatment of UTI.

The first Phase 2 study, conducted in the United States, was designed to evaluate the efficacy, safety, tolerability and PK of oral-only omadacycline compared to an oral-only regimen of nitrofurantoin in female patients with cystitis, or uncomplicated urinary tract infections. In the study, 225 subjects were randomized to receive one of four omadacycline dosing regimens or nitrofurantoin.

The second Phase 2 study, conducted globally, was designed to evaluate the efficacy, safety, tolerability and pharmacokinetics of once-daily IV or IV-to-oral omadacycline compared to a once-daily regimen of IV-to-oral levofloxacin, in patients with acute pyelonephritis, a common clinical subset of complicated UTI. In the study, 201 patients were randomized into four omadacycline dosing regimens or levofloxacin.

In both studies, omadacycline showed generally comparable levels of clinical success to either nitrofurantoin or levofloxacin, as determined by the investigator’s assessment of clinical response at the post-treatment evaluation. However, the microbiological responses were generally lower than the comparators. Consistent with safety results from previously completed pivotal Phase 3 clinical trials, omadacycline was generally safe and well-tolerated in both studies. Additional analyses of data from the two phase 2

studies are ongoing, including pathogen-specific level efficacy and relationships of both clinical and microbiological responses to urinary pharmacokinetic data. We will present data from both studies at a future medical conference.

Due to the exploratory intent and small numbers of subjects enrolled in each dose in these phase 2 studies, we have identified dose regimens that require additional exploratory clinical study investigation before determining if any future late-stage development plans for these indications would be warranted. As a result, we are currently not planning for any additional clinical development activities in UTI.

In October 2018, we submitted a Market Authorization Applications, or MAA, submission to the European Medicines Agency, or the EMA, for the treatment of adults with ABSSSI and CABP caused by susceptible bacteria. Based on the review of the data and the application, the EMA has recommended approval for NUZYRA for the treatment of ABSSSI but not for CABP. The EMA stated that a second study is required for the pneumonia indication, which is consistent with EU guidance that typically requires two Phase 3 studies per indication for approval. In the EU, the ten-year market exclusivity for NUZYRA would begin with the first approval. As a result, in the fourth quarter of 2019, we withdrew our submission to the EMA of the MMA for NUZYRA to preserve exclusivity until such time as both the ABSSI and CABP indications can be approved concurrently in an effort to maximize the value of NUZYRA in the EU. The EU represents only a modest market opportunity compared to the United States. Our goal to partner in the EU once both indications are approved remains unchanged.

To date, we have devoted a substantial amount of our resources to research and development efforts, including conducting clinical trials for omadacycline, protecting our intellectual property and providing selling, general and administrative support for these operations. We began generating revenue from product sales in February 2019; as such, we have financed our operations primarily through sales of our common stock, debt financings, strategic collaborations, and grant funding.

We have incurred significant losses since our inception in 1996. Our accumulated deficit at September 30, 2019 was $683.9 million and our net loss for the nine months ended September 30, 2019 was $101.0 million. A substantial amount of our net losses resulted from costs incurred in connection with our research and development programs and selling, general and administrative costs associated with our operations. The net losses and negative operating cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders’ equity and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate offsetting revenue, if any. We expect to continue to incur significant expenses and operating losses for the foreseeable future.

Until we can generate a sufficient amount of revenue from our commercial products, if ever, we anticipate that we will need to raise additional capital in order to continue the commercialization of omadacycline and to advance the development of our other product candidates. Until we can generate a sufficient amount of product revenue to finance our cash requirements, we expect to finance our future cash needs primarily through a combination of public or private equity offerings, debt or other structured financings, strategic collaborations and grant funding. We may be unable to raise capital when needed or on attractive terms, which would force us to delay, limit, reduce or terminate our development programs or commercialization efforts. We will need to generate significant revenue to achieve and sustain profitability, and we may never be able to do so.

Recent Financing Activities

On February 25, 2019, we, through our wholly-owned subsidiary Paratek Royalty Corporation, or the Subsidiary, entered into a royalty-backed loan agreement, or the Royalty-Backed Loan Agreement, with Healthcare Royalty Partners III, L.P. Pursuant to the terms of the Royalty-Backed Loan Agreement, upon the satisfaction of the conditions precedent set forth therein, we borrowed a $32.5 million loan, which was secured by, and will be repaid based upon, royalties from the Almirall Collaboration Agreement. On May 1, 2019, we received $27.8 million, net of $0.5 million lender discount, $0.2 million in lender expenses incurred, and $4.0 million that was deposited into an interest reserve account. We also paid $1.2 million in other lender fees related to the Royalty-Backed Loan Agreement.

On July 2, 2019, we entered into an At the Market Sales Agreement, or 2019 Sales Agreement, with Jefferies LLC, or Jefferies, and BTIG, LLC, or BTIG, under which we may offer and sell our common stock having aggregate sales proceeds of up to $50.0 million from time to time through Jefferies and BTIG as our sales agents. Sales of our common stock through Jefferies and BTIG, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Global Market or any other existing trading market for its common stock. Jefferies and BTIG will use commercially reasonable efforts to sell our common stock from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay Jefferies and BTIG, as applicable, a commission of 3% of the gross sales proceeds of any common stock sold through Jefferies and BTIG under the 2019 Sales Agreement. We have also provided Jefferies and BTIG with customary indemnification rights. During the three months ended September 30, 2019, we sold 360,575 shares of our common stock pursuant to

the 2019 Sales Agreement for $1.9 million in proceeds, after deducting commissions of $0.1 million. As of October 31, 2019, $48.0 million remains available for sale under the 2019 Sales Agreement.

Financial Operations Overview

Revenues

Revenue earned during the three and nine months ended September 30, 2019 was attributable to net U.S. NUZYRA product sales of $3.1 million and $6.1 million, respectively, and collaboration and royalty revenue of $0.9 million and $1.5 million, respectively, consisting primarily of royalties earned from SEYSARA sales in the United States.

Cost of Product Revenue

Cost of product revenue consisted of the cost of the product itself, labor and overhead, as well as stability studies, inventory scrap and royalty expense.

Research and Development Expense

Research and development expenses consisted primarily of costs directly incurred by us for the development of our product candidates, which include:

•

expenses incurred under agreements with clinical research organizations, or CROs, and investigative sites that conduct our clinical trials;

•

the cost of acquiring and manufacturing preclinical and clinical study materials and developing manufacturing processes;

•

direct employee-related expenses, including salaries, benefits, travel and stock-based compensation expense of our research and development personnel;

•

allocated facilities, depreciation, and other expenses, which include rent and maintenance of facilities, insurance and other supplies; and

•

costs associated with preclinical activities and regulatory compliance.

Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.

We cannot determine with certainty the duration and completion costs of the current or future clinical trials of our product candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our products or product candidates for which we or any partner obtain regulatory approval, such as NUZYRA and SEYSARA. Aside from the FDA approval of NUZYRA and SEYSARA in the United States, we or our partners may never succeed in achieving regulatory approval for any of our other product candidates. The duration, costs and timing of clinical trials and development of our product candidates depend on a variety of factors, including:

•

the scope, rate of progress, and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;

•

future clinical trial results;

•

potential changes in government regulation; and

•

the timing and receipt of any regulatory approvals.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that therapeutic candidate. For example, if the FDA, or another regulatory authority, were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of the clinical development of product candidates, such as omadacycline for the treatment of UTI, or if we experience significant delays in the enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

We manage certain activities, such as clinical trial operations, manufacture of clinical trial material, and preclinical animal toxicology studies, through third-party contract organizations. The only costs we track by each product candidate are external costs such as services provided to us by CROs, manufacturing of preclinical and clinical drug product, and other outsourced research and development expenses. We do not assign or allocate to individual development programs internal costs such as salaries and benefits, facilities costs, lab supplies and the costs of preclinical research and studies. Our external research and development expenses for omadacycline and other projects during the three and nine months ended September 30, 2019 and 2018 are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2019		2018		2019		2018
Omadacycline costs	$	5,433	$	10,285	$	18,366	$	28,169
Other research and development costs		2,917		5,755		12,055		17,537
Total	$	8,350	$	16,040	$	30,421	$	45,706

Selling, General and Administrative Expense

Selling, general and administrative expenses consist principally of costs associated with our contract sales force, commercial support personnel, and medical affairs professionals, as well as personnel in executive and other administrative functions. Other selling, general and administrative expenses include marketing, trade, and other commercial costs and distribution fees necessary to support the launch of NUZYRA and professional fees for legal, consulting and accounting services.

Interest Expense

Interest expense represents interest incurred on the Hercules Loan Agreement, the Notes, and the Royalty-Backed Loan Agreement as well as the adjustment of our marketable securities to amortized cost.

Interest Income

Interest income represents interest earned on our money market funds and marketable securities.

Results of Operations

Comparison of the three months ended September 30, 2019 and 2018

	Three Months Ended September 30,
(in thousands)	2019			2018			$ Change
Product revenue, net	$	3,053		$	—		$	3,053
Collaboration and royalty revenue		881			50			831
Net revenue	$	3,934		$	50		$	3,884
Expenses:
Cost of revenue		958			—			958
Research and development		8,350			16,040			(7,690	)
Selling, general and administrative		23,636			13,610			10,026
Impairment of intangible asset		—			21			(21	)
Changes in fair value of contingent consideration		—			(11	)		11
Total operating expenses		32,944			29,660			3,284
Loss from operations		(29,010	)		(29,610	)		600
Other income and expenses:
Interest income		992			922			70
Interest expense		(4,560	)		(3,383	)		(1,177	)
Other losses, net		(36	)		(12	)		(24	)
Loss before provision for income taxes	$	(32,614	)	$	(32,083	)	$	(531	)
Provision for income taxes		—			—			—
Net loss	$	(32,614	)	$	(32,083	)	$	(531	)

Revenue

Net product revenue recognized on sales of NUZYRA in the United States was $3.1 million for the three months ended September 30, 2019. No product revenue was recorded for the three months ended September 30, 2018.

Collaboration and Royalty Revenues

Collaboration and royalty revenue was $0.9 million for the three months ended September 30, 2019 compared to $0.1 million for the three months ended September 30, 2018. The increase primarily relates to royalty revenues earned on sales of SEYSARA and XERAVA in the United States by Almirall and Tetraphase, respectively. Royalty revenue recognized for sales of SEYSARA in the United States was estimated using third party data and an approximation of discounts and allowances to calculate net product sales, to which we then applied the applicable royalty percentage specified in the Almirall Collaboration Agreement. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is expected to be the following quarter. SEYSARA royalty revenue for the three months ended September 30, 2019, of $0.8 million, was comprised of estimated royalty revenue incurred during the period of $0.7 million and an adjustment of $0.1 million to increase estimated royalty revenue recorded in the prior quarter based on actual royalties received.

Cost of Product Revenue

Cost of product revenues of $1.0 million for the three months ended September 30, 2019 consists primarily of costs associated with the manufacturing of NUZYRA as well as costs of product provided under our sampling and other commercial programs, royalties on sales of NUZYRA owed to Tufts, and certain period costs. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of NUZYRA units recognized as revenue during the three months ended September 30, 2019 were expensed prior to FDA approval in October 2018, and therefore are not included in cost of sales during the period. We expect cost of sales to increase in relation to net product revenues as we deplete these inventories, which we anticipate will occur in the first quarter of 2020. No cost of product revenue was recorded for the three months ended September 30, 2018.

Research and Development Expense

Research and development expenses were $8.4 million for the three months ended September 30, 2019 compared to $16.0 million for the same period in 2018. The $7.6 million decrease is primarily the result of the capitalization of NUZYRA commercial supply costs, which were classified as research and development expense until FDA approval of NUZYRA on October 2, 2018, partially offset by higher clinical study costs associated with our Phase 2 UTI program.

We anticipate that research and development expenses will remain relatively consistent in future periods as a result of winding down of our Phase 2 program evaluating omadacycline for the treatment of UTI and beginning our FDA post marketing commitments.

Selling, General and Administrative Expense

Selling, general and administrative expenses were $23.6 million for the three months ended September 30, 2019, compared to $13.6 million for the same period in 2018. The $10.0 million increase is primarily the result of the cost of our contract sales force, higher marketing, trade and distribution fees, and increased salaries, benefits and other personnel-related costs in support of the commercialization of NUZYRA.

We anticipate that our selling, general and administrative expenses will continue to increase in the future in support of our commercial activities related to NUZYRA as well as the continued costs of operating as a public company. These increases will likely include costs related to the hiring of additional personnel, executing marketing and promotional programs, and engaging consultants, legal and other professional fees, and other expenses.

Other Income and Expenses

Interest expense for the three months ended September 30, 2019 represents interest incurred on the Notes of $2.2 million, the Hercules Loan Agreement of $1.7 million, and the Royalty-Backed Loan Agreement of $1.0 million, partially offset by the net accretion of our marketable securities of $0.3 million. Interest income for the three months ended September 30, 2019 primarily represents interest earned on our money market funds and marketable securities of $0.9 million. Interest expense for the three months ended September 30, 2018 represents interest incurred on the Notes of $2.2 million and the Hercules Loan Agreement, as amended, of $1.8 million, partially offset by the net accretion of our marketable securities of $0.6 million. Interest income for the three months ended September 30, 2018 primarily represents interest earned on our money market funds and marketable securities of $0.9 million.

Comparison of the nine months ended September 30, 2019 and 2018

	Nine Months Ended September 30,
(in thousands)	2019			2018			$ Change
Product revenue, net	$	6,102		$	—		$	6,102
Collaboration and royalty revenue		1,475			101			1,374
Net revenue	$	7,577		$	101		$	7,476
Expenses:
Cost of revenue		1,731			—			1,731
Research and development		30,421			45,706			(15,285	)
Selling, general and administrative		67,874			38,395			29,479
Impairment of intangible asset		—			107			(107	)
Changes in fair value of contingent consideration		—			(57	)		57
Total operating expenses		100,026			84,151			15,875
Loss from operations		(92,449	)		(84,050	)		(8,399	)
Other income and expenses:
Interest income		2,873			2,292			581
Interest expense		(11,777	)		(7,793	)		(3,984	)
Other losses, net		(72	)		(14	)		(58	)
Loss before provision for income taxes	$	(101,425	)	$	(89,565	)	$	(11,860	)
Provision for income taxes		—			—			—
Net loss	$	(101,425	)	$	(89,565	)	$	(11,860	)

Revenue

Net product revenue recognized on sales of NUZYRA in the United States was $6.1 million for the nine months ended September 30, 2019. No product revenue was recorded for the nine months ended September 30, 2018.

Collaboration and Royalty Revenues

Collaboration and royalty revenue was $1.5 million for the nine months ended September 30, 2019 compared to $0.1 million for the nine months ended September 30, 2018. The increase primarily relates to royalty revenues earned on sales of SEYSARA and XERAVA in the United States by Almirall and Tetraphase, respectively. Royalty revenue recognized for sales of SEYSARA in the United States was estimated using third party data and an approximation of discounts and allowances to calculate net product sales, to we then applied the applicable royalty percentage specified in the Almirall Collaboration Agreement. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is expected to be the following quarter. Revenue for the nine months ended September 30, 2018 represents fifty percent of net royalties earned pursuant to the Royalty Sharing Agreement.

Cost of Product Revenue

Cost of product revenues of $1.7 million for the nine months ended September 30, 2019 consists primarily of costs associated with the manufacturing of NUZYRA as well as costs of product provided under our sampling and other commercial programs, royalties on sales of NUZYRA owed to Tufts, and certain period costs. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the costs of NUZYRA units recognized as revenue during the nine months ended September 30, 2019 were expensed prior to FDA approval in October 2018, and therefore are not included in cost of sales during the period. We expect cost of sales to increase in relation to net product revenues as we deplete these inventories, which we anticipate will occur in the first quarter of 2020. No cost of product revenue was recorded for the nine months ended September 30, 2018.

Research and Development Expense

Research and development expenses were $30.4 million for the nine months ended September 30, 2019, compared to $45.7 million for the nine months ended September 30, 2018. The $15.3 million decrease is primarily the result of the capitalization of NUZYRA commercial supply costs, which were classified as research and development expense until FDA approval of NUZYRA on October 2, 2018, and lower NDA user fees due to timing of our NDA submissions, partially offset by higher clinical study costs associated with our Phase 2 UTI program.

Selling, General and Administrative Expense

Selling, general and administrative expenses were $67.9 million for the nine months ended September 30, 2019 compared to $38.4 million for the nine months ended September 30, 2018. The $29.5 million increase is primarily the result of the cost of our contract sales force, higher marketing, trade and distribution fees, and increased salaries, benefits and other personnel-related costs in support of the commercialization of NUZYRA.

Impairment

There were no impairments recorded during the nine months ended September 30, 2019. During the nine months ended September 30, 2018, we recorded an impairment charge of $0.1 million in connection with an expected decline in Intermezzo sales.

Other Income and Expenses

Interest expense for the nine months ended September 30, 2019 represents interest incurred on the Notes of $6.6 million, the Hercules Loan Agreement of $5.1 million, and the Royalty-Backed Loan Agreement of $1.7 million, partially offset by the net accretion of our marketable securities of $1.5 million. Interest income for the nine months ended September 30, 2019 primarily represents interest earned on our money market funds and marketable securities of $2.6 million. Interest expense for the nine months ended September 30, 2018 represents interest incurred on the Hercules Loan Agreement of $5.0 million and the Notes of $3.8 million, partially offset by the net accretion of our marketable securities of $1.0 million. Interest income for the nine months ended September 30, 2018 primarily represents interest earned on our money market funds and marketable securities of $2.3 million.

Liquidity and Capital Resources

On July 2, 2019, we entered into the 2019 Sales Agreement with Jefferies and BTIG, under which we may offer and sell our common stock having aggregate sales proceeds of up to $50.0 million from time to time through Jefferies and BTIG as our sales agents. Sales of our common stock through Jefferies and BTIG, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. For the three months ended September 30, 2019, we sold 360,575 shares of its common stock pursuant to the 2019 Sales Agreement for $1.9 million in proceeds, after deducting commissions of $0.1 million. As of October 31, 2019, $48.0 million remains available for sale under the 2019 Sales Agreement.

On February 25, 2019, we, through our wholly-owned subsidiary Paratek Royalty Corporation, entered into the Royalty-Backed Loan Agreement with Healthcare Royalty Partners III, L.P. Pursuant to the terms of the Royalty-Backed Loan Agreement, upon the satisfaction of the conditions precedent set forth therein, we borrowed a $32.5 million loan, which was secured by, and will be repaid based upon, royalties from the Almirall Collaboration Agreement. On May 1, 2019, we received $27.8 million, net of $0.5 million lender discount, $0.2 million in lender expenses incurred, and $4.0 million that was deposited into an interest reserve account. We also paid $1.2 million in other lender fees related to the Royalty-Backed Loan Agreement.

On April 18, 2018, we entered into a Purchase Agreement, or the Purchase Agreement, with several initial purchasers, or the Initial Purchasers for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Partners LLC acted as representatives, relating to the sale of $135.0 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2024, or the Notes. We also granted the Initial Purchasers an option to purchase up to an additional $25.0 million aggregate principal amount of Notes, which was exercised in full on April 20, 2018. In addition, J. Wood Capital Advisors LLC, our financial advisor, purchased $5.0 million aggregate principal amount of Notes in a separate, concurrent private placement on the same terms as other investors. After deducting costs incurred of $6.0 million, we received proceeds from the sale of the Notes of $159.0 million in April 2018.

On January 22, 2018, we completed an underwritten public offering of 3,205,128 shares of our common stock, resulting in total proceeds of $50.0 million. Offering expenses incurred were $0.2 million.

On December 12, 2016, we filed a registration statement on Form S-3 with the SEC, which was declared effective on December 20, 2016, to sell certain of our securities in an aggregate amount of up to $225.0 million. As of September 30, 2019, $175.0 million remains available on this shelf registration statement.

Additionally, on December 1, 2017, we filed a registration statement on Form S-3 with the SEC, which was declared effective on December 8, 2017, to sell certain of our securities in an aggregate amount of up to $250.0 million. As of September 30, 2019, $248.0 million remains available on this shelf registration statement, with $48.0 million reserved for potential sales under the 2019 Sales Agreement.

In October 2015 and February 2017, we entered into the Controlled Equity Offering^SM Sales Agreements, or the 2015 Sales Agreement and 2017 Sales Agreement, respectively, with Cantor Fitzgerald & Co., or Cantor, under which we could, at our discretion, from time to time sell shares of our common stock, with a sales value of up to $50.0 million under each Sales Agreement through Cantor. We provided Cantor with customary indemnification rights, and Cantor was entitled to a commission at a fixed rate of 3% of the gross proceeds per share sold. Sales of the shares under the Sales Agreements were to be made in transactions deemed to be “at the market offerings”, as defined in Rule 415 under the Securities Act. We have sold all $50 million of shares of our common stock under the 2015 Sales Agreement.

We sold 2,102,315 shares of common stock pursuant to the 2017 Sales Agreement for $47.7 million in proceeds, after deducting commissions of $1.5 million. The 2017 Sales Agreement was terminated effective on June 22, 2019.

We have used and we intend to continue to use the net proceeds from the above offerings of our common stock and the Notes, as well as from the Hercules Loan Agreement and the Royalty-Backed Loan Agreement, together with our existing capital resources and future NUZYRA product sales, to fund our ongoing company operations, including clinical studies of omadacycline, NUZYRA commercial operations, and for working capital and other general corporate purposes. Refer to Note 13, Long-Term Debt, for further details on the Royalty-Backed Loan Agreement and the Hercules Loan Agreement.

As of September 30, 2019, we had cash, cash equivalents and marketable securities of $225.6 million.

The following table summarizes our cash provided by and used in operating, investing and financing activities:

	Nine Months Ended September 30,
(in thousands)	2019			2018
Net cash used in operating activities	$	(98,515	)	$	(62,194	)
Net cash provided by (used in) investing activities	$	126,878		$	(104,728	)
Net cash provided by financing activities	$	32,777		$	220,727

Operating Activities

Cash used in operating activities for the nine months ended September 30, 2019 of $98.5 million is primarily the result of our $101.4 million net loss, partially offset by $14.7 million in non-cash items, including, $10.7 million in stock-based compensation expense and $5.1 million of interest expense, net against $1.1 million in net depreciation, amortization and accretion. In addition, there was a $1.8 million increase in accounts payable and accrued expenses, a $1.5 million increase in long-term lease liability, a $6.1 million increase in accounts receivable and other current assets and a $7.6 million increase in inventories. Cash used in operating activities for the nine months ended September 30, 2018 of $62.2 million is primarily the result of our $89.6 million net loss, partially offset by $17.1 million in non-cash items, including, $13.0 million in stock-based compensation expense, and $4.6 million of interest expense, net against $0.5 million in net depreciation, amortization and accretion. In addition, there was a $5.2 million increase in accounts payable and accrued expenses and a $5.0 million decrease in accounts receivable.

Investing Activities

Net cash provided by investing activities during the nine months ended September 30, 2019 consists of our $77.1 million investment in short-term marketable securities (U.S. treasury bills), offset by proceeds from maturities of marketable securities of $204.0 million. Net cash used in investing activities during the nine months ended September 30, 2018 consists of $220.7 million investments in short-term marketable securities (U.S. treasury and government agency securities) offset by proceeds from maturities of marketable securities of $116.1 million.

Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2019 primarily represents net proceeds of $30.6 million received through the execution of the Royalty-Backed Loan Agreement and $1.9 million in proceeds, after deducting commissions of $0.1 million, received through the sale of common stock pursuant to the 2019 Sales Agreement. Net cash provided by financing activities during the nine months ended September 30, 2018 primarily represents net proceeds of $159.0 million raised through the sales of the Notes, net proceeds of $49.8 million raised through the January 2018 public offering of common stock, $10.0

million in net proceeds received from borrowings under the Loan Agreement, and net proceeds of $1.8 million raised through the sale of shares of our common stock under the Sales Agreements.

Future Funding Requirements

We began generating revenue from product sales in February 2019 when we launched NUZYRA in the United States and from Almirall’s launch of SEYSARA in the United States in January 2019. Our future funding requirements will depend on our ability to generate revenue from sales of NUZYRA, and our partner, Almirall’s, ability to generate revenues from sales of SEYSARA, with respect to which we are entitled to tiered royalties. We do not expect to generate any other revenue unless and until our partner, Zai, obtains regulatory approval of and commercializes one or more of our product candidates in the Zai territory. We anticipate that we will need substantial additional funding in connection with our continuing operations to support ongoing development and commercial activities associated with NUZYRA.

We expect to continue to incur significant expenditures and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:

•

conduct additional clinical trials of omadacycline;

•

seek regulatory approvals for additional indications for omadacycline, such as omadacycline for the treatment of UTI;

•

continue to establish a sales, marketing and distribution infrastructure and increase our manufacturing demand and capabilities to commercialize NUZYRA;

•

add personnel to support our planned commercialization efforts

•

build product inventory; and

•

service and pay down our debt

Based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities of $225.6 million as of September 30, 2019, and estimated NUZYRA product sales, will fund company operating expenses, capital expenditures, and debt service beyond the first quarter of 2021.

We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our pharmaceutical products, and the unknown extent to which we will maintain existing or enter into new collaborations with third parties to participate in the development and commercialization of our product and product candidates, we are unable to estimate with certainty the amounts of increased capital outlays and operating expenditures that we will require to fund our continuing operations, including for our clinical development programs and commercialization efforts for NUZYRA. Our future capital requirements will depend on many factors, including:

•

the progress of clinical development of omadacycline in additional indications;

•

the costs and timing of commercialization activities for NUZYRA;

•

product revenue received from commercial sales of NUZYRA;

•

royalty revenue received from commercial sales of SEYSARA by Almirall;

•

the ability of Zai to develop, manufacture and commercialize omadacycline in the Zai territory;

•

the number and characteristics of other product candidates that we may pursue;

•

the scope, progress, timing, cost and results of research, preclinical development and clinical trials;

•

the costs, timing and outcome of seeking, obtaining, maintaining and expanding FDA and non-U.S. regulatory approvals;

•

the costs associated with manufacturing and establishing sales, marketing and distribution capabilities;

•

our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;

•

our need and ability to hire additional management, scientific and medical personnel;

•

the effect of competing products that may limit market penetration of our products;

•

our need to implement additional internal systems and infrastructure, including financial and reporting systems; and

•

the economic and other terms, timing and success of our existing collaboration and licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under such arrangements.

Until we can generate a sufficient amount of product and royalty revenue to finance our cash requirements, if ever, we expect to finance our future cash needs primarily through a combination of public or private equity offerings, debt or other structured financings, strategic collaborations and grant funding. We do not have any committed external sources of funds other than rights to contingent milestone payments and/or royalties under the Almirall Collaboration Agreement and the Zai Collaboration Agreement, which are terminable by Almirall and Zai, respectively, upon prior written notice. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect stockholders’ rights. Future debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, NUZYRA, sarecycline, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market NUZYRA, sarecycline or our other product candidates that we may otherwise prefer to develop and market ourselves.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles of the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to, among other items, accounts receivable and related reserves, inventory, intangible assets, goodwill, stock-based compensation arrangements, manufacturing and clinical accruals, accrued sales allowances, product revenue, useful lives for depreciation and amortization of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

During the nine months ended September 30, 2019, we adopted ASU No. 2016-02, Leases (Topic 842) and ASU 2018-07, Compensation – Stock Compensation (Topic 718). Refer to Note 17, Recent Accounting Pronouncements, to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

During the nine months ended September 30, 2019, we began earning revenue from commercial product sales. As mentioned in Note 2, Summary of Significant Accounting Policies and Basis of Presentation, we recognize revenue when the customer obtains control of our product, which typically occurs once we have transferred physical possession of the good to the customer.

Recent Accounting Pronouncements

Refer to Note 17, Recent Accounting Pronouncements, to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

Off-Balance Sheet Arrangements

During the nine months ended September 30, 2019 and the year ended December 31, 2018 we did not engage in any off-balance sheet financing activities, including the use of structured finance, special purpose entities or variable interest entities.

Contractual Obligations and Commitments

There have been no material changes in our contractual obligations and commitments as of September 30, 2019, as compared to those disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Contractual Obligations and Commitments” in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 6, 2019, with the exception of those discussed in Note 13, Long-Term Debt, and Note 16, Commitments and Contingencies, in this Quarterly Report on Form 10-Q.

Item 3.

Quantitative and Qualitative Disclosures about Market Risks

Our cash, cash equivalents and investments balance as of September 30, 2019 consisted of cash and cash equivalents, U.S. treasury securities and government agency securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates, particularly because our investments are in short-term marketable securities. Due to the short-term duration of our investment portfolio and the low-risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio. We have the ability and intention to hold our investments, although they are available for immediate sale, until maturity and, therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio.

We engage CROs and contract manufacturers on a global scale. We may be subject to fluctuations in foreign currency rates in connection with certain of these agreements. We currently do not hedge any such foreign currency exchange rate risk. Transactions denominated in currencies other than U.S. dollars are recorded based on exchange rates at the time such transactions arise and were less than 3.3% of total liabilities as of September 30, 2019.

Item 4.

Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

As of September 30, 2019, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of September 30, 2019, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2019, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, as amended, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1.

Legal Proceedings

Information in response to this Item is incorporated herein by reference from Note 16, Commitments and Contingencies, to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

Item 1A.

Risk Factors

There have been no material changes from the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 6, 2019, and in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the SEC on May 8, 2019.

Item 6.

Exhibits

EXHIBIT INDEX

		Incorporated by Reference
Exhibit No.	Exhibit Description	Schedule/ Form	File Number	Exhibit	Filing Date

3.1	Amended and Restated Certificate of Incorporation.	Form 8-K	001-36066	3.1	October 31, 2014

3.2	Certificate of Amendment of Amended and Restated Certificate of Incorporation.	Form 8-K	001-36066	3.2	October 31, 2014

3.3	Certificate of Elimination of Series A Junior Participating Preferred Stock	Form 8-K	001-36066	3.1	July 24, 2015

3.4	Amended and Restated Bylaws.	Form 8-K	001-36066	3.1	April 16, 2015

4.1	Specimen Common Stock Certificate.	Form S-3	333-201458	4.2	January 12, 2015

4.2	Form of Warrant Agreement issued to Hercules Technology II, L.P. and Hercules Technology III, L.P.	Form 8-K	001-36066	4.1	October 5, 2015

4.3	Form of Warrant Agreement issued to Hercules Technology II, L.P. and Hercules Technology III, L.P.	Form 8-K	001-36066	4.1	December 13, 2016

4.4	Warrant Agreement, dated as of June 27, 2017 issued to Hercules Capital, Inc.	Form 8-K	001-36066	4.1	June 29, 2017

4.5	Warrant Agreement, dated as of August 1, 2018 issued to Hercules Capital, Inc.	Form 10-Q	001-36066	4.5	August 2, 2018

4.6	Warrant, dated as of April 7, 2014 issued to HBM Healthcare Investments (Cayman) Ltd.	Form 10-K	001-36066	10.22	April 2, 2015

4.7	Warrant, dated as of April 18, 2014 issued to K/S Danish BioVenture.	Form 10-K	001-36066	10.23	April 2, 2015

4.8	Warrant, dated as of April 7, 2014 issued to Omega Fund III, L.P.	Form 10-K	001-36066	10.24	April 2, 2015

31.1*	Certification of the Company’s Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*	Certification of the Company’s Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*	Certification of the Company’s Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*	Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*	XBRL Instance Document.

101.SCH*	XBRL Taxonomy Extension Schema Document.

101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 12^thday of November 2019.

Paratek Pharmaceuticals, Inc.

By:		/s/ Evan Loh M.D.
		Evan Loh M.D.
		Chief Executive Officer (Principal Executive Officer)
By:		/s/ Sarah Higgins
		Sarah Higgins
		Vice President, Controller (Principal Financial and Accounting Officer)

EX-31.1 2 prtk-ex311_10.htm EX-31.1 prtk-ex311_10.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Evan Loh, certify that:

1.	I have reviewed this Form 10-Q of Paratek Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision; to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ EVAN LOH, M.D.

Evan Loh, M.D.

Chief Executive Officer

November 12, 2019

EX-31.2 3 prtk-ex312_9.htm EX-31.2 prtk-ex312_9.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sarah Higgins, certify that:

1.	I have reviewed this Form 10-Q of Paratek Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ SARAH HIGGINS

Sarah Higgins

Principal Financial Officer

November 12, 2019

EX-32.1 4 prtk-ex321_12.htm EX-32.1 prtk-ex321_12.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Evan Loh, M.D., Chief Executive Officer of Paratek Pharmaceuticals, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 (the “Quarterly Report”), to which this Certification is attached as Exhibit 32.1 fully complies with the requirements of Section 13(a) or Section 15(d), of the Exchange Act; and

2.	The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations the Company.

In Witness Whereof, the undersigned has set his hand hereto as of the 12^th day of November, 2019.

/s/ EVAN LOH, M.D.

Evan Loh, M.D.

Chief Executive Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Paratek Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 prtk-ex322_8.htm EX-32.2 prtk-ex322_8.htm

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Sarah Higgins, Principal Financial Officer of Paratek Pharmaceuticals, Inc. (the “Company”), hereby certifies that, to the best of her knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 (the “Quarterly Report”), to which this Certification is attached as Exhibit 32.2 fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.	The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned has set her hand hereto as of the 12^th day of November, 2019.

/s/ SARAH HIGGINS

Sarah Higgins

Principal Financial Officer

EX-101.INS 6 prtk-20190930.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares prtk:Segment prtk:Obligation xbrli:pure prtk:Installment prtk:Tranche utr:D utr:sqft 0001178711 2019-01-01 2019-09-30 0001178711 2019-10-31 0001178711 2019-09-30 0001178711 2018-12-31 0001178711 us-gaap:ProductMember 2019-07-01 2019-09-30 0001178711 us-gaap:ProductMember 2019-01-01 2019-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember 2019-07-01 2019-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember 2018-07-01 2018-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember 2019-01-01 2019-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember 2018-01-01 2018-09-30 0001178711 2019-07-01 2019-09-30 0001178711 2018-07-01 2018-09-30 0001178711 2018-01-01 2018-09-30 0001178711 us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001178711 prtk:RoyaltyBackedLoanAgreementMember 2019-01-01 2019-09-30 0001178711 2017-12-31 0001178711 2018-09-30 0001178711 us-gaap:CommonStockMember 2018-12-31 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001178711 us-gaap:RetainedEarningsMember 2018-12-31 0001178711 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001178711 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001178711 2019-01-01 2019-03-31 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001178711 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001178711 us-gaap:CommonStockMember 2019-03-31 0001178711 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001178711 us-gaap:RetainedEarningsMember 2019-03-31 0001178711 2019-03-31 0001178711 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001178711 2019-04-01 2019-06-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001178711 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001178711 us-gaap:CommonStockMember 2019-06-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001178711 us-gaap:RetainedEarningsMember 2019-06-30 0001178711 2019-06-30 0001178711 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001178711 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001178711 us-gaap:CommonStockMember 2019-09-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001178711 us-gaap:RetainedEarningsMember 2019-09-30 0001178711 us-gaap:CommonStockMember 2017-12-31 0001178711 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001178711 us-gaap:RetainedEarningsMember 2017-12-31 0001178711 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001178711 2018-01-01 2018-03-31 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001178711 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001178711 us-gaap:CommonStockMember 2018-03-31 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001178711 us-gaap:RetainedEarningsMember 2018-03-31 0001178711 2018-03-31 0001178711 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001178711 2018-04-01 2018-06-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001178711 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001178711 us-gaap:CommonStockMember 2018-06-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001178711 us-gaap:RetainedEarningsMember 2018-06-30 0001178711 2018-06-30 0001178711 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001178711 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001178711 us-gaap:CommonStockMember 2018-09-30 0001178711 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001178711 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001178711 us-gaap:RetainedEarningsMember 2018-09-30 0001178711 prtk:HerculesTermLoanMember 2019-01-01 2019-09-30 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2019-01-01 2019-09-30 0001178711 prtk:OtherAccruedExpensesMember 2018-12-31 0001178711 us-gaap:InventoriesMember 2018-12-31 0001178711 us-gaap:TradeAccountsReceivableMember 2019-09-30 0001178711 prtk:AlmirallMember 2019-09-30 0001178711 prtk:ChargebacksDiscountsAndFeesMember 2019-01-01 2019-09-30 0001178711 prtk:GovernmentAndOtherRebatesMember 2019-01-01 2019-09-30 0001178711 prtk:SalesReturnsMember 2019-01-01 2019-09-30 0001178711 prtk:PatientAssistanceMember 2019-01-01 2019-09-30 0001178711 prtk:ChargebacksDiscountsAndFeesMember 2019-09-30 0001178711 prtk:GovernmentAndOtherRebatesMember 2019-09-30 0001178711 prtk:SalesReturnsMember 2019-09-30 0001178711 prtk:PatientAssistanceMember 2019-09-30 0001178711 us-gaap:USTreasurySecuritiesMember 2019-09-30 0001178711 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001178711 prtk:RoyaltyBackedLoanAgreementMember prtk:HealthcareRoyaltyPartnersIIILPMember 2019-05-01 2019-05-01 0001178711 prtk:RoyaltyBackedLoanAgreementMember prtk:HealthcareRoyaltyPartnersIIILPMember 2019-09-30 0001178711 us-gaap:StandbyLettersOfCreditMember 2019-09-30 0001178711 us-gaap:StandbyLettersOfCreditMember 2018-12-31 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember 2019-09-30 0001178711 us-gaap:EquipmentMember 2019-09-30 0001178711 us-gaap:EquipmentMember 2018-12-31 0001178711 us-gaap:ComputerEquipmentMember 2019-09-30 0001178711 us-gaap:ComputerEquipmentMember 2018-12-31 0001178711 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-09-30 0001178711 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001178711 us-gaap:LeaseholdImprovementsMember 2019-09-30 0001178711 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001178711 us-gaap:ConstructionInProgressMember 2019-09-30 0001178711 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0001178711 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0001178711 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001178711 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001178711 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001178711 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001178711 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001178711 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001178711 prtk:EmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001178711 prtk:EmployeeStockPurchasePlanMember 2018-01-01 2018-09-30 0001178711 prtk:TetraphaseLicenseAgreementMember 2019-07-01 2019-09-30 0001178711 prtk:TetraphaseLicenseAgreementMember 2019-01-01 2019-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember prtk:TetraphaseLicenseAgreementMember 2019-07-01 2019-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember prtk:TetraphaseLicenseAgreementMember 2019-01-01 2019-09-30 0001178711 prtk:ZaiLabShanghaiCoLtdMember prtk:ParatekBermudaLtdMember 2017-04-01 2017-04-30 0001178711 prtk:ZaiLabShanghaiCoLtdMember srt:MaximumMember prtk:ParatekBermudaLtdMember 2019-09-30 0001178711 prtk:ZaiLabShanghaiCoLtdMember prtk:ParatekBermudaLtdMember 2018-10-02 2018-10-02 0001178711 prtk:ZaiLabShanghaiCoLtdMember prtk:ParatekBermudaLtdMember 2019-09-30 0001178711 prtk:ZaiLabShanghaiCoLtdMember 2019-01-01 2019-09-30 0001178711 prtk:ZaiLabShanghaiCoLtdMember 2017-01-01 2017-12-31 0001178711 prtk:ZaiLabShanghaiCoLtdMember 2018-10-01 2018-12-31 0001178711 prtk:ZaiLabShanghaiCoLtdMember 2018-01-01 2018-12-31 0001178711 prtk:AlmirallMember 2019-01-01 2019-09-30 0001178711 prtk:AlmirallMember prtk:CollaborativeResearchAndLicenseAgreementMember 2009-02-01 2010-01-31 0001178711 prtk:AlmirallMember prtk:NewDrugApplicationMember 2009-02-01 2010-01-31 0001178711 prtk:AlmirallMember prtk:CollaborativeResearchAndLicenseAgreementPhaseTwoTrialsMember 2011-02-01 2012-01-31 0001178711 prtk:AlmirallMember prtk:CollaborativeResearchAndLicenseAgreementPhaseThreeTrialsMember 2014-12-01 2014-12-31 0001178711 prtk:AlmirallMember 2017-12-01 2017-12-31 0001178711 prtk:AlmirallMember 2018-10-01 2018-10-31 0001178711 prtk:AlmirallMember 2018-10-01 2018-12-31 0001178711 prtk:CollaborationAndRoyaltyRevenueMember prtk:AlmirallMember 2019-07-01 2019-09-30 0001178711 prtk:CollaborationAndRoyaltyRevenueMember prtk:AlmirallMember 2019-01-01 2019-09-30 0001178711 prtk:TuftsMember 1997-02-01 1997-02-28 0001178711 prtk:TuftsMember 2019-01-01 2019-09-30 0001178711 prtk:TuftsMember 2018-10-31 0001178711 prtk:TuftsMember 2019-09-30 0001178711 prtk:TuftsMember srt:MinimumMember 2019-01-01 2019-09-30 0001178711 prtk:TuftsMember srt:MaximumMember 2019-01-01 2019-09-30 0001178711 prtk:TuftsMember 2019-07-01 2019-09-30 0001178711 prtk:TuftsMember 2018-07-01 2018-09-30 0001178711 prtk:TuftsMember 2018-01-01 2018-09-30 0001178711 prtk:NovartisInternationalPharmaceuticalLtdMember 2019-01-01 2019-09-30 0001178711 prtk:NovartisInternationalPharmaceuticalLtdMember 2014-06-01 2014-06-30 0001178711 prtk:OtherLongTermLiabilitiesMember prtk:NovartisInternationalPharmaceuticalLtdMember 2019-09-30 0001178711 prtk:OtherLongTermLiabilitiesMember prtk:NovartisInternationalPharmaceuticalLtdMember 2018-12-31 0001178711 us-gaap:OtherCurrentLiabilitiesMember prtk:NovartisInternationalPharmaceuticalLtdMember 2019-09-30 0001178711 srt:MaximumMember prtk:CantorMember prtk:TwoThousandFifteenSalesAgreementMember 2015-10-31 0001178711 prtk:CantorMember prtk:TwoThousandFifteenSalesAgreementMember 2015-10-01 2015-10-31 0001178711 srt:MaximumMember prtk:CantorMember prtk:TwoThousandSeventeenSalesAgreementMember 2017-02-28 0001178711 prtk:CantorMember prtk:TwoThousandSeventeenSalesAgreementMember 2017-02-01 2017-02-28 0001178711 prtk:CantorMember prtk:TwoThousandFifteenSalesAgreementMember 2015-10-01 2018-09-30 0001178711 prtk:CantorMember prtk:TwoThousandFifteenSalesAgreementMember 2019-01-01 2019-09-30 0001178711 prtk:CantorMember prtk:TwoThousandSeventeenSalesAgreementMember 2019-01-01 2019-09-30 0001178711 srt:MaximumMember prtk:JefferiesLimitedLiabilityCompanyAndBTIGLimitedLiabilityCompanyMember prtk:TwoThousandNineteenSalesAgreementMember 2019-07-02 0001178711 prtk:JefferiesLimitedLiabilityCompanyAndBTIGLimitedLiabilityCompanyMember prtk:TwoThousandNineteenSalesAgreementMember 2019-07-01 2019-07-02 0001178711 prtk:JefferiesLimitedLiabilityCompanyAndBTIGLimitedLiabilityCompanyMember prtk:TwoThousandNineteenSalesAgreementMember 2019-07-01 2019-09-30 0001178711 prtk:JefferiesLimitedLiabilityCompanyAndBTIGLimitedLiabilityCompanyMember prtk:TwoThousandNineteenSalesAgreementMember 2019-01-01 2019-09-30 0001178711 prtk:JefferiesLimitedLiabilityCompanyAndBTIGLimitedLiabilityCompanyMember prtk:TwoThousandNineteenSalesAgreementMember us-gaap:SubsequentEventMember 2019-10-31 0001178711 prtk:WarrantsExpiresInTwoThousandTwentyOneMember 2019-09-30 0001178711 prtk:WarrantsExpiresInTwoThousandTwentyOneMember 2019-01-01 2019-09-30 0001178711 prtk:WarrantsExpiresInTwoThousandSixteenMember 2019-09-30 0001178711 prtk:WarrantsExpiresInTwoThousandSixteenMember 2019-01-01 2019-09-30 0001178711 prtk:HerculesTermLoanMember prtk:HerculesTechnologyIILPMember 2015-09-29 2015-09-30 0001178711 prtk:HerculesTermLoanMember prtk:HerculesTechnologyIIILPMember 2015-09-29 2015-09-30 0001178711 prtk:HerculesTermLoanMember 2015-09-29 2015-09-30 0001178711 prtk:HerculesTermLoanMember 2015-09-30 0001178711 prtk:HerculesTermLoanMember prtk:HerculesTechnologyIILPMember prtk:SecondAmendmentMember 2016-12-11 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:HerculesTechnologyIIILPMember prtk:SecondAmendmentMember 2016-12-11 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:SecondAmendmentMember 2016-12-11 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:SecondAmendmentMember 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:HerculesCapitalIncMember 2017-06-26 2017-06-27 0001178711 prtk:HerculesTermLoanMember prtk:HerculesCapitalIncMember 2017-06-27 0001178711 prtk:HerculesTermLoanMember prtk:HerculesCapitalIncMember prtk:FifthAmendmentMember 2018-07-30 2018-08-01 0001178711 prtk:HerculesTermLoanMember prtk:FifthAmendmentMember 2018-08-01 0001178711 prtk:FifthAmendmentMember 2018-07-30 2018-08-01 0001178711 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2019-09-30 0001178711 us-gaap:FairValueInputsLevel1Member 2019-09-30 0001178711 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001178711 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001178711 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001178711 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001178711 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001178711 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001178711 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001178711 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001178711 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001178711 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001178711 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001178711 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001178711 prtk:TwoThousandFifteenPlanMember prtk:DirectorsOfficersEmployeesAndConsultantsMember 2015-06-09 0001178711 prtk:TwoThousandFourteenPlanMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandSixPlanMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember 2019-01-01 2019-01-02 0001178711 prtk:TwoThousandFifteenPlanMember 2016-01-01 2016-01-02 0001178711 prtk:TwoThousandFifteenPlanMember 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-12-10 2019-12-10 0001178711 prtk:TwoThousandFifteenPlanMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember prtk:FebruaryTwoThousandEighteenMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember prtk:FebruaryTwoThousandEighteenMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember prtk:FebruaryTwoThousandEighteenMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-12-31 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-12-31 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-12-31 0001178711 prtk:TwoThousandFifteenPlanMember prtk:PerformanceBasedRestrictedStockUnitAwardsMember 2019-07-01 2019-09-30 0001178711 prtk:TwoThousandFifteenInducementPlanMember prtk:NewEmployeeMember 2019-09-30 0001178711 prtk:TwoThousandFifteenInducementPlanMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandFifteenInducementPlanMember 2019-09-30 0001178711 prtk:TwoThousandSeventeenInducementPlanMember prtk:EmployeesEnteringIntoEmploymentOrReturningToEmploymentMember 2017-06-30 0001178711 prtk:TwoThousandSeventeenInducementPlanMember 2018-10-31 0001178711 prtk:TwoThousandSeventeenInducementPlanMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandSeventeenInducementPlanMember us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandSeventeenInducementPlanMember srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandSeventeenInducementPlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-01-01 2019-09-30 0001178711 prtk:TwoThousandSeventeenInducementPlanMember 2019-09-30 0001178711 2018-01-01 2018-12-31 0001178711 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001178711 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001178711 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001178711 us-gaap:EmployeeStockMember 2018-06-30 0001178711 us-gaap:EmployeeStockMember 2018-03-30 2018-03-31 0001178711 us-gaap:EmployeeStockMember 2018-06-01 2018-06-30 0001178711 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0001178711 us-gaap:EmployeeStockMember us-gaap:CommonStockMember 2019-09-30 0001178711 us-gaap:EmployeeStockMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001178711 prtk:RevenuePerformanceIncentivePlanMember srt:MaximumMember 2018-10-04 0001178711 prtk:RevenuePerformanceIncentivePlanMember 2019-09-30 0001178711 prtk:RevenuePerformanceIncentivePlanMember srt:MinimumMember prtk:ShareBasedCompensationAwardTrancheOneMilestoneMember 2019-01-01 2019-09-30 0001178711 prtk:RevenuePerformanceIncentivePlanMember srt:MinimumMember prtk:ShareBasedCompensationAwardTrancheTwoMilestoneMember 2019-01-01 2019-09-30 0001178711 prtk:RevenuePerformanceIncentivePlanMember prtk:ShareBasedCompensationAwardTrancheOneMilestoneMember 2019-01-01 2019-09-30 0001178711 prtk:RevenuePerformanceIncentivePlanMember prtk:ShareBasedCompensationAwardTrancheTwoMilestoneMember 2019-01-01 2019-09-30 0001178711 prtk:RevenuePerformanceIncentivePlanMember 2019-01-01 2019-09-30 0001178711 prtk:HerculesTermLoanMember 2019-06-27 0001178711 prtk:HerculesTermLoanMember prtk:FirstTrancheMember 2015-09-30 0001178711 prtk:HerculesTermLoanMember prtk:FirstTrancheMember 2015-09-29 2015-09-30 0001178711 prtk:HerculesTermLoanMember prtk:FirstTrancheMember 2019-06-26 2019-06-27 0001178711 prtk:HerculesTermLoanMember prtk:SecondTrancheMember 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:SecondTrancheMember 2016-12-11 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:SecondTrancheMember 2019-06-26 2019-06-27 0001178711 prtk:HerculesTermLoanMember prtk:ThirdTrancheMember 2019-06-27 0001178711 prtk:HerculesTermLoanMember prtk:FourthTrancheMember 2019-06-27 0001178711 prtk:HerculesTermLoanMember prtk:FifthTrancheMember 2019-06-27 0001178711 prtk:HerculesTermLoanMember srt:MinimumMember prtk:FirstTrancheMember 2015-09-30 0001178711 prtk:HerculesTermLoanMember srt:MinimumMember prtk:SecondTrancheMember 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:EqualToFourPointFivePercentageOfFirstTrancheMember 2015-09-30 0001178711 prtk:HerculesTermLoanMember prtk:EqualToTwoPointTwoFivePercentageOfFirstTrancheMember 2015-09-30 0001178711 prtk:HerculesTermLoanMember prtk:EqualToSixPointNineFivePercentageOfSecondTrancheMember 2016-12-12 0001178711 prtk:HerculesTermLoanMember prtk:PriorToJanuaryOneTwoThousandTwentyMember 2019-01-01 2019-09-30 0001178711 prtk:HerculesTermLoanMember prtk:AfterJanuaryOneTwoThousandTwentyMember 2019-01-01 2019-09-30 0001178711 prtk:HerculesTermLoanMember 2019-06-26 2019-06-27 0001178711 prtk:HerculesTermLoanMember 2018-07-30 2018-08-01 0001178711 prtk:HerculesTermLoanMember 2018-08-01 0001178711 prtk:HerculesTermLoanMember 2019-07-01 2019-09-30 0001178711 prtk:HerculesTermLoanMember 2019-09-30 0001178711 prtk:HerculesTermLoanMember 2018-12-31 0001178711 prtk:PurchaseAgreementMember prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-18 0001178711 prtk:JWoodCapitalAdvisorsLLCMember prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-18 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-22 2018-04-23 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-23 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-18 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-16 2018-04-18 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-01 2018-04-30 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-04-30 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2019-09-30 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2019-07-01 2019-09-30 0001178711 prtk:FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember 2018-12-31 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember prtk:RoyaltyBackedLoanAgreementMember 2019-02-25 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember prtk:RoyaltyBackedLoanAgreementMember 2019-05-01 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember prtk:RoyaltyBackedLoanAgreementMember 2019-07-01 2019-09-30 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember prtk:RoyaltyBackedLoanAgreementMember 2019-02-24 2019-02-25 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember prtk:RoyaltyBackedLoanAgreementMember srt:MaximumMember 2019-02-24 2019-02-25 0001178711 prtk:HealthcareRoyaltyPartnersIIILPMember prtk:RoyaltyBackedLoanAgreementMember 2019-01-01 2019-09-30 0001178711 prtk:RoyaltyBackedLoanAgreementMember 2019-09-30 0001178711 prtk:BostonMember 2019-01-01 2019-09-30 0001178711 prtk:KingOfPrussiaMember 2019-01-01 2019-09-30 0001178711 prtk:KingOfPrussiaMember 2015-01-31 0001178711 prtk:BostonMember 2015-04-30 0001178711 prtk:KingOfPrussiaMember 2015-01-01 2015-01-31 0001178711 prtk:BostonMember 2015-04-01 2015-04-30 0001178711 prtk:BostonMember 2016-07-31 0001178711 prtk:KingOfPrussiaMember 2016-10-30 0001178711 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 10-Q false 2019-09-30 2019 Q3 PRTK PARATEK PHARMACEUTICALS, INC. 0001178711 Yes --12-31 Accelerated Filer true false false 001-36066 33-0960223 75 Park Plaza Boston MA 02116 617 807-6600 33287946 Yes Common Stock, par value $0.001 per share NASDAQ DE true false

104907000

46987000

120730000

203364000

788000

266000

3976000

41000

8826000

598000

854000

208000

5095000

3779000

245176000

255243000

2947000

249000

42487000

967000

1173000

829000

2701000

154000

211000

252774000

300192000

3956000

2090000

20042000

15619000

1020000

25018000

17709000

260410000

228959000

2344000

5608000

5946000

293380000

252614000

33000

32000

643106000

630142000

148000

-128000

-683893000

-582468000

-40606000

47578000

252774000

300192000

0.001

5000000

0.001

100000000

32901446

32259363

32901446

32259363

3053000

6102000

881000

50000

1475000

101000

3934000

50000

7577000

101000

958000

1731000

8350000

16040000

30421000

45706000

23636000

13610000

67874000

38395000

21000

107000

-11000

-57000

32944000

29660000

100026000

84151000

-29010000

-29610000

-92449000

-84050000

992000

922000

2873000

2292000

4560000

3383000

11777000

7793000

-36000

-12000

-72000

-14000

-32614000

-32083000

-101425000

-89565000

-32614000

-32083000

-101425000

-89565000

-68000

-103000

276000

-170000

-32682000

-32186000

-101149000

-89735000

-1.00

-1.01

-3.12

-2.86

32590454

31742854

32458010

31301249

-1124000

-530000

10742000

12955000

5097000

4608000

6052000

-4966000

-153000

548000

7555000

-534000

1843000

5164000

-1468000

-740000

-706000

-98515000

-62194000

45000

54000

77077000

220732000

204000000 116058000

126878000

-104728000

158974000

9950000

30554000

294000

287000

1929000

51516000

32777000

220727000

61140000

53805000

47502000

35828000

108642000

89633000

9579000

3751000

151000

32259363

32000

630142000

-128000

-582468000

156614

24000

200000

3839000

-35610000

32415977

32000

634005000

72000

-618078000

16031000

5000

24000

95212

294000

144000

3031000

-33201000

32516189

32000

637354000

216000

-651279000

-13677000

360575

1000

1928000

1929000

24682

25000

-68000

3799000

-32614000

32901446

33000

643106000

148000

-683893000

27941015

28000

552720000

-158000

-470112000

82478000

3301436

3000

51512000

51515000

171999

28699

177000

-21000

4367000

-27750000

31443149

31000

608776000

-179000

-497862000

110766000

271500

1000

-47000

4503000

-29733000

31714649

32000

613279000

-226000

-527595000

85490000

41600

130000

25239

110000

-103000

4085000

-32083000

31781488

32000

617604000

-329000

-559678000

57629000

2.   Summary of Significant Accounting Policies and Basis of Presentation Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America, or U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB, and pursuant to the rules and regulations of the SEC.   The accompanying condensed consolidated financial statements are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2018, except as described below related to Note 10, Other Accrued Expenses, and the adoption of ASU No. 2018-07 and ASC 842, and, in the opinion of management, reflect all normal recurring adjustments necessary for the fair presentation of the Company’s financial position as of September 30, 2019, results of operations for the three month and nine month periods ended September 30, 2019, cash flows for the nine month period ended September 30, 2019 and changes in stockholders’ equity (deficit) for the three month and nine month periods ended September 30, 2019. Beginning on April 1, 2019, the Company presented “accrued interest” as a separate line item in Note 10, Other Accrued Expenses. The Company reclassified accrued interest of $1.8 million as of December 31, 2018, previously presented as part of “accrued professional fees” into “accrued interest” in Note 10, Other Accrued Expenses. On December 31, 2018, the Company presented “accrued contract manufacturing costs” as a separate line item on its consolidated balance sheet. Beginning on January 1, 2019, the Company reclassified the December 31, 2018 accrued contract manufacturing costs balance of $2.8 million, into “other accrued expenses”. Also, beginning on January 1, 2019, the Company reclassified inventories of $0.6 million as of December 31, 2018 previously presented as part of “prepaid and other current assets” into “inventories” on the condensed consolidated balance sheet. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2018, and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 6, 2019. Summary of Significant Accounting Policies As of September 30, 2019, the Company’s significant accounting policies and estimates, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 6, 2019, have not changed except as discussed below. Accounts Receivable, Net Accounts receivable as of September 30, 2019 represents trade accounts receivable of $3.2 million consisting of payments to be received from customers for sales of NUZYRA, net of prompt payment discounts, chargebacks, rebates and certain fees. An additional $0.7 million in accounts receivable consists of royalty revenue earned, but not yet received, during the three months ended September 30, 2019 in connection with SEYSARA sales under the Company’s collaboration agreement with Almirall. Refer to Note 8, License and Collaboration Agreements, for further details.   Leases Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases, or ASC 842, using the required modified retrospective approach and utilizing the effective date as its date of initial application. Results and disclosure requirements for reporting periods after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under Topic 840. The adoption of ASC 842 resulted in changes to the Company’s accounting policies for leases previously recognized under ASC 840, as detailed below. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of a distinct identified asset(s) and the Company’s control over the use of that identified asset. Most leases are recognized on the balance sheet as right-of-use assets and lease liabilities, current and non-current, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. These lease costs will be expensed as incurred. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.  The Company monitors its plans to renew its material leases on a quarterly basis. Right-of-use assets and lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received or initial direct costs. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.).  The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is otherwise required, certain expedients are available. Entities may elect to not separate lease and non-lease components by class of underlying asset and account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for each lease component and related non-lease component as a single lease component and allocate all of the contract consideration to the lease component only.   Product Revenue The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the United States. These customers subsequently resell the Company’s product to health care providers or dispense the product to patients. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of our product.   Revenues from product sales are recognized when the customer obtains control of the Company’s product, which typically occurs once the company has transferred physical possession of the good to the customer.  The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration based on the Company’s estimates of channel mix. The types of variable consideration in our product revenue are as follows:   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Trade discounts and allowances</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Product returns</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Chargebacks and rebates</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Government rebates</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Commercial payer and other rebates</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Voluntary patient assistance programs</td></tr></table></div>   In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration.     The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> a)</td> <td valign="top"> The “expected value” is the sum of probability-weighted amounts in a range of possible consideration amounts. Under ASC Topic 606, Revenue from Contracts with Customers, or Topic 606, an expected value may be an appropriate estimate of the amount of variable consideration if the Company has many contracts with similar characteristics.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> b)</td> <td valign="top"> The “most likely amount” is the single most likely amount in a range of possible consideration amounts (i.e., the single most likely outcome of the contract). Under Topic 606, the most likely amount may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes (i.e., either achieve or do not achieve a threshold specified in a contract).</td></tr></table></div>   The method selected is applied consistently throughout the contract when estimating the effect of an uncertainty on an amount of variable consideration. In addition, the Company considers all the information (historical, current, and forecasted) that is reasonably available to the Company and shall identify a reasonable number of possible consideration amounts. The relevant factors used in this determination include, but are not limited to, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns.   In assessing whether a constraint is necessary, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows:   Trade Discounts and Allowances - The Company generally provides customers with discounts that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  In addition, the Company receives sales order management, data and distribution services from certain customers.  To the extent the services received are distinct from the Company’s sale of products to the customer, these payments are classified in selling, general and administrative expenses in the condensed consolidated statements of operation and comprehensive loss of the Company.   Product Returns – Generally, the Company’s customers have the right to return any unopened/unused product supply during the 18-month period beginning six months prior to the labeled expiration date and ending 12 months after the labeled expiration date. Since the Company currently does not have history of NUZYRA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establish historical sales over a longer period of time (i.e., two years), the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns.   At the end of each reporting period for any of our products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products.   Chargebacks – Although the Company primarily sells products to specialty distributors in the United States, the Company also enters into agreements with hospitals and outpatient infusion centers, either directly or through group purchasing organizations acting on behalf of their members, in connection with the purchase of product. Based on these agreements, some of the Company’s customers have the right to receive a discounted price on product purchases. In the case of discounted pricing, the Company typically provides a credit to our specialty distributors customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price.   Government Rebates –We are subject to discount obligations under state Medicaid programs and Medicare.  We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix.  These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.  For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.  Our liability for these rebates consists of an estimate of claims for the current quarter and estimated future claims that will be made for product sales that have been recognized as revenue but remain in distribution channel inventory at period end.   Commercial Payer and Other Rebates – The Company plans to contract with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of NUZYRA and contracted formulary status. The Company estimates these rebates and records reserves for such estimates in the same period the related revenue is recognized. Currently, the reserve for customer payer rebates considers future utilization based on third party studies of payer prescription data; the utilization is applied to product that remains in the distribution and retail pharmacy channel inventories at the end of each reporting period. As the Company distributes its product and establishes historical sales over a longer period of time (i.e., two years), the Company will be able to place more reliance on historical data related to commercial payer rebates (i.e., actual utilization units) while continuing to rely on third party data related to payer prescriptions and utilization.   Patient Assistance – The Company offers certain voluntary patient assistance programs for prescriptions, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product sale that has been recognized as revenue but remains in the distribution and pharmacy channel inventories at the end of each reporting period.   At the end of each reporting period, the Company adjusts its allowances for cash discounts, product returns, chargebacks, and other rebates and discounts when the Company believes actual experience may differ from current estimates.   The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">discounts and <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">fees</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">rebates</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patient <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assistance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to current period sales</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">995</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment related to prior period sales</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit or payments made during the period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(272</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(309</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(597</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   Contract costs The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any significant incremental costs of obtaining a contract with a customer.</div>   Cost of Revenue Cost of revenue consists primarily of the manufacturing costs for NUZYRA. All manufacturing costs incurred prior to NUZYRA’s approval in the United States on October 2, 2018 were expensed in research and development and were not included in cost of revenue.   Stock-Based Compensation Prior to the adoption of ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”, or ASU No. 2018-07, as discussed in Note 17, Recent Accounting Pronouncements, the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After the adoption of ASU No. 2018-07, the measurement date for non-employee awards is the later of the adoption date of ASU No. 2018-07 or the date of grant, without changes in the fair value of the award. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the results of operations of Paratek Pharmaceuticals, Inc. and its wholly-owned subsidiaries, Paratek Pharma, LLC, Paratek Securities Corporation, Transcept Pharma, Inc., Paratek UK, Limited, Paratek Royalty Corporation, Paratek Bermuda Ltd. and Paratek Ireland Limited. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the accompanying unaudited condensed consolidated financial statements, in conformity with U.S. GAAP, requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent liabilities in the Company’s financial statements. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to, among other items, accounts receivable and related reserves, inventory, intangible assets, goodwill, leases, stock-based compensation arrangements, manufacturing and clinical accruals, net product revenue, useful lives for depreciation and amortization of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known by the Company’s management. Segment and Geographic Information Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.

5. Inventories, Net The following table presents inventories (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,705</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,826</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   When recorded, inventory reserves reduce the carrying value of inventories to their net realizable value. The Company reviews inventories on hand at least quarterly and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value.

10.   Other Accrued Expenses Other accrued expenses consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">809</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,529</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,199</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contract research</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,514</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,747</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued commercial</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,330</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,280</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued manufacturing</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,408</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,784</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales allowances</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued inventory</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,042</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,619</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

11.   Fair Value Measurements   Financial instruments, including cash, cash equivalents, restricted cash, money market funds, U.S. treasury securities, accounts receivable, accounts payable, and accrued expenses are carried on the condensed consolidated financial statements at amounts that approximate fair value. The fair value of the Company’s long-term debt is determined using current applicable rates for similar instruments as of the balance sheet date.  The fair value of the Company’s debt (including the Notes as defined in Note 13, Long-Term Debt), is $187.5 million as of September 30, 2019. The fair value of the Company’s debt was determined using Level 3 inputs.  Fair values are based on assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.   The following table presents information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2019 and December 31, 2018 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities or other inputs that are observable market data. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability (in thousands):     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> Marketable Securities   U.S. treasury securities fair values can be obtained through quoted market prices in active exchange markets and are therefore classified as Level 1.

12.   Stock-Based and Incentive Compensation     Stock-based Compensation   The following table presents stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,442</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,868</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,264</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,642</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,874</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,499</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,824</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,084</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,742</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,955</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period. The Company estimates the fair value of its stock options using the Black-Scholes option-pricing model. The weighted-average assumptions used to determine the fair value of the stock option grants is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Stock Option Plan Activity The Company’s Board of Directors adopted the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, or the 2015 Plan, which was approved by Company stockholders at the annual meeting of shareholders held on June 9, 2015, reserving 1,200,000 shares of common stock for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards, performance cash awards and other stock awards to directors, officers, employees and consultants. The 2015 Plan is intended to be the successor to and continuation of the Paratek Pharmaceuticals, Inc., 2006 Incentive Award Plan and the Paratek Pharmaceuticals, Inc. 2014 Equity Incentive Plan, or collectively, the Prior Plans.  When the 2015 Plan became effective, no additional stock awards were granted under the Prior Plans, although all outstanding stock awards granted under the Prior Plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the Prior Plans. On January 1, 2019, 1,612,969 shares of common stock were automatically added to the shares authorized for issuance under the 2015 Plan pursuant to a “Share Reserve” provision contained in the 2015 Plan.  The Share Reserve automatically increases on January 1st of each year, for the period commencing on (and including) January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors of the Company may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise automatically occur.  Total shares available for future issuance under the 2015 Plan are 501,818 shares as of September 30, 2019. The Company recognizes the compensation cost of awards subject to performance-based vesting conditions over the requisite service period, to the extent achievement of the performance condition is deemed probable relative to targeted performance using the accelerated attribution method. If achievement of the performance condition is not probable, but the award will vest based on the service condition, the Company recognizes the expense over the requisite service period. A change in the requisite service period that does not change the estimate of the total compensation cost (i.e., it does not affect the grant-date fair value or quantity of awards to be recognized) is recognized prospectively over the remaining requisite service period.   During the nine months ended September 30, 2019, the Company’s Board of Directors granted 56,210 stock options and 2,211,740 RSUs to directors, executives and employees of the Company under the 2015 Plan. The stock option awards are subject to time-based vesting over a period of one to four years. The RSU awards made in February 2019 to executives are subject to time-based vesting, with 10/40 of the shares vesting on December 10, 2019, or the Initial Vest Date, with an additional 15/40 of the shares vesting on the succeeding two anniversaries of the Initial Vesting Date. The RSU awards made in February 2019 to non-executive employees of the Company are subject to time-based vesting and vest in three equal installments commencing on each of the one-year anniversaries of the grant date. The grants also included performance-based RSU, or PRSU, awards to certain executives and employees of the Company. The PRSU awards issued in February 2019 and July 2019 will vest as follows: (a) 25/60 and (b) 25/60, each, on certain net product revenue achievements and (c) the remaining 10/60 on certain other business achievements. Since the Company believes it is probable that milestones (a) and (b) above will be achieved, the Company recognized compensation cost for a total of $0.8 million for the performance condition during the nine months ended September 30, 2019 using the accelerated attribution method. During the year ended December 31, 2018, the Company’s Board of Directors granted PRSU awards to certain executives and employees of the Company and have vested or will vest as follows: (a) 10/55 shall be earned and time vest on achievement of European Medicines Agency, or EMA, filing preliminary validation, which occurred in October 2018, (b) 20/55 shall be earned and time vest on achievement of EMA approval, and (c) 25/55 shall be earned on achievement of the launch of omadacycline in the United States and time vest on the date that is 15 months following such launch date. During the three months ended September 30, 2019, the Company’s Board of Directors modified the vesting terms related to the PRSU that were expected to time vest on achievement of EMA approval. The modification resulted in stock-based compensation expense of $0.5 million during the three months ended September 30, 2019.   The Company’s Board of Directors adopted the Paratek Pharmaceuticals, Inc. 2015 Inducement Plan, or the 2015 Inducement Plan, in accordance with Nasdaq Rule 5635(c)(4), reserving 360,000 shares of common stock solely for the grant of inducement stock options to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company. The Company has not made any grants under the 2015 Inducement Plan since December 31, 2015. Although the Company does not currently anticipate the issuance of additional grants under the 2015 Inducement Plan, as of September 30, 2019, 306,500 shares remain available for grant under that plan, as well as any shares underlying outstanding stock options that may become available for grant pursuant to the plan’s terms. It is therefore possible that the Company may, based on the business and recruiting needs of the Company, issue additional stock options under the 2015 Inducement Plan.    In June 2017, the Company’s Board of Directors adopted the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, or the 2017 Inducement Plan, in accordance with Nasdaq Rule 5635(c)(4), reserving 550,000 shares of common stock solely for the grant of inducement stock options and RSU awards to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company. In October 2018, the Company’s Board of Directors approved the reserve of an additional 500,000 shares for the 2017 Inducement Plan, for a total of 1,050,000 shares reserved for issuance under it. During the nine months ended September 30, 2019, the Company’s Board of Directors granted 130,500 stock options and 57,600 RSUs to employees of the Company under the 2017 Inducement Plan. The stock option awards are subject to time-based vesting over a period of one to four years. The RSU awards are generally subject to time-based vesting, with 100% of the shares of common stock subject to the RSU award vesting three years from the grant date. As of September 30, 2019, 403,624 shares remain available for grant under the 2017 Inducement Plan, as well as any shares underlying awards that may become available for grant pursuant to the plan’s terms. Stock Options   A summary of stock option activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,777,162</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.65</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">506</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,710</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled or forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(670,770</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,293,102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.57</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.53</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,768,725</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.16</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Restricted Stock Units A summary of RSU activity for the nine months ended September 30, 2019 is as follows:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,470,237</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.28</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,269,340</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186,296</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.06</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(597,523</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,955,758</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.14</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Total unrecognized stock-based compensation expense for all stock-based awards was $16.8 million as of September 30, 2019. This amount will be recognized over a weighted-average period of 1.72 years.   2018 Employee Stock Purchase Plan  The Company’s Board of Directors adopted, and in June 2018 Company’s stockholders approved, the Paratek Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, or the 2018 ESPP. The 2018 ESPP was amended in October 2018 to change the commencement dates of the offering periods. The maximum aggregate number of shares of our common stock that may be purchased under the 2018 ESPP is 943,294 shares, or the ESPP Share Pool, subject to adjustment as provided for in the 2018 ESPP.  The ESPP Share Pool represented 3% of the total number of shares of our common stock outstanding as of March 31, 2018. The 2018 ESPP allows eligible employees to purchase shares during certain offering periods, which will be six -month periods commencing June 1 and ending November 30 and commencing December 1 and ending May 31 of each year. The first offering under the 2018 ESPP occurred on December 1, 2018. As of September 30, 2019, 884,621 shares remained available for issuance. During the nine months ended September 30, 2019, the Company issued 95,212 shares of common stock and recognized approximately $0.3 million in related stock-based compensation expense.    Revenue Performance Incentive Plan   On October 4, 2018, the Company adopted the Revenue Performance Incentive Plan, or the Plan, to grant performance-based cash incentive awards to key employees and consultants of the Company.  The Plan provides for an incentive pool of up to $50.0 million, plus accrued interest during the period between the awards’ vesting date and payment dates.  Each participant will be allocated a percentage of the incentive pool.   The incentive pool will be divided into two equal tranches with the first tranche vesting upon the Company’s achievement of cumulative net product revenues over $300.0 million by December 31, 2025, or Tranche 1, and the second tranche vesting upon the Company’s achievement of cumulative product revenues over $600.0 million by December 31, 2026, or Tranche 2.  Participants will vest annually in each tranche of their awards in four equal installments on December 31, 2019, December 31, 2020, December 31, 2021, and December 31, 2022, subject to their continued employment with the Company through the applicable vesting date.  If a participant’s employment terminates prior to December 31, 2022 due to death or disability, the participant will automatically vest in an additional 25% of each tranche of his or her award.  Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant who has remained in continuous employment with the Company through December 31, 2022 will be 100% vested in the applicable tranche. In the event of a change of control of the Company prior to December 31, 2026, participants whose employment has terminated prior to such date will be eligible for payouts under the Plan based on the then-vested portion of their awards, and participants who have remained employed through the change of control will be deemed to have time vested in full in each tranche of their awards.   Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant’s payout in respect of the applicable tranche of his or her award will equal (a) the participant’s then-vested percentage, multiplied by (b) $25 million, multiplied by (c) the participant’s individual percentage allocation of the incentive pool.   If a change of control occurs prior to December 31, 2026, and the Tranche 1 milestone was not achieved prior to the change of control, the Tranche 1 milestone will be deemed to be achieved at a percentage equal to the greater of (1) 50% and (2) the cumulative product revenues as of the change of control, divided by $300.0 million.  If a change of control occurs prior to December 31, 2026, and the Tranche 2 milestone was not achieved prior to the change of control, the Tranche 2 milestone will be deemed to be achieved at a percentage equal to the greater of (1) 30% and (2) the cumulative product revenues as of the change of control, divided by $600.0 million.  A participant’s payout in respect of each tranche of his or her award in a change of control will equal (1) the participant’s then-vested percentage of such tranche, multiplied by (2) the percentage of that tranche’s milestone that has been achieved or is deemed to have been achieved, multiplied by (3) $25.0 million, multiplied by (4) the participant’s individual percentage allocation of the incentive pool.   Amounts that become payable upon achievement of the Tranche 1 milestone will be paid in a lump-sum in the first quarter of 2026 and amounts that become payable upon achievement of the Tranche 2 milestone will be paid in a lump-sum in the first quarter of 2027.  In the event of a change of control, any portion of the incentive pool that is earned, but unpaid, or deemed earned in connection with the change of control will be paid at the time of the change of control.   If a change of control occurs prior to the achievement of either or both of the Tranche 1 and Tranche 2 milestones, the awards will remain outstanding and the remaining unpaid portion of the incentive pool applicable to the Tranche 1 or Tranche 2 milestone, as applicable, will be paid following the achievement of either such milestone at the time or times the bonuses would otherwise be paid out.  Any successor in interest to the Company upon or following a change of control will be required to assume all obligations under the Plan.   Awards may be paid out in cash or in a combination of cash and registered securities of equal value (based on the Company’s 20-day trailing average closing common stock price), with the portion paid in registered securities not to exceed 50% of the aggregate payment amount with respect to each tranche; provided, however, that any amounts payable with respect to an award in connection with a change in control will be paid in cash.   <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize the compensation cost over the requisite service period, to the extent achievement of the performance condition is deemed probable relative to targeted performance. The performance condition is not yet deemed probable; as such, no amounts were accrued under the Plan during the nine months ended September 30, 2019.

13.   Long-Term Debt Hercules Loan Agreement                   On June 27, 2019, the Company entered into an Amended and Restated Loan and Security Agreement, or the Loan Agreement, with Hercules Technology III, L.P., certain other lenders, together, the Lenders, and Hercules Capital, Inc. (as agent), under which the Company may borrow up to $100.0 million in multiple tranches, each, a Term Loan Tranche. The Loan Agreement amends and restates in its entirety the Company’s prior Loan and Security Agreement with the Lenders dated as of September 30, 2015 to, among other things, provide for an extension of the scheduled maturity date of the $60.0 million Term Loan Tranche, or the First Tranche, from September 1, 2021 to September 1, 2023, upon certain events set forth in the Loan Agreement, and an extension of the scheduled maturity date of the $10.0 million Term Loan Tranche, or the Second Tranche, and additional Term Loan Tranches (if any), from August 1, 2022 to August 1, 2024, upon certain events set forth in the Loan Agreement. The Loan Agreement also provides for an additional $10.0 million of additional Term Loan Tranches (up to a total of $30.0 million of additional Term Loan Tranches) that may be available to the Company, subject to approval by Hercules, in its sole discretion, whether to provide such tranches. As such there can be no assurance as to whether or not the additional Term Loan Tranches shall be funded. The interest rate with respect to the First Tranche is a floating per annum rate equal to the greater of (i) 8.50% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.75%, and (ii) 8.50%. The interest rate with respect to the Second Tranche is, and the interest rate with respect to additional Term Loan Tranches (if any) will be, a floating per annum rate equal to the greater of (i) 7.85% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.75%, and (ii) 7.85%. An end of term charge equal to 4.5% with respect to $50.0 million of the First Tranche and equal to 2.25% with respect to the remaining $10.0 million of the First Tranche, and an end of term charge equal to 6.95% of the Second Tranche, and the Additional Term Loan Tranches (if any), of the issued principal balance of the term loans is payable at maturity, including in the event of any prepayment, and is being accrued as interest expense over the term of the term loans using the effective interest method. Payments under the Loan Agreement with respect to the First Tranche are interest only until January 1, 2021, followed by equal monthly payments of principal and interest through the scheduled maturity date. Payments under the Loan Agreement with respect to the Second Tranche are, and with respect to additional Term Loan Tranches (if any) will be, interest only until January 1, 2021 (which can be extended to May 1, 2021 or September 1, 2021, upon certain events set forth in the Loan Agreement), followed by equal monthly payments of principal and interest through the scheduled maturity date. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its and Paratek Pharma, LLC’s assets, other than intellectual property. If the Company prepays the loan prior to maturity, it will pay the Lenders a prepayment charge, based on a percentage of the then outstanding principal balance, equal to 1.75% if the prepayment occurs prior to January 1, 2020, or equal to 0% if the prepayment occurs on or after January 1, 2020. The Loan Agreement includes customary affirmative and restrictive covenants, including a liquidity covenant and a covenant against suffering a “change of control,” and also includes customary events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of Lenders’ security interest or in the value of the collateral, cross acceleration to the debt and certain events relating to bankruptcy or insolvency. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the assets of the Company. Upon an Event of Default, an additional 5.0% interest would be applied, and Hercules could, at its option, accelerate and demand payment of all or any part of the term loans together with the prepayment and end of term charges. An Event of Default is defined in the Hercules Loan Agreement as (i) failure to make required payments; (ii) failure to adhere to financial, operating and reporting loan covenants; (iii) an event or development occurs that would be reasonably expected to have a material adverse effect; (iv) false representations in the Hercules Loan Agreement; (v) insolvency, as described in the Hercules Loan Agreement; (vi) levy or attachments on any of the Company's assets; and (vii) default of any other agreement or subordinated debt greater than $1.0 million. In the event of insolvency, this acceleration and declaration would be automatic. In addition, in connection with the Hercules Loan Agreement, the Company agreed to provide Hercules with a contingent security interest in the Company's bank accounts. The Company's control of its bank accounts is not adversely affected unless Hercules elects to obtain unilateral control of the Company's bank accounts by declaring that an Event of Default has occurred. The principal of the term loans, which is not due within 12 months of September 30, 2019, has been classified as long-term debt. The Company recognized interest expense of $1.7 and $5.1 million for the three and nine months ended September 30, 2019, respectively.   The following table summarizes the impact of the Hercules Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross proceeds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(423</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(606</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,577</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,394</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.   <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan Agreement as of September 30, 2019 are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal Year</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,835</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,165</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> Convertible Senior Subordinated Notes On April 18, 2018, the Company entered into a Purchase Agreement, or the Purchase Agreement, with several initial purchasers, or the Initial Purchasers, for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Partners LLC acted as representatives, relating to the sale of $135.0 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2024, or the Notes, to the Initial Purchasers. The Company also granted the Initial Purchasers an option to purchase up to an additional $25.0 million aggregate principal amount of Notes, which was exercised in full on April 20, 2018. The Purchase Agreement includes customary representations, warranties and covenants. Under the terms of the Purchase Agreement, the Company agreed to indemnify the Initial Purchasers against certain liabilities. In addition, J. Wood Capital Advisors LLC, the Company’s financial advisor, purchased $5.0 million aggregate principal amount of Notes in a separate, concurrent private placement on the same terms as other investors. The Notes were issued by the Company on April 23, 2018, pursuant to an Indenture, dated as of such date, or the Indenture, between the Company and U.S. Bank National Association, as trustee, or the Trustee. The Notes bear cash interest at the annual rate of 4.75%, payable on November 1 and May 1 of each year, beginning on November 1, 2018, and mature on May 1, 2024 unless earlier repurchased, redeemed or converted.  The Company will settle conversions of the Notes through delivery of shares of common stock of the Company, in accordance with the terms of the Indenture. The initial conversion rate for the Notes is 62.8931 shares of common stock (subject to adjustment as provided for in the Indenture) per $1,000 principal amount of the Notes, which is equal to an initial conversion price of approximately $15.90 per share, representing a conversion premium of approximately 20% above the closing price of the common stock of $13.25 per share on April 18, 2018. Holders of the Notes may convert all or any portion of their Notes, in multiples of $1,000 principal amount, at their option at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date. The Company may not redeem the Notes prior to May 6, 2021. The Company may redeem for cash all or part of the Notes, at its option, on or after May 6, 2021 if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company experiences a fundamental change, as described in the Indenture, prior to the maturity date of the Notes, holders of the Notes will, subject to specified conditions, have the right, at their option, to require the Company to repurchase for cash all or a portion of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date of the Notes and following a notice of redemption of the Notes, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event or redemption. The Indenture provides for customary events of default. In the case of an event of default with respect to the Notes arising from specified events of bankruptcy or insolvency, all outstanding Notes will become due and payable immediately without further action or notice. If any other event of default with respect to the Notes under the Indenture occurs or is continuing, the Trustee or holders of at least 25% in aggregate principal amount of the then outstanding Notes may declare the principal amount of the Notes to be immediately due and payable. After deducting costs incurred of $6.0 million, the Company raised net proceeds from the issuance of long-term convertible debt of $159.0 million in April 2018. All costs were deferred and are being amortized over the life of the Notes at an effective interest rate of 5.47% and recorded as additional interest expense. The Company recognized coupon interest expense of $2.0 million and $5.9 million, and amortization expense on the debt issuance costs of $0.2 million and $0.6 million, for the three and nine months ended September 30, 2019, respectively. The Company has evaluated the Indenture for derivatives pursuant to ASC 815, Derivatives and Hedging, or ASC 815, and identified an embedded derivative that requires bifurcation as the feature is not clearly and closely related to the host instrument. The embedded derivative is a default provision, which could require additional interest payments. The Company determined in the prior year that the fair value of this embedded derivative was nominal. The Company evaluated the conversion feature and determined it was not within the scope of ASC 815 and therefore is not required to be accounted for separately. The Company concluded that the embedded conversion option is not subject to separate accounting pursuant to either the cash conversion guidance or the beneficial conversion feature guidance.  Under the general conversion guidance in ASC 470, Debt, all of the proceeds received from the Notes was recorded as a liability on the condensed consolidated balance sheet. The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross proceeds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,762</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,238</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,566</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Royalty-Backed Loan Agreement On February 25, 2019, the Company, through its wholly-owned subsidiary Paratek Royalty Corporation, or the Subsidiary, entered into a royalty-backed loan agreement, or the Royalty-Backed Loan Agreement, with Healthcare Royalty Partners III, L.P., or HCRP. Pursuant to the terms of the Royalty-Backed Loan Agreement, upon the satisfaction of the conditions precedent set forth therein, the Subsidiary borrowed a $32.5 million loan, which was secured by, and will be repaid based upon, royalties from the Almirall Collaboration Agreement. On May 1, 2019, the Company received $27.8 million, net of $0.5 million lender discount, $0.2 million in lender expenses incurred, and $4.0 million that was deposited into an interest reserve account. The Company also paid $1.2 million in other lender fees related to the Royalty-Backed Loan Agreement. During the three months ended September 30, 2019, the Company paid $1.0 million to HCRP based upon royalties earned from the Almirall Collaboration Agreement and outstanding interest payments due to HCRP. Under the Royalty-Backed Loan Agreement, the outstanding principal balance will bear interest at an annual rate of 12.0%.  Payments of interest under the Royalty-Backed Loan Agreement are made quarterly out of the Almirall Collaboration Agreement royalty payments received since the immediately preceding payment date. On each interest payment date, any royalty payments in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid.  In addition, the Subsidiary made up-front payments to HCRP of (i) a 1.5% fee and (ii) up to $300,000 for HCRP’s expenses. The Royalty-Backed Loan Agreement matures on May 1, 2029, at which time, if not earlier repaid in full, the outstanding principal amount of the loan, together with any accrued and unpaid interest, and all other obligations then outstanding, shall be due and payable in cash. The Company has entered into a Pledge and Security Agreement in favor of HCRP, pursuant to which the Subsidiary’s obligations under the Loan Agreement are secured by a pledge of all of the Company’s holdings of the Subsidiary’s capital stock. The Royalty-Backed Loan Agreement contains certain customary affirmative covenants, including those relating to: use of proceeds; maintenance of books and records; financial reporting and notification; compliance with laws; and protection of Company intellectual property. The Royalty-Backed Loan Agreement also contains certain customary negative covenants, barring the Subsidiary from: certain fundamental transactions; issuing dividends and distributions; incurring additional indebtedness outside of the ordinary course of business; engaging in any business activity other than related to the Almirall Collaboration Agreement; and permitting any additional liens on the collateral provided to HCRP under the Royalty-Backed Loan Agreement. The Royalty-Backed Loan Agreement contains customary defined events of default, upon which any outstanding principal and unpaid interest shall be immediately due and payable. These include: failure to pay any principal or interest when due; any uncured breach of a representation, warranty or covenant; any uncured failure to perform or observe covenants; any uncured cross default under a material contract; any uncured breach of the Company’s representations, warranties or covenants under its Contribution and Servicing Agreement with the Subsidiary; any termination of the Almirall Collaboration Agreement; and certain bankruptcy or insolvency events.  The Company recognized interest expense of $1.0 and $1.6 million for the three and nine months ended September 30, 2019, respectively. The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross proceeds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,905</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,595</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Long-term debt on the Company’s consolidated balance sheets at September 30, 2019 includes the carrying value of the Hercules Loan Agreement, the Notes and the Royalty-Backed Loan Agreement. Long-term debt on the Company’s consolidated balance sheet at December 31, 2018 includes the carrying value of the Hercules Loan Agreement and the Notes.

14. Leases   Operating Leases The Company leases its Boston, Massachusetts and King of Prussia, Pennsylvania office spaces under non-cancelable operating leases expiring in 2021 and 2024, respectively. The Company entered into the original King of Prussia and Boston leases in January 2015 and April 2015, respectively. The lease terms under the original agreements were for six and four years, respectively. Each agreement had one renewal option for an extended term, which are not included in the measurement of these leases as these options are not reasonably certain to be exercised. The King of Prussia and Boston lease terms under the original agreements began in June 2015 and July 2015, respectively.   The Company executed an amended lease agreement on its Boston office space in July 2016. The amended lease agreement added 4,153 rentable square feet of office space and extended the original lease term by two years. In accordance with the amended lease agreement, the Company paid a security deposit of $0.1 million. Subsequent to the amended lease agreement, the Company records monthly lease expense of approximately $49,000 for the Boston office space. In applying the ASC 842 transition guidance, the Company retained the classification of this lease to be operating and recorded a lease liability and a right-of-use asset on the ASC 842 effective date. The Company executed an amended lease agreement on its King of Prussia office space in October 2016.  The amended lease agreement is for 19,708 rentable square feet of office space and the Company took control of this office space during the first quarter of 2017. The amended lease agreement contains rent escalation and a partial rent abatement period, which is accounted for as rent expense under the straight-line method. In applying the ASC 842 transition guidance, the Company retained the classification of this lease to be operating and recorded a lease liability and a right-of-use asset on the ASC 842 effective date. The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost (in thousands)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost (in thousands)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">765</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">852</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">770</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of September 30, 2019, are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liabilities (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,178</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">518</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024 and thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(580</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,275</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The total operating liability is presented on the Company’s condensed consolidated balance sheet based on maturity dates. $0.9 million of the total operating liabilities is classified under “other current liabilities” for the portion due within twelve months, and $2.3 million is classified under “long-term lease liability”.   The Company is party to a manufacturing and services agreement for which space within the manufacturing facility will be leased. This lease has not yet commenced as of the reporting date and is not included in the maturity table above.

Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America, or U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASU, of the Financial Accounting Standards Board, or FASB, and pursuant to the rules and regulations of the SEC.   The accompanying condensed consolidated financial statements are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2018, except as described below related to Note 10, Other Accrued Expenses, and the adoption of ASU No. 2018-07 and ASC 842, and, in the opinion of management, reflect all normal recurring adjustments necessary for the fair presentation of the Company’s financial position as of September 30, 2019, results of operations for the three month and nine month periods ended September 30, 2019, cash flows for the nine month period ended September 30, 2019 and changes in stockholders’ equity (deficit) for the three month and nine month periods ended September 30, 2019. Beginning on April 1, 2019, the Company presented “accrued interest” as a separate line item in Note 10, Other Accrued Expenses. The Company reclassified accrued interest of $1.8 million as of December 31, 2018, previously presented as part of “accrued professional fees” into “accrued interest” in Note 10, Other Accrued Expenses. On December 31, 2018, the Company presented “accrued contract manufacturing costs” as a separate line item on its consolidated balance sheet. Beginning on January 1, 2019, the Company reclassified the December 31, 2018 accrued contract manufacturing costs balance of $2.8 million, into “other accrued expenses”. Also, beginning on January 1, 2019, the Company reclassified inventories of $0.6 million as of December 31, 2018 previously presented as part of “prepaid and other current assets” into “inventories” on the condensed consolidated balance sheet. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2018, and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 6, 2019.

Accounts Receivable, Net Accounts receivable as of September 30, 2019 represents trade accounts receivable of $3.2 million consisting of payments to be received from customers for sales of NUZYRA, net of prompt payment discounts, chargebacks, rebates and certain fees. An additional $0.7 million in accounts receivable consists of royalty revenue earned, but not yet received, during the three months ended September 30, 2019 in connection with SEYSARA sales under the Company’s collaboration agreement with Almirall. Refer to Note 8, License and Collaboration Agreements, for further details.

Leases Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases, or ASC 842, using the required modified retrospective approach and utilizing the effective date as its date of initial application. Results and disclosure requirements for reporting periods after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under Topic 840. The adoption of ASC 842 resulted in changes to the Company’s accounting policies for leases previously recognized under ASC 840, as detailed below. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of a distinct identified asset(s) and the Company’s control over the use of that identified asset. Most leases are recognized on the balance sheet as right-of-use assets and lease liabilities, current and non-current, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. These lease costs will be expensed as incurred. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.  The Company monitors its plans to renew its material leases on a quarterly basis. Right-of-use assets and lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received or initial direct costs. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.).  The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is otherwise required, certain expedients are available. Entities may elect to not separate lease and non-lease components by class of underlying asset and account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for each lease component and related non-lease component as a single lease component and allocate all of the contract consideration to the lease component only.

Product Revenue The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the United States. These customers subsequently resell the Company’s product to health care providers or dispense the product to patients. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of our product.   Revenues from product sales are recognized when the customer obtains control of the Company’s product, which typically occurs once the company has transferred physical possession of the good to the customer.  The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration based on the Company’s estimates of channel mix. The types of variable consideration in our product revenue are as follows:   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Trade discounts and allowances</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Product returns</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Chargebacks and rebates</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Government rebates</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Commercial payer and other rebates</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> Voluntary patient assistance programs</td></tr></table></div>   In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. Making these determinations involves analyzing third party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration.     The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> a)</td> <td valign="top"> The “expected value” is the sum of probability-weighted amounts in a range of possible consideration amounts. Under ASC Topic 606, Revenue from Contracts with Customers, or Topic 606, an expected value may be an appropriate estimate of the amount of variable consideration if the Company has many contracts with similar characteristics.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> b)</td> <td valign="top"> The “most likely amount” is the single most likely amount in a range of possible consideration amounts (i.e., the single most likely outcome of the contract). Under Topic 606, the most likely amount may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes (i.e., either achieve or do not achieve a threshold specified in a contract).</td></tr></table></div>   The method selected is applied consistently throughout the contract when estimating the effect of an uncertainty on an amount of variable consideration. In addition, the Company considers all the information (historical, current, and forecasted) that is reasonably available to the Company and shall identify a reasonable number of possible consideration amounts. The relevant factors used in this determination include, but are not limited to, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns.   In assessing whether a constraint is necessary, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows:   Trade Discounts and Allowances - The Company generally provides customers with discounts that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.  In addition, the Company receives sales order management, data and distribution services from certain customers.  To the extent the services received are distinct from the Company’s sale of products to the customer, these payments are classified in selling, general and administrative expenses in the condensed consolidated statements of operation and comprehensive loss of the Company.   Product Returns – Generally, the Company’s customers have the right to return any unopened/unused product supply during the 18-month period beginning six months prior to the labeled expiration date and ending 12 months after the labeled expiration date. Since the Company currently does not have history of NUZYRA returns, the Company estimated returns based on industry data for comparable products in the market. As the Company distributes its product and establish historical sales over a longer period of time (i.e., two years), the Company will be able to place more reliance on historical purchasing, demand and return patterns of its customers when evaluating its reserves for product returns.   At the end of each reporting period for any of our products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products.   Chargebacks – Although the Company primarily sells products to specialty distributors in the United States, the Company also enters into agreements with hospitals and outpatient infusion centers, either directly or through group purchasing organizations acting on behalf of their members, in connection with the purchase of product. Based on these agreements, some of the Company’s customers have the right to receive a discounted price on product purchases. In the case of discounted pricing, the Company typically provides a credit to our specialty distributors customers (i.e., chargeback), representing the difference between the customer’s acquisition list price and the discounted price.   Government Rebates –We are subject to discount obligations under state Medicaid programs and Medicare.  We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix.  These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.  For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.  Our liability for these rebates consists of an estimate of claims for the current quarter and estimated future claims that will be made for product sales that have been recognized as revenue but remain in distribution channel inventory at period end.   Commercial Payer and Other Rebates – The Company plans to contract with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of NUZYRA and contracted formulary status. The Company estimates these rebates and records reserves for such estimates in the same period the related revenue is recognized. Currently, the reserve for customer payer rebates considers future utilization based on third party studies of payer prescription data; the utilization is applied to product that remains in the distribution and retail pharmacy channel inventories at the end of each reporting period. As the Company distributes its product and establishes historical sales over a longer period of time (i.e., two years), the Company will be able to place more reliance on historical data related to commercial payer rebates (i.e., actual utilization units) while continuing to rely on third party data related to payer prescriptions and utilization.   Patient Assistance – The Company offers certain voluntary patient assistance programs for prescriptions, such as co-pay assistance programs, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product sale that has been recognized as revenue but remains in the distribution and pharmacy channel inventories at the end of each reporting period.   At the end of each reporting period, the Company adjusts its allowances for cash discounts, product returns, chargebacks, and other rebates and discounts when the Company believes actual experience may differ from current estimates.   The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">discounts and <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">fees</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">rebates</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patient <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assistance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to current period sales</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">995</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment related to prior period sales</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit or payments made during the period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(272</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(309</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(597</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Contract costs The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any significant incremental costs of obtaining a contract with a customer.

Use of Estimates The preparation of the accompanying unaudited condensed consolidated financial statements, in conformity with U.S. GAAP, requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent liabilities in the Company’s financial statements. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to, among other items, accounts receivable and related reserves, inventory, intangible assets, goodwill, leases, stock-based compensation arrangements, manufacturing and clinical accruals, net product revenue, useful lives for depreciation and amortization of long-lived assets and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known by the Company’s management.

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">discounts and <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">fees</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">rebates</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patient <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assistance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to current period sales</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">995</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment related to prior period sales</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit or payments made during the period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(272</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(309</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(597</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following is a summary of available-for-sale securities as of September 30, 2019 and December 31, 2018 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,582</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,582</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,979</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(193</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,979</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(193</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statement of cash flows that sum to the total of the same such amounts shown in the condensed consolidated statement of cash flows. <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,907</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,117</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term restricted cash</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term restricted cash</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,947</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   on the condensed consolidated statement of cash flows</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,642</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,633</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table presents inventories (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,705</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,826</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Fixed assets, net, consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">866</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">866</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">909</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross fixed assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,180</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,985</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,213</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,812</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net fixed assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">967</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,173</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following outstanding shares subject to stock options and restricted stock units, warrants to purchase shares of common stock, common stock issuable upon conversion of convertible debt and shares issuable under the employee stock purchase plan were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation as of the three and nine months ended September 30, 2019 and 2018 as indicated below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excluded potentially dilutive securities (1):</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issuable under outstanding convertible <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   notes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,377,361</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,377,361</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to outstanding options to purchase <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,293,102</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,762,912</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,955,758</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,937,512</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to warrants to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,455</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,455</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable under employee stock purchase plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,621</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">979,833</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,615,297</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,162,073</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.44%;white-space:nowrap"> (1)</td> <td valign="top"> The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of September 30, 2019. Such amounts have not been adjusted for the treasury-stock method or weighted-average outstanding calculations as required if the securities were dilutive.</td></tr></table></div>

Other accrued expenses consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">809</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,529</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,199</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contract research</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,514</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,747</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued commercial</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,330</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,280</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued manufacturing</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,408</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,784</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales allowances</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued inventory</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,042</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,619</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Fair values determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities or other inputs that are observable market data. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability (in thousands):     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,730</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,851</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Stock-based Compensation   The following table presents stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,442</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,868</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,264</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,642</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,874</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,499</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,824</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,084</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,742</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,955</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The weighted-average assumptions used to determine the fair value of the stock option grants is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,777,162</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.65</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">506</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,710</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled or forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(670,770</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,293,102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.57</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.53</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,768,725</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.16</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,470,237</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.28</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,269,340</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186,296</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.06</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(597,523</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,955,758</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.14</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes the impact of the Hercules Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross proceeds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(423</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(606</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,577</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,394</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan Agreement as of September 30, 2019 are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal Year</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,835</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,165</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross proceeds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,762</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,238</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,566</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross proceeds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,905</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,595</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost (in thousands)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost (in thousands)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">765</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">852</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">770</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of September 30, 2019, are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liabilities (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,178</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">518</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024 and thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(580</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,275</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

225600000

2800000 600000

1813000

3200000

700000

514 995 149 249 1907 272 309 16 597 242 686 149 233 1310

120582000

245979000

155000

65000

7000

193000

120730000

245851000

0 0 0 0

89117000

266000

250000

300000

300000 4000000 800000

300000

2600000

8705000

598000

121000

866000

412000

798000

920000

909000

184000

3180000

2985000

2213000

1812000

10377361

3293102

3762912

2955758

1937512

104455

884621

979833

17615297

17162073

2023-10 2023-10

22500

100000

7500000

9000000 40500000 5000000 3000000 P11Y 2

7500000

5000000

4000000

1000000

2500000

4000000

5000000

12000000

800000

1400000

100000 1024 300000 50000 100000 150000 25000 0.10 0.14

46000

100000

P60D 0.0025 P10Y 3500000 3600000 100000 50000000 0.03 50000000 0.03

50000000

2102315

47700000

1500000

50000000 0.03

360575

1900000

100000

48000000 0.05

9614

0.15

2021

5120

73.66

2016-04

16346

P5Y

16346

P5Y

32692

24.47

18574

37148

13.46

5374

23.26

19627

10.19

The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years (or seven years, in the case of the Fifth Amendment Warrant) from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the various agreements for the Warrants. P5Y P7Y 271000 366000 54000 809000

754000

750000

5529000

6070000

4199000

3514000 1747000

2330000

1280000

1408000 2784000

1310000

673000

187500000

120730000

245851000

560000

1442000

2868000

4456000

3264000

2642000

7874000

8499000

3824000

4084000

10742000

12955000

0.633

0.674

0.020

0.027

0.000

P5Y10M24D

1200000

The Share Reserve automatically increases on January 1st of each year, for the period commencing on (and including) January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year.

1612969

0.05

501818

56210

2211740

P1Y

P4Y

0.25 0.375 3

P1Y

0.417 0.417 0.167

800000

0.182 0.364 0.454

500000

360000

306500

550000

500000

130500

57600

P1Y

P4Y

1.00

P3Y

403624

1050000

3777162

186710

670770

3293102

2768725

16.65

15.57

16.13

P7Y1M6D

P6Y6M10D

P6Y1M28D

506000

126000

12000

1470237

2269340

186296

597523

2955758

15.28

6.01

14.06

10.84

9.14

16800000

P1Y8M19D

943294

0.03

P6M The 2018 ESPP allows eligible employees to purchase shares during certain offering periods, which will be six -month periods commencing June 1 and ending November 30 and commencing December 1 and ending May 31 of each year 2018-12-01

884621

95212

300000

50000000 2 300000000 600000000 4 4 If a participant’s employment terminates prior to December 31, 2022 due to death or disability, the participant will automatically vest in an additional 25% of each tranche of his or her award. 0.25 1.00 Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant’s payout in respect of the applicable tranche of his or her award will equal (a) the participant’s then-vested percentage, multiplied by (b) $25 million, multiplied by (c) the participant’s individual percentage allocation of the incentive pool 25000000 0.50 300000000 0.30 600000000 25000000 25000000 0.50 0

100000000

60000000

2021-09-01

2023-09-01

10000000

2022-08-01

2024-08-01

10000000 10000000 10000000

0.0850

0.0785

0.0575

2021-01-01 2021-01-01

(which can be extended to May 1, 2021 or September 1, 2021, upon certain events set forth in the Loan Agreement), followed by equal monthly payments of principal and interest through the scheduled maturity date.

0.045

50000000

0.0225

10000000

0.0695 0.0175 0.00 0.05 0.050 1000000

1700000

5100000

70000000

423000

606000

69577000

69394000

65835000

4165000

135000000

0.0475

25000000

5000000

payable on November 1 and May 1 of each year, beginning on November 1, 2018

2018-11-01

2024-05-01

62.8931

1000

15.90

0.20 13.25

1.30

1.00

0.25

159000000

6000000

0.0547

2000000 5900000

200000

600000

165000000

4762000

5434000

160238000

159566000

32500000

27800000

500000 200000

1200000

1000000

0.120

0.015

300000

2029-05-01

1000000

1600000

32500000

1905000

30595000

2021 2024

P6Y

P4Y

2015-06 2015-07 2016-07 4153

P2Y

100000

49000 2016-10 19708

255000

43000

298000

289000

765000

87000

852000

770000

P3Y9M18D

0.0875

291000

1178000

964000

508000

518000

396000

3855000

580000

3275000

900000

3700000

3200000

EX-101.SCH 7 prtk-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Description of the Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Cash and Cash Equivalents and Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Restricted Cash link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Inventories, Net link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Fixed Assets, Net link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Capital Stock link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Other Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Stock-Based and Incentive Compensation link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Cash and Cash Equivalents and Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Restricted Cash (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Inventories, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Fixed Assets, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Other Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stock-Based and Incentive Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Description of the Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Summary of Product Revenue Allowance and Reserve Categories (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Summary of Available for Sale Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Condensed Consolidated Statement of Cash Flows (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Restricted Cash - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Inventories, Net - Schedule of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Fixed Assets, Net - Schedule of Fixed Assets, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Net Loss Per Share - Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Capital Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Other Accrued Expenses - Schedule of Other Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stock-Based and Incentive Compensation - Summary of Stock-Based Compensation Expense Included in Company's Condensed Consolidated Statements of Operations and Comprehensive loss (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stock-Based and Incentive Compensation - Schedule of Share-based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Stock-Based and Incentive Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, RSU, Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Long-Term Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Long-Term Debt - Summary of Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Leases - Summary of Lease Costs Recognized Under Topic 842 and Other Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Leases - Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Leases - Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases (Detail)2 link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 prtk-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 prtk-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 prtk-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Available For Sale Securities Debt Securities Current Restricted cash Restricted Cash Current Accounts receivable, net Accounts Receivable Net Current Inventories, net Inventory Net Other receivables Other Receivables Net Current Prepaid and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Long-term restricted cash Restricted Cash Noncurrent Long-term marketable securities Available For Sale Securities Debt Securities Noncurrent Fixed assets, net Property Plant And Equipment Net Goodwill Goodwill Right-of-use asset Operating Lease Right Of Use Asset Other long-term assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity (Deficit) Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Other accrued expenses Other Accrued Liabilities Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Long-term debt Long Term Debt Noncurrent Long-term lease liabilities Operating Lease Liability Noncurrent Other liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 16) Commitments And Contingencies Stockholders’ equity (deficit) Stockholders Equity [Abstract] Undesignated preferred stock: $0.001 par value; 5,000,000 authorized; no shares issued and outstanding Preferred Stock Value Common stock, $0.001 par value, 100,000,000 shares authorized, 32,901,446 and 32,259,363 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity (deficit) Stockholders Equity Total liabilities and stockholders’ equity (deficit) Liabilities And Stockholders Equity Undesignated preferred stock, par value Preferred Stock Par Or Stated Value Per Share Undesignated preferred stock, shares authorized Preferred Stock Shares Authorized Undesignated preferred stock, shares issued Preferred Stock Shares Issued Undesignated preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Product Revenue, Net [Member] Product [Member] Collaboration and royalty revenue. Collaboration and Royalty Revenue [Member] Collaboration And Royalty Revenue [Member] Statement [Line Items] Statement [Line Items] Net revenue Revenue From Contract With Customer Excluding Assessed Tax Expenses: Operating Expenses [Abstract] Cost of product revenue Cost Of Revenue Research and development Research And Development Expense Excluding Acquired In Process Cost Selling, general and administrative Selling General And Administrative Expense Impairment of intangible asset Impairment Of Intangible Assets Finitelived Changes in fair value of contingent consideration Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 Total operating expenses Costs And Expenses Loss from operations Operating Income Loss Other income and expenses: Other Income And Expenses [Abstract] Interest income Investment Income Interest Interest expense Interest Expense Other gains (losses), net Other Nonoperating Income Expense Net loss before provision for income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit Net loss Net Income Loss Other comprehensive income (loss): Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized gain (loss) on available-for-sale securities, net of tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Basic and diluted net loss per share Earnings Per Share Basic And Diluted Weighted average common stock outstanding Basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Increase (decrease) in operating lease right-of-use asset. Increase (decrease) in operating lease liability. Proceeds from maturities of marketable securities. Statement Of Cash Flows [Abstract] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Convertible Debt [Member] Convertible Debt [Member] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Royalty backed loan agreement. Royalty Backed Loan Agreement [Member] Royalty Backed Loan Agreement [Member] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation, amortization and accretion Depreciation Amortization And Accretion Net Stock-based compensation expense Share Based Compensation Noncash interest expense Paid In Kind Interest Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Accounts receivable and other current assets Increase Decrease In Accounts Receivable And Other Operating Assets Purchase of prepaid interest - marketable securities Increase Decrease In Prepaid Interest Inventories Increase Decrease In Inventories Operating lease right-of-use asset Increase Decrease In Operating Lease Right Of Use Asset Accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities Operating lease liability Increase Decrease In Operating Lease Liability Other liabilities and other assets Increase Decrease In Other Operating Capital Net Net cash used in operating activities Net Cash Provided By Used In Operating Activities Investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchase of fixed assets Payments To Acquire Productive Assets Purchase of marketable securities Payments To Acquire Marketable Securities Proceeds from maturities of marketable securities Proceeds From Maturities Of Marketable Securities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from the issuance of long-term debt, net of costs Proceeds From Issuance Of Long Term Debt Proceeds from the employee stock purchase plan Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Proceeds from exercise of stock options Proceeds From Stock Options Exercised Proceeds from sale of common stock, net of costs Proceeds From Issuance Of Common Stock Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Purchases of equipment included in accounts payable and accrued expenses Capital Expenditures Incurred But Not Yet Paid Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Other Comprehensive Income [Member] Accumulated Deficit [Member] Retained Earnings [Member] Beginning balance Beginning balance, shares Shares Issued Issuance of common stock, net of expenses Stock Issued During Period Value New Issues Issuance of common stock, net of expenses, shares Stock Issued During Period Shares New Issues Vesting of restricted stock unit awards Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Vesting of restricted stock unit awards, shares Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Issuance of warrants for common stock Adjustments To Additional Paid In Capital Warrant Issued Issuance of common stock under stock option plan Stock Issued During Period Value Stock Options Exercised Issuance of common stock under stock option plan, shares Stock Issued During Period Shares Stock Options Exercised Employee stock purchase plan expense Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition Issuance of stock under the employee stock purchase plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of stock under the employee stock purchase plan, shares Stock Issued During Period Shares Employee Stock Purchase Plans Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Ending balance Ending balance, shares Accounting Policies [Abstract] Description of the Business Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Summary of Significant Accounting Policies and Basis of Presentation Basis Of Presentation And Significant Accounting Policies [Text Block] Cash And Cash Equivalents [Abstract] Cash and Cash Equivalents and Marketable Securities Cash Cash Equivalents And Marketable Securities [Text Block] Restricted Cash And Investments [Abstract] Restricted Cash Restricted Assets Disclosure [Text Block] Inventory Disclosure [Abstract] Inventories, Net Inventory Disclosure [Text Block] Property Plant And Equipment [Abstract] Fixed Assets, Net Property Plant And Equipment Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] License and collaboration agreements. Text Block [Abstract] License and Collaboration Agreements License And Collaboration Agreements [Text Block] Equity [Abstract] Capital Stock Stockholders Equity Note Disclosure [Text Block] Other accrued expenses. Payables And Accruals [Abstract] Other Accrued Expenses Other Accrued Expenses Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based and Incentive Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Debt Disclosure [Abstract] Long-Term Debt Debt Disclosure [Text Block] Leases [Abstract] Leases Lessee Operating Leases [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] New Accounting Pronouncements And Changes In Accounting Principles [Abstract] Recent Accounting Pronouncements EX-101.PRE 11 prtk-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R15.htm IDEA: XBRL DOCUMENT

Capital Stock

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Capital Stock

9. Capital Stock

Warrants to Purchase Common Stock

XML 13 R11.htm IDEA: XBRL DOCUMENT

Inventories, Net

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Inventories, Net

5. Inventories, Net

The following table presents inventories (in thousands):

	September 30, 2019		December 31, 2018
Work in process	$	8,705	$	598
Finished goods		121		—
Total inventories	$	8,826	$	598

XML 14 R19.htm IDEA: XBRL DOCUMENT

Long-Term Debt

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Long-Term Debt

13. Long-Term Debt

Hercules Loan Agreement

Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the assets of the Company.

The Company recognized interest expense of $1.7 and $5.1 million for the three and nine months ended September 30, 2019, respectively.

The following table summarizes the impact of the Hercules Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):

	September 30, 2019			December 31, 2018
Gross proceeds	$	70,000		$	70,000
Unamortized debt issuance costs		(423	)		(606	)
Carrying value	$	69,577		$	69,394

Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan Agreement as of September 30, 2019 are as follows (in thousands):

Fiscal Year
2019	$	—
2020		—
2021		65,835
2022		4,165
Total	$	70,000

Convertible Senior Subordinated Notes

The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Gross proceeds	$	165,000		$	165,000
Unamortized debt issuance costs		(4,762	)		(5,434	)
Carrying value	$	160,238		$	159,566

Royalty-Backed Loan Agreement

The Company recognized interest expense of $1.0 and $1.6 million for the three and nine months ended September 30, 2019, respectively.

The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):

	September 30, 2019			December 31, 2018
Gross proceeds	$	32,500		$	—
Unamortized debt issuance costs		(1,905	)		—
Carrying value	$	30,595		$	—

XML 15 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value

Description	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
September 30, 2019
Assets:
U.S. treasury securities	$	120,730	$	—	$	—	$	120,730
Total Assets	$	120,730	$	—	$	—	$	120,730
December 31, 2018
Assets:
U.S. treasury securities	$	245,851	$	—	$	—	$	245,851
Total Assets	$	245,851	$	—	$	—	$	245,851

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 16 R36.htm IDEA: XBRL DOCUMENT

Description of the Business - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ (683,893)	$ (582,468)
Cash, cash equivalents and available for sale marketable securities current	$ 225,600

XML 18 R57.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Apr. 30, 2018
Royalty Backed Loan Agreement [Member]
Debt Instrument [Line Items]
Gross proceeds	$ 32,500
Unamortized debt issuance costs	(1,905)
Carrying value	30,595
4.75% Convertible Senior Subordinated Notes due 2024 [Member]
Debt Instrument [Line Items]
Gross proceeds	165,000	$ 165,000
Unamortized debt issuance costs	(4,762)	(5,434)	$ (6,000)
Carrying value	160,238	159,566
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Gross proceeds	70,000	70,000
Unamortized debt issuance costs	(423)	(606)
Carrying value	$ 69,577	$ 69,394

XML 19 R53.htm IDEA: XBRL DOCUMENT

Stock-Based and Incentive Compensation - Additional Information (Detail)					1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 10, 2019	Jan. 02, 2019 shares	Mar. 31, 2018	Jan. 02, 2016	Jun. 30, 2018 shares	Sep. 30, 2019 USD ($) Tranche shares	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) Installment Tranche shares	Sep. 30, 2018 USD ($)	Dec. 31, 2018	Oct. 31, 2018 shares	Oct. 04, 2018 USD ($)	Jun. 30, 2017 shares	Jun. 09, 2015 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								186,710
Compensation cost recognized \| $						$ 3,824,000	$ 4,084,000	$ 10,742,000	$ 12,955,000
Unrecognized stock-based compensation expense related to unvested share-based arrangements \| $						$ 16,800,000		$ 16,800,000
Weighted-average stock-based compensation expense recognition period								1 year 8 months 19 days
2018 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares			3.00%
Common stock shares, authorized					943,294
ESPP, eligible employees to purchase shares, offering periods					6 months
ESPP, eligible employees to purchase shares, offering periods, description								The 2018 ESPP allows eligible employees to purchase shares during certain offering periods, which will be six -month periods commencing June 1 and ending November 30 and commencing December 1 and ending May 31 of each year
First offering under the 2018 ESPP, date								Dec. 01, 2018
2018 Employee Stock Purchase Plan [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized \| $								$ 300,000
Shares remained available for issuance						884,621		884,621
Shares issued								95,212
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of annual increase in percentage of share reserved for issuance								The Share Reserve automatically increases on January 1st of each year, for the period commencing on (and including) January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year.
Share based compensation, increase in shares issued		1,612,969
Percentage of shares				5.00%
Total shares available for future issuance						501,818		501,818
2015 Plan [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								56,210
2015 Plan [Member] \| RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								2,211,740
2015 Plan [Member] \| RSU [Member] \| Tranche One[ Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio	0.25
2015 Plan [Member] \| RSU [Member] \| Tranche Two [ Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio								0.375
2015 Plan [Member] \| RSU [Member] \| Tranche Three [ Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period								1 year
Number of vesting installment period \| Installment								3
2015 Plan [Member] \| PRSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized \| $						$ 500,000		$ 800,000
2015 Plan [Member] \| PRSUs [Member] \| Tranche One[ Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio										0.182
2015 Plan [Member] \| PRSUs [Member] \| Tranche One[ Member] \| February 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio								0.417
2015 Plan [Member] \| PRSUs [Member] \| Tranche Two [ Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio										0.364
2015 Plan [Member] \| PRSUs [Member] \| Tranche Two [ Member] \| February 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio								0.417
2015 Plan [Member] \| PRSUs [Member] \| Tranche Three [ Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio										0.454
2015 Plan [Member] \| PRSUs [Member] \| Tranche Three [ Member] \| February 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio								0.167
2015 Plan [Member] \| Minimum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period								1 year
2015 Plan [Member] \| Maximum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period								4 years
2015 Plan [Member] \| Directors, Officers, Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance														1,200,000
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								0
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								0
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								0
Common stock shares, authorized						306,500		306,500
2015 Inducement Plan [Member] \| New Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance						360,000		360,000
2017 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance											500,000
Total shares available for future issuance						1,050,000		1,050,000
Common stock shares, authorized						403,624		403,624
2017 Inducement Plan [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								130,500
2017 Inducement Plan [Member] \| RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan								57,600
Time-based vesting period								3 years
Vesting percentage								100.00%
2017 Inducement Plan [Member] \| Minimum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period								1 year
2017 Inducement Plan [Member] \| Maximum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period								4 years
2017 Inducement Plan [Member] \| Employees Entering into Employment Or Returning to Employment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance													550,000
Revenue Performance Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches \| Tranche						2		2
Employment termination description								If a participant’s employment terminates prior to December 31, 2022 due to death or disability, the participant will automatically vest in an additional 25% of each tranche of his or her award.
Percentage of additional performance-based cash incentive awards								25.00%
Revenue incentive plan, vesting percentage								100.00%
Revenue incentive plan upon achievement of milestone description								Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant’s payout in respect of the applicable tranche of his or her award will equal (a) the participant’s then-vested percentage, multiplied by (b) $25 million, multiplied by (c) the participant’s individual percentage allocation of the incentive pool
Payout of revenues to participants \| $								$ 25,000,000
Percentage of cash and registered securities of aggregate payment								50.00%
Accrued compensation cost \| $						$ 0		$ 0
Revenue Performance Incentive Plan [Member] \| Tranche 1 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equal installments \| Installment								4
Payout of revenues to participants \| $								$ 25,000,000
Percentage of milestone deemed to be achieved if milestone not achieved prior to change of control								50.00%
Base amount for dividing cumulative product revenue if milestone not achieved prior to change of control \| $								$ 300,000,000
Revenue Performance Incentive Plan [Member] \| Tranche 2 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equal installments \| Installment								4
Payout of revenues to participants \| $								$ 25,000,000
Percentage of milestone deemed to be achieved if milestone not achieved prior to change of control								30.00%
Base amount for dividing cumulative product revenue if milestone not achieved prior to change of control \| $								$ 600,000,000
Revenue Performance Incentive Plan [Member] \| Minimum [Member] \| Tranche 1 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative net product revenues \| $								300,000,000
Revenue Performance Incentive Plan [Member] \| Minimum [Member] \| Tranche 2 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative net product revenues \| $								$ 600,000,000
Revenue Performance Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive pool amount plus accrued interest \| $												$ 50,000,000

XML 20 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 21 R42.htm IDEA: XBRL DOCUMENT

Restricted Cash - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended
	May 01, 2019	Mar. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Restricted Cash And Cash Equivalents Items [Line Items]
Royalty income received but not yet paid				$ 0.3
Royalty paid		$ 0.3
Healthcare Royalty Partners III, L.P [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Remaining balance in interest reserve account expected to be paid held as long term restricted cash			$ 2.6
Royalty Backed Loan Agreement [Member] \| Healthcare Royalty Partners III, L.P [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Line of credit deposits into interest reserve account	$ 4.0
Estimated interest amount expected to be paid out of interest reserve account held as restricted cash			0.8
Letters of Credit [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Letters of credit amount collateralized			$ 0.3	$ 0.3

XML 22 R46.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Additional Information (Detail)		1 Months Ended						3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 02, 2018 USD ($)	Oct. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Apr. 30, 2017 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2014	Feb. 28, 1997 shares	Sep. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) Obligation	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jan. 31, 2012 USD ($)	Jan. 31, 2010 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue								$ 3,934,000		$ 50,000	$ 7,577,000	$ 101,000
Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license fee payment received and recognized as revenue			$ 5,000,000						$ 12,000,000
Milestone payments on acceptance of an NDA submission		$ 12,000,000
Number of performance obligations \| Obligation											2
Tufts [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares issued \| shares							1,024
Milestone payments, maximum											$ 300,000
Milestone payments, paid											50,000
Second milestone payment											100,000
Third and final milestone payment due on acceptance of an NDA submission		$ 150,000
Royalty, payable								25,000			25,000
Royalty expense								46,000		0	$ 100,000	0
Maximum [Member] \| Tufts [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement, sublicensing Fees percent											14.00%
Minimum [Member] \| Tufts [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement, sublicensing Fees percent											10.00%
Collaboration and Royalty Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue								881,000		$ 50,000	$ 1,475,000	$ 101,000
Collaboration and Royalty Revenue [Member] \| Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue								800,000			$ 1,400,000
Adjustment related to increase estimated revenue to actual revenue from contract with customer								$ 100,000
Tetraphase License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expire date								2023-10			2023-10
Tetraphase License Agreement [Member] \| Collaboration and Royalty Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue								$ 22,500			$ 100,000
Zai Lab (Shanghai) Co., Ltd. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue									5,000,000		$ 0		$ 0
Upfront license fee payment received and recognized as revenue														$ 7,500,000
Period of anniversary for first commercial sale of licensed product											11 years
Number of performance obligations \| Obligation											2
Zai Lab (Shanghai) Co., Ltd. [Member] \| Paratek Bermuda Ltd [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license fee payment received and recognized as revenue				$ 7,500,000
Milestone payments on acceptance of an NDA submission	$ 5,000,000
Milestone payments upon submission of the first regulatory approval application for a licensed product								3,000,000			$ 3,000,000
Zai Lab (Shanghai) Co., Ltd. [Member] \| Paratek Bermuda Ltd [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive potential regulatory milestone payments								9,000,000			9,000,000
Eligible to receive potential commercial milestone payments								40,500,000			$ 40,500,000
Collaborative Research and License Agreement [Member] \| Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fees received																$ 4,000,000
New Drug Application [Member] \| Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fees received																$ 1,000,000
Collaborative Research and License Agreement Phase 2 Trials [Member] \| Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fees received															$ 2,500,000
Collaborative Research and License Agreement Phase 3 Trials [Member] \| Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fees received					$ 4,000,000
Novartis International Pharmaceutical Ltd [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Advance notice to terminate collaboration agreement											60 days
Royalty based on annual net sales						0.25%
Period of patent claim						10 years
Novartis International Pharmaceutical Ltd [Member] \| Other Liabilities [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Liability under collaboration agreement								3,500,000	$ 3,600,000		$ 3,500,000		$ 3,600,000
Novartis International Pharmaceutical Ltd [Member] \| Other Current Liabilities [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Liability under collaboration agreement								$ 100,000			$ 100,000

XML 23 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Oct. 31, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	PRTK
Entity Registrant Name	PARATEK PHARMACEUTICALS, INC.
Entity Central Index Key	0001178711
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-36066
Entity Tax Identification Number	33-0960223
Entity Address, Address Line One	75 Park Plaza
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02116
City Area Code	617
Local Phone Number	807-6600
Entity Common Stock, Shares Outstanding		33,287,946
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

XML 24 R61.htm IDEA: XBRL DOCUMENT

Leases - Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Leases [Abstract]
2019	$ 291
2020	1,178
2021	964
2022	508
2023	518
2024 and thereafter	396
Total lease payments	3,855
Less: imputed interest	(580)
Total operating lease liabilities	$ 3,275

XML 25 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Net loss	$ (101,425)	$ (89,565)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accretion	(1,124)	(530)
Stock-based compensation expense	10,742	12,955
Noncash interest expense	5,097	4,608
Impairment of intangible asset		107
Changes in fair value of contingent consideration		(57)
Changes in operating assets and liabilities
Accounts receivable and other current assets	(6,052)	4,966
Purchase of prepaid interest - marketable securities	153	(548)
Inventories	(7,555)
Operating lease right-of-use asset	534
Accounts payable and accrued expenses	1,843	5,164
Operating lease liability	(1,468)
Other liabilities and other assets	740	706
Net cash used in operating activities	(98,515)	(62,194)
Investing activities
Purchase of fixed assets	(45)	(54)
Purchase of marketable securities	(77,077)	(220,732)
Proceeds from maturities of marketable securities	204,000	116,058
Net cash provided by (used in) investing activities	126,878	(104,728)
Financing activities
Proceeds from the issuance of long-term debt, net of costs		9,950
Proceeds from the employee stock purchase plan	294
Proceeds from exercise of stock options		287
Proceeds from sale of common stock, net of costs	1,929	51,516
Net cash provided by financing activities	32,777	220,727
Net increase in cash, cash equivalents and restricted cash	61,140	53,805
Cash, cash equivalents and restricted cash at beginning of period	47,502	35,828
Cash, cash equivalents and restricted cash at end of period	108,642	89,633
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	9,579	3,751
Purchases of equipment included in accounts payable and accrued expenses	151
Royalty Backed Loan Agreement [Member]
Financing activities
Proceeds from the issuance of long-term debt, net of costs	$ 30,554
Convertible Debt [Member]
Financing activities
Proceeds from the issuance of long-term debt, net of costs		$ 158,974

XML 26 R9.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents and Marketable Securities

9 Months Ended

Sep. 30, 2019

Cash And Cash Equivalents [Abstract]

Cash and Cash Equivalents and Marketable Securities

3. Cash and Cash Equivalents and Marketable Securities

The following is a summary of available-for-sale securities as of September 30, 2019 and December 31, 2018 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
September 30, 2019
U.S. treasury securities	$	120,582	$	155	$	(7	)	$	120,730
Total	$	120,582	$	155	$	(7	)	$	120,730
December 31, 2018
U.S. treasury securities	$	245,979	$	65	$	(193	)	$	245,851
Total	$	245,979	$	65	$	(193	)	$	245,851

No available-for-sale securities held as of September 30, 2019 and December 31, 2018 had remaining maturities greater than twelve months and fifteen months, respectively.

XML 27 R27.htm IDEA: XBRL DOCUMENT

Restricted Cash (Tables)

9 Months Ended

Sep. 30, 2019

Restricted Cash And Investments [Abstract]

Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Condensed Consolidated Statement of Cash Flows

	September 30, 2019		September 30, 2018
Cash and cash equivalents	$	104,907	$	89,117
Short-term restricted cash		788		266
Long-term restricted cash		2,947		250
Total cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$	108,642	$	89,633

XML 28 R23.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2019

New Accounting Pronouncements And Changes In Accounting Principles [Abstract]

Recent Accounting Pronouncements

17. Recent Accounting Pronouncements

XML 29 R43.htm IDEA: XBRL DOCUMENT

Inventories, Net - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Work in process	$ 8,705	$ 598
Finished goods	121
Total inventories	$ 8,826	$ 598

XML 30 R47.htm IDEA: XBRL DOCUMENT

Capital Stock - Additional Information (Detail) - USD ($)						1 Months Ended		3 Months Ended		9 Months Ended		36 Months Ended
	Jul. 02, 2019	Aug. 01, 2018	Jun. 27, 2017	Dec. 12, 2016	Sep. 30, 2015	Feb. 28, 2017	Oct. 31, 2015	Sep. 30, 2019	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2018	Oct. 31, 2019
Class Of Stock [Line Items]
Common stock sold, value								$ 1,929,000	$ 51,515,000
Proceeds from issuance of common stock										$ 1,929,000	$ 51,516,000
Beneficial owners minimum required percentage of common stock exchanged for warrant										5.00%
Warrants exercisable description										The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years (or seven years, in the case of the Fifth Amendment Warrant) from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the various agreements for the Warrants.
Term of warrants										5 years
Fifth Amendment [Member]
Class Of Stock [Line Items]
Term of warrants		7 years
Hercules Term Loan [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$ 24.47
Warrants issued to purchase common stock					32,692
Hercules Term Loan [Member] \| Second Amendment [Member]
Class Of Stock [Line Items]
Exercise price of warrants				$ 13.46
Warrants issued to purchase common stock				37,148
Hercules Term Loan [Member] \| Fifth Amendment [Member]
Class Of Stock [Line Items]
Exercise price of warrants		$ 10.19
Hercules Term Loan [Member] \| Hercules Technology II, L.P. [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock					16,346
Expected life of options (in years)					5 years
Hercules Term Loan [Member] \| Hercules Technology II, L.P. [Member] \| Second Amendment [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock				18,574
Hercules Term Loan [Member] \| Hercules Technology III, L.P. [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock					16,346
Expected life of options (in years)					5 years
Hercules Term Loan [Member] \| Hercules Technology III, L.P. [Member] \| Second Amendment [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock				18,574
Hercules Term Loan [Member] \| Hercules Capital Inc [Member]
Class Of Stock [Line Items]
Exercise price of warrants			$ 23.26
Warrants issued to purchase common stock			5,374
Hercules Term Loan [Member] \| Hercules Capital Inc [Member] \| Fifth Amendment [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock		19,627
Warrants Expires in 2021 [Member]
Class Of Stock [Line Items]
Warrants outstanding								9,614		9,614
Exercise price of warrants								$ 0.15		$ 0.15
Warrants expiration year										2021
Warrants Expires in 2016 [Member]
Class Of Stock [Line Items]
Warrants outstanding								5,120		5,120
Exercise price of warrants								$ 73.66		$ 73.66
Warrants expiration month and year										2016-04
2015 Sales Agreement [Member] \| Cantor [Member]
Class Of Stock [Line Items]
Percentage of proceeds payable as compensation to underwriter							3.00%
Common stock sold, value												$ 50,000,000
Common stock issued on public offering										0
2017 Sales Agreement [Member] \| Cantor [Member]
Class Of Stock [Line Items]
Percentage of proceeds payable as compensation to underwriter						3.00%
Common stock issued on public offering						2,102,315				0
Proceeds from issuance of common stock						$ 47,700,000
Proceeds payable as commission to underwriter						1,500,000
2019 Sales Agreement [Member] \| Jefferies and BTIG [Member]
Class Of Stock [Line Items]
Percentage of proceeds payable as compensation to underwriter	3.00%
Common stock issued on public offering								360,575		360,575
Proceeds from issuance of common stock								$ 1,900,000		$ 1,900,000
Proceeds payable as commission to underwriter								$ 100,000		$ 100,000
2019 Sales Agreement [Member] \| Jefferies and BTIG [Member] \| Subsequent Event [Member]
Class Of Stock [Line Items]
Common stock for sale													$ 48,000,000
Maximum [Member] \| 2015 Sales Agreement [Member] \| Cantor [Member]
Class Of Stock [Line Items]
Common stock for sale							$ 50,000,000
Maximum [Member] \| 2017 Sales Agreement [Member] \| Cantor [Member]
Class Of Stock [Line Items]
Common stock for sale						$ 50,000,000
Maximum [Member] \| 2019 Sales Agreement [Member] \| Jefferies and BTIG [Member]
Class Of Stock [Line Items]
Common stock for sale	$ 50,000,000

XML 31 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. Summary of Significant Accounting Policies and Basis of Presentation

Basis of Presentation

Summary of Significant Accounting Policies

Accounts Receivable, Net

Leases

Product Revenue

•

Trade discounts and allowances

•

Product returns

•

Chargebacks and rebates

•

Government rebates

•

Commercial payer and other rebates

•

Voluntary patient assistance programs

The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled:

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:

	Chargebacks, discounts and fees			Government and other rebates			Returns		Patient assistance			Total
Balance at December 31, 2018	$	—		$	—		$	—	$	—		$	—
Provision related to current period sales		514			995			149		249			1,907
Adjustment related to prior period sales		—			—			—		—			—
Credit or payments made during the period		(272	)		(309	)		—		(16	)		(597	)
Balance at September 30, 2019	$	242		$	686		$	149	$	233		$	1,310

Contract costs

Cost of Revenue

Stock-Based Compensation

Principles of Consolidation

Use of Estimates

Segment and Geographic Information

XML 32 R60.htm IDEA: XBRL DOCUMENT

Leases - Summary of Lease Costs Recognized Under Topic 842 and Other Information (Detail) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)
Leases [Abstract]
Operating lease cost	$ 255	$ 765
Variable lease cost	43	87
Total lease cost	298	852
Cash paid for amounts included in the measurement of lease liabilities:	$ 289	$ 770
Weighted average remaining lease term (in years)	3 years 9 months 18 days	3 years 9 months 18 days
Weighted average discount rate	8.75%	8.75%

XML 33 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net revenue	$ 3,934,000	$ 50,000	$ 7,577,000	$ 101,000
Expenses:
Cost of product revenue	958,000		1,731,000
Research and development	8,350,000	16,040,000	30,421,000	45,706,000
Selling, general and administrative	23,636,000	13,610,000	67,874,000	38,395,000
Impairment of intangible asset		21,000		107,000
Changes in fair value of contingent consideration		(11,000)		(57,000)
Total operating expenses	32,944,000	29,660,000	100,026,000	84,151,000
Loss from operations	(29,010,000)	(29,610,000)	(92,449,000)	(84,050,000)
Other income and expenses:
Interest income	992,000	922,000	2,873,000	2,292,000
Interest expense	(4,560,000)	(3,383,000)	(11,777,000)	(7,793,000)
Other gains (losses), net	(36,000)	(12,000)	(72,000)	(14,000)
Net loss before provision for income taxes	(32,614,000)	(32,083,000)	(101,425,000)	(89,565,000)
Provision for income taxes	0	0	0	0
Net loss	(32,614,000)	(32,083,000)	(101,425,000)	(89,565,000)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net of tax	(68,000)	(103,000)	276,000	(170,000)
Comprehensive loss	$ (32,682,000)	$ (32,186,000)	$ (101,149,000)	$ (89,735,000)
Basic and diluted net loss per share	$ (1.00)	$ (1.01)	$ (3.12)	$ (2.86)
Weighted average common stock outstanding Basic and diluted	32,590,454	31,742,854	32,458,010	31,301,249
Product Revenue, Net [Member]
Net revenue	$ 3,053,000		$ 6,102,000
Collaboration and Royalty Revenue [Member]
Net revenue	$ 881,000	$ 50,000	$ 1,475,000	$ 101,000

XML 34 R26.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents and Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2019

Cash And Cash Equivalents [Abstract]

Summary of Available for Sale Securities

The following is a summary of available-for-sale securities as of September 30, 2019 and December 31, 2018 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
September 30, 2019
U.S. treasury securities	$	120,582	$	155	$	(7	)	$	120,730
Total	$	120,582	$	155	$	(7	)	$	120,730
December 31, 2018
U.S. treasury securities	$	245,979	$	65	$	(193	)	$	245,851
Total	$	245,979	$	65	$	(193	)	$	245,851

XML 35 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

16. Commitments and Contingencies

Other Legal Proceedings

XML 36 R18.htm IDEA: XBRL DOCUMENT

Stock-Based and Incentive Compensation

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based and Incentive Compensation

12. Stock-Based and Incentive Compensation

Stock-based Compensation

The following table presents stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development expense	$	560	$	1,442	$	2,868	$	4,456
Selling, general and administrative expense		3,264		2,642		7,874		8,499
Total stock-based compensation expense	$	3,824	$	4,084	$	10,742	$	12,955

	Nine Months Ended September 30,
	2019			2018
Volatility		63.3	%		67.4	%
Weighted-average risk-free interest rate		2.0	%		2.7	%
Expected dividend yield		0.0	%		0.0	%
Expected life of options (in years)		5.9			5.9

Stock Option Plan Activity

Stock Options

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		3,777,162		$	16.65		7.10	$	506
Granted		186,710
Cancelled or forfeited		(670,770	)
Outstanding at September 30, 2019		3,293,102		$	15.57		6.53	$	126
Exercisable at September 30, 2019		2,768,725		$	16.13		6.16	$	12

Restricted Stock Units

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:

	Number of Shares			Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2018		1,470,237		$	15.28
Granted		2,269,340		$	6.01
Released		(186,296	)	$	14.06
Forfeited		(597,523	)	$	10.84
Unvested balance at September 30, 2019		2,955,758		$	9.14

Total unrecognized stock-based compensation expense for all stock-based awards was $16.8 million as of September 30, 2019. This amount will be recognized over a weighted-average period of 1.72 years.

2018 Employee Stock Purchase Plan

Revenue Performance Incentive Plan

XML 37 R14.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements

9 Months Ended

Sep. 30, 2019

Text Block [Abstract]

License and Collaboration Agreements

8. License and Collaboration Agreements

Tetraphase Pharmaceuticals, Inc.

The Company recognized $22,500 and $0.1 million of royalty revenue for the three and nine months ended September 30, 2019, respectively, under the Tetraphase License Agreement.

Zai Lab (Shanghai) Co., Ltd.

The Company recognized an insignificant amount of collaboration revenue for the three and nine months ended September 30, 2019 under the Zai Collaboration Agreement.

Almirall, LLC

Tufts University

Past Collaborations

Novartis International Pharmaceutical Ltd.

XML 38 R10.htm IDEA: XBRL DOCUMENT

Restricted Cash

9 Months Ended

Sep. 30, 2019

Restricted Cash And Investments [Abstract]

Restricted Cash

4. Restricted Cash

	September 30, 2019		September 30, 2018
Cash and cash equivalents	$	104,907	$	89,117
Short-term restricted cash		788		266
Long-term restricted cash		2,947		250
Total cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$	108,642	$	89,633

Short-term restricted cash

Long-term restricted cash

XML 39 R33.htm IDEA: XBRL DOCUMENT

Stock-Based and Incentive Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock-Based Compensation Expense Included in Company's Consolidated Statements of Operations and Comprehensive Loss

Stock-based Compensation

The following table presents stock-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Research and development expense	$	560	$	1,442	$	2,868	$	4,456
Selling, general and administrative expense		3,264		2,642		7,874		8,499
Total stock-based compensation expense	$	3,824	$	4,084	$	10,742	$	12,955

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The weighted-average assumptions used to determine the fair value of the stock option grants is as follows:

	Nine Months Ended September 30,
	2019			2018
Volatility		63.3	%		67.4	%
Weighted-average risk-free interest rate		2.0	%		2.7	%
Expected dividend yield		0.0	%		0.0	%
Expected life of options (in years)		5.9			5.9

Schedule of Share-based Compensation, Stock Options, Activity

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		3,777,162		$	16.65		7.10	$	506
Granted		186,710
Cancelled or forfeited		(670,770	)
Outstanding at September 30, 2019		3,293,102		$	15.57		6.53	$	126
Exercisable at September 30, 2019		2,768,725		$	16.13		6.16	$	12

Schedule of Share-based Compensation, RSU, Activity

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:

	Number of Shares			Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2018		1,470,237		$	15.28
Granted		2,269,340		$	6.01
Released		(186,296	)	$	14.06
Forfeited		(597,523	)	$	10.84
Unvested balance at September 30, 2019		2,955,758		$	9.14

XML 40 R37.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($) Segment	Dec. 31, 2018 USD ($)
Accounting Policies [Line Items]
Accrued Contract Research Current	$ 3,514	$ 1,747
Accrued interest	4,199	1,813
Accounts receivable, net	$ 3,976	41
Royalty revenue earned but not yet received		300
Number of operating segments \| Segment	1
Almirall [Member]
Accounting Policies [Line Items]
Royalty revenue earned but not yet received	$ 700
Trade Accounts Receivable [Member]
Accounting Policies [Line Items]
Accounts receivable, net	$ 3,200
Other Accrued Expenses [Member]
Accounting Policies [Line Items]
Accrued contract manufacturing costs		2,800
Inventories [Member]
Accounting Policies [Line Items]
Accrued Contract Research Current		$ 600

XML 41 R56.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Additional Information (Detail)									1 Months Ended	3 Months Ended	9 Months Ended
Long-Term Debt - Additional Information (Detail)	Jun. 27, 2019 USD ($)	May 01, 2019 USD ($)	Feb. 25, 2019 USD ($)	Aug. 01, 2018 USD ($)	Apr. 23, 2018 USD ($) $ / shares	Apr. 18, 2018 USD ($) d $ / shares	Dec. 12, 2016 USD ($)	Sep. 30, 2015 USD ($)	Apr. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)
Royalty Backed Loan Agreement [Member]
Debt Instrument [Line Items]
Costs incurred on issuance of debt										$ 1,905,000	$ 1,905,000
Healthcare Royalty Partners III, L.P [Member] \| Royalty Backed Loan Agreement [Member]
Debt Instrument [Line Items]
Interest expense										1,000,000	$ 1,600,000
Line of credit facility, borrowing capacity			$ 32,500,000
Proceeds from lines of credit		$ 27,800,000
Line of credit net of lender discount		500,000
Line of credit lender expenses		200,000
Line of credit deposits into interest reserve account		4,000,000
Repayment of other lender fees		$ 1,200,000
Repayments of loan										$ 1,000,000
Interest rate of annual rate			12.00%
Line of credit facility, fee			1.50%
Line of credit maturity period			May 01, 2029
Maximum [Member] \| Healthcare Royalty Partners III, L.P [Member] \| Royalty Backed Loan Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, periodic payment			$ 300,000
4.75% Convertible Senior Subordinated Notes due 2024 [Member]
Debt Instrument [Line Items]
Loan maturity date					May 01, 2024
Loan interest rate										5.47%	5.47%
Loan agreement payment terms					payable on November 1 and May 1 of each year, beginning on November 1, 2018
Loan repayment beginning date					Nov. 01, 2018
Debt instrument initial conversion rate					62.8931
Debt instrument conversion, principal amount of each note converted					$ 1,000
Debt instrument conversion, conversion price per share \| $ / shares					$ 15.90
Debt instrument conversion premium					20.00%
Closing price of the common stock \| $ / shares						$ 13.25
Percentage of common stock price						130.00%
Debt instrument, convertible, threshold trading days \| d						20
Debt instrument, convertible, threshold consecutive trading days \| d						30
Percentage of debt instrument redemption price						100.00%
Debt instrument, debt default, minimum percentage of aggregate principal amount due					25.00%
Net proceeds from issuance of long-term convertible debt									$ 159,000,000
Costs incurred on issuance of debt									$ 6,000,000	$ 4,762,000	$ 4,762,000	$ 5,434,000
Coupon interest expense										2,000,000	5,900,000
Amortization expense on debt issuance costs										200,000	$ 600,000
4.75% Convertible Senior Subordinated Notes due 2024 [Member] \| J. Wood Capital Advisors LLC [Member]
Debt Instrument [Line Items]
Principal amount outstanding						$ 5,000,000
4.75% Convertible Senior Subordinated Notes due 2024 [Member] \| Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal amount outstanding						$ 135,000,000
Debt instrument, interest rate						4.75%
Additional principal amount outstanding						$ 25,000,000
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Principal amount outstanding	$ 100,000,000
Loan agreement description											On June 27, 2019, the Company entered into an Amended and Restated Loan and Security Agreement, or the Loan Agreement, with Hercules Technology III, L.P., certain other lenders, together, the Lenders, and Hercules Capital, Inc. (as agent), under which the Company may borrow up to $100.0 million in multiple tranches, each, a Term Loan Tranche. The Loan Agreement amends and restates in its entirety the Company’s prior Loan and Security Agreement with the Lenders dated as of September 30, 2015 to, among other things, provide for an extension of the scheduled maturity date of the $60.0 million Term Loan Tranche, or the First Tranche, from September 1, 2021 to September 1, 2023, upon certain events set forth in the Loan Agreement, and an extension of the scheduled maturity date of the $10.0 million Term Loan Tranche, or the Second Tranche, and additional Term Loan Tranches (if any), from August 1, 2022 to August 1, 2024, upon certain events set forth in the Loan Agreement.
Loan interest rate description											The interest rate with respect to the First Tranche is a floating per annum rate equal to the greater of (i) 8.50% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.75%, and (ii) 8.50%. The interest rate with respect to the Second Tranche is, and the interest rate with respect to additional Term Loan Tranches (if any) will be, a floating per annum rate equal to the greater of (i) 7.85% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.75%, and (ii) 7.85%.
Loan agreement payment terms											(which can be extended to May 1, 2021 or September 1, 2021, upon certain events set forth in the Loan Agreement), followed by equal monthly payments of principal and interest through the scheduled maturity date.
Additional interest rate on default	5.00%			5.00%
Minimum subordinated debt for event of default				$ 1,000,000
Interest expense										1,700,000	$ 5,100,000
Costs incurred on issuance of debt										$ 423,000	$ 423,000	$ 606,000
Hercules Term Loan [Member] \| Prior to January 1, 2020 [Member]
Debt Instrument [Line Items]
Percentage of prepayment											1.75%
Hercules Term Loan [Member] \| After January 1, 2020 [Member]
Debt Instrument [Line Items]
Percentage of prepayment											0.00%
Hercules Term Loan [Member] \| First Tranche [Member]
Debt Instrument [Line Items]
Principal amount outstanding								$ 60,000,000
Loan maturity date	Sep. 01, 2023							Sep. 01, 2021
Basis spread on prime rate								5.75%
Loan interest only maturity date								Jan. 01, 2021
Hercules Term Loan [Member] \| First Tranche [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Loan interest rate								8.50%
Hercules Term Loan [Member] \| Second Tranche [Member]
Debt Instrument [Line Items]
Principal amount outstanding							$ 10,000,000
Loan maturity date	Aug. 01, 2024						Aug. 01, 2022
Basis spread on prime rate							5.75%
Loan interest only maturity date							Jan. 01, 2021
Hercules Term Loan [Member] \| Second Tranche [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Loan interest rate							7.85%
Hercules Term Loan [Member] \| Third Tranche [Member]
Debt Instrument [Line Items]
Additional borrowing capacity subject to sole discretion of Hercules	$ 10,000,000
Hercules Term Loan [Member] \| Fourth Tranche [Member]
Debt Instrument [Line Items]
Additional borrowing capacity subject to sole discretion of Hercules	10,000,000
Hercules Term Loan [Member] \| Fifth Tranche [Member]
Debt Instrument [Line Items]
Additional borrowing capacity subject to sole discretion of Hercules	$ 10,000,000
Hercules Term Loan [Member] \| Equal to 4.5% of First Tranche [Member]
Debt Instrument [Line Items]
Principal amount outstanding								$ 50,000,000
End of term charge								4.50%
Hercules Term Loan [Member] \| Equal to 2.25% of FirstTranche [Member]
Debt Instrument [Line Items]
Principal amount outstanding								$ 10,000,000
End of term charge								2.25%
Hercules Term Loan [Member] \| Equal to 6.95% of Second Tranche [Member]
Debt Instrument [Line Items]
End of term charge							6.95%

XML 42 R52.htm IDEA: XBRL DOCUMENT

Stock-Based and Incentive Compensation - Schedule of Share-based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	63.30%	67.40%
Weighted-average risk-free interest rate	2.00%	2.70%
Expected dividend yield	0.00%	0.00%
Expected life of options (in years)	5 years 10 months 24 days	5 years 10 months 24 days

XML 43 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 104,907	$ 46,987
Marketable securities	120,730	203,364
Restricted cash	788	266
Accounts receivable, net	3,976	41
Inventories, net	8,826	598
Other receivables	854	208
Prepaid and other current assets	5,095	3,779
Total current assets	245,176	255,243
Long-term restricted cash	2,947	249
Long-term marketable securities		42,487
Fixed assets, net	967	1,173
Goodwill	829	829
Right-of-use asset	2,701	0
Other long-term assets	154	211
Total assets	252,774	300,192
Current liabilities
Accounts payable	3,956	2,090
Other accrued expenses	20,042	15,619
Other current liabilities	1,020
Total current liabilities	25,018	17,709
Long-term debt	260,410	228,959
Long-term lease liabilities	2,344
Other liabilities	5,608	5,946
Total liabilities	293,380	252,614
Commitments and contingencies (Note 16)
Stockholders’ equity (deficit)
Undesignated preferred stock: $0.001 par value; 5,000,000 authorized; no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 32,901,446 and 32,259,363 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	33	32
Additional paid-in capital	643,106	630,142
Accumulated other comprehensive income (loss)	148	(128)
Accumulated deficit	(683,893)	(582,468)
Total stockholders’ equity (deficit)	(40,606)	47,578
Total liabilities and stockholders’ equity (deficit)	$ 252,774	$ 300,192

XML 44 R62.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0	$ 0	$ 0

XML 45 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2017	$ 82,478	$ 28	$ 552,720	$ (158)	$ (470,112)
Beginning balance, shares at Dec. 31, 2017		27,941,015
Issuance of common stock, net of expenses	51,515	$ 3	51,512
Issuance of common stock, net of expenses, shares		3,301,436
Vesting of restricted stock unit awards, shares		171,999
Issuance of common stock under stock option plan	177		177
Issuance of common stock under stock option plan, shares		28,699
Unrealized gain (loss) on available-for-sale securities, net of tax	(21)			(21)
Stock-based compensation expense	4,367		4,367
Net loss	(27,750)				(27,750)
Ending balance at Mar. 31, 2018	110,766	$ 31	608,776	(179)	(497,862)
Ending balance, shares at Mar. 31, 2018		31,443,149
Beginning balance at Dec. 31, 2017	82,478	$ 28	552,720	(158)	(470,112)
Beginning balance, shares at Dec. 31, 2017		27,941,015
Unrealized gain (loss) on available-for-sale securities, net of tax	(170)
Net loss	(89,565)
Ending balance at Sep. 30, 2018	57,629	$ 32	617,604	(329)	(559,678)
Ending balance, shares at Sep. 30, 2018		31,781,488
Beginning balance at Mar. 31, 2018	110,766	$ 31	608,776	(179)	(497,862)
Beginning balance, shares at Mar. 31, 2018		31,443,149
Vesting of restricted stock unit awards	1	$ 1
Vesting of restricted stock unit awards, shares		271,500
Unrealized gain (loss) on available-for-sale securities, net of tax	(47)			(47)
Stock-based compensation expense	4,503		4,503
Net loss	(29,733)				(29,733)
Ending balance at Jun. 30, 2018	85,490	$ 32	613,279	(226)	(527,595)
Ending balance, shares at Jun. 30, 2018		31,714,649
Vesting of restricted stock unit awards, shares		41,600
Issuance of warrants for common stock	130		130
Issuance of common stock under stock option plan	110		110
Issuance of common stock under stock option plan, shares		25,239
Unrealized gain (loss) on available-for-sale securities, net of tax	(103)			(103)
Stock-based compensation expense	4,085		4,085
Net loss	(32,083)				(32,083)
Ending balance at Sep. 30, 2018	57,629	$ 32	617,604	(329)	(559,678)
Ending balance, shares at Sep. 30, 2018		31,781,488
Beginning balance at Dec. 31, 2018	47,578	$ 32	630,142	(128)	(582,468)
Beginning balance, shares at Dec. 31, 2018		32,259,363
Vesting of restricted stock unit awards, shares		156,614
Employee stock purchase plan expense	24		24
Unrealized gain (loss) on available-for-sale securities, net of tax	200			200
Stock-based compensation expense	3,839		3,839
Net loss	(35,610)				(35,610)
Ending balance at Mar. 31, 2019	16,031	$ 32	634,005	72	(618,078)
Ending balance, shares at Mar. 31, 2019		32,415,977
Beginning balance at Dec. 31, 2018	47,578	$ 32	630,142	(128)	(582,468)
Beginning balance, shares at Dec. 31, 2018		32,259,363
Unrealized gain (loss) on available-for-sale securities, net of tax	276
Net loss	(101,425)
Ending balance at Sep. 30, 2019	(40,606)	$ 33	643,106	148	(683,893)
Ending balance, shares at Sep. 30, 2019		32,901,446
Beginning balance at Mar. 31, 2019	16,031	$ 32	634,005	72	(618,078)
Beginning balance, shares at Mar. 31, 2019		32,415,977
Vesting of restricted stock unit awards, shares		5,000
Employee stock purchase plan expense	24		24
Issuance of stock under the employee stock purchase plan	294		294
Issuance of stock under the employee stock purchase plan, shares		95,212
Unrealized gain (loss) on available-for-sale securities, net of tax	144			144
Stock-based compensation expense	3,031		3,031
Net loss	(33,201)				(33,201)
Ending balance at Jun. 30, 2019	(13,677)	$ 32	637,354	216	(651,279)
Ending balance, shares at Jun. 30, 2019		32,516,189
Issuance of common stock, net of expenses	1,929	$ 1	1,928
Issuance of common stock, net of expenses, shares		360,575
Vesting of restricted stock unit awards, shares		24,682
Employee stock purchase plan expense	25		25
Unrealized gain (loss) on available-for-sale securities, net of tax	(68)			(68)
Stock-based compensation expense	3,799		3,799
Net loss	(32,614)				(32,614)
Ending balance at Sep. 30, 2019	$ (40,606)	$ 33	$ 643,106	$ 148	$ (683,893)
Ending balance, shares at Sep. 30, 2019		32,901,446

XML 46 R49.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) $ in Millions	Sep. 30, 2019 USD ($)
Fair Value Disclosures [Abstract]
Carrying value of debt	$ 187.5

XML 47 R41.htm IDEA: XBRL DOCUMENT

Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Condensed Consolidated Statement of Cash Flows (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Restricted Cash And Investments [Abstract]
Cash and cash equivalents	$ 104,907	$ 46,987	$ 89,117
Short-term restricted cash	788	266	266
Long-term restricted cash	2,947	249	250
Total cash, cash equivalents and restricted cash shown on the condensed consolidated statement of cash flows	$ 108,642	$ 47,502	$ 89,633	$ 35,828

XML 48 R45.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	17,615,297	17,162,073
Outstanding Convertible Notes [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	10,377,361	10,377,361
Stock Option [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	3,293,102	3,762,912
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	2,955,758	1,937,512
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	104,455	104,455
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	884,621	979,833

XML 49 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

Summary of Significant Accounting Policies

Accounts Receivable, Net

Leases

Product Revenue

•

Trade discounts and allowances

•

Product returns

•

Chargebacks and rebates

•

Government rebates

•

Commercial payer and other rebates

•

Voluntary patient assistance programs

The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled:

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:

	Chargebacks, discounts and fees			Government and other rebates			Returns		Patient assistance			Total
Balance at December 31, 2018	$	—		$	—		$	—	$	—		$	—
Provision related to current period sales		514			995			149		249			1,907
Adjustment related to prior period sales		—			—			—		—			—
Credit or payments made during the period		(272	)		(309	)		—		(16	)		(597	)
Balance at September 30, 2019	$	242		$	686		$	149	$	233		$	1,310

Contract costs

Cost of Revenue

Share-Based Compensation

Stock-Based Compensation

Principles of Consolidation

Use of Estimates

Segment and Geographic Information

XML 50 R20.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Leases

14. Leases

Operating Leases

The Company leases its Boston, Massachusetts and King of Prussia, Pennsylvania office spaces under non-cancelable operating leases expiring in 2021 and 2024, respectively.

Operating leases	For the Three Months Ended September 30, 2019
Lease cost (in thousands)
Operating lease cost	$	255
Variable lease cost		43
Total lease cost	$	298
Cash paid for amounts included in the measurement of lease liabilities:		289

	For the Nine Months Ended September 30, 2019
Lease cost (in thousands)
Operating lease cost	$	765
Variable lease cost		87
Total lease cost	$	852
Cash paid for amounts included in the measurement of lease liabilities:	$	770

Other information
Weighted average remaining lease term (in years)		3.8
Weighted average discount rate		8.75	%

Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of September 30, 2019, are as follows:

Maturity of lease liabilities (in thousands)	As of September 30, 2019
2019	$	291
2020		1,178
2021		964
2022		508
2023		518
2024 and thereafter		396
Total lease payments	$	3,855
Less: imputed interest		(580	)
Total operating lease liabilities	$	3,275

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 52 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories, Net (Tables)
9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventories
The following table presents inventories (in thousands):

September 30,

2019

December 31,

2018

Work in process

$

8,705

$

598

Finished goods

121

—

Total inventories

$

8,826

$

598

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Cash and Cash Equivalents and Marketable Securities - Summary of Available for Sale Securities (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost $ 120,582 $ 245,979

Unrealized Gains 155 65

Unrealized Losses (7) (193)

Fair Value 120,730 245,851

U.S. Treasury Securities [Member]

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 120,582 245,979

Unrealized Gains 155 65

Unrealized Losses (7) (193)

Fair Value $ 120,730 $ 245,851

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R31.htm IDEA: XBRL DOCUMENT v3.19.3

Other Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2019

Payables And Accruals [Abstract]

Schedule of Other Accrued Expenses
Other accrued expenses consist of the following (in thousands):

September 30,

December 31,

2019

2018

Accrued legal costs

$

271

$

366

Accrued other

54

809

Accrued professional fees

754

750

Accrued compensation

5,529

6,070

Accrued interest

4,199

1,813

Accrued contract research

3,514

1,747

Accrued commercial

2,330

1,280

Accrued manufacturing

1,408

2,784

Accrued sales allowances

1,310

—

Accrued inventory

673

—

Total

$

20,042

$

15,619

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Leases (Tables)
9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Summary of Lease Costs Recognized Under Topic 842 and Other Information
The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for the three and nine months ended September 30, 2019:

Operating leases

For the Three

Months Ended

September 30,

2019

Lease cost (in thousands)

Operating lease cost

$

255

Variable lease cost

43

Total lease cost

$

298

Cash paid for amounts included in the measurement of lease liabilities:

289

For the Nine

Months Ended

September 30,

2019

Lease cost (in thousands)

Operating lease cost

$

765

Variable lease cost

87

Total lease cost

$

852

Cash paid for amounts included in the measurement of lease liabilities:

$

770

Other information

Weighted average remaining lease term (in years)

3.8

Weighted average discount rate

8.75

%

Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases
Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of September 30, 2019, are as follows:

Maturity of lease liabilities (in thousands)

As of

September 30,

2019

2019

$

291

2020

1,178

2021

964

2022

508

2023

518

2024 and thereafter

396

Total lease payments

$

3,855

Less: imputed interest

(580

)

Total operating lease liabilities

$

3,275

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Other Accrued Expenses
9 Months Ended

Sep. 30, 2019

Payables And Accruals [Abstract]

Other Accrued Expenses
10. Other Accrued Expenses

Other accrued expenses consist of the following (in thousands):

September 30,

December 31,

2019

2018

Accrued legal costs

$

271

$

366

Accrued other

54

809

Accrued professional fees

754

750

Accrued compensation

5,529

6,070

Accrued interest

4,199

1,813

Accrued contract research

3,514

1,747

Accrued commercial

2,330

1,280

Accrued manufacturing

1,408

2,784

Accrued sales allowances

1,310

—

Accrued inventory

673

—

Total

$

20,042

$

15,619

X

- Definition
Other accrued expenses.
+ References
No definition available.
+ Details

Name: prtk_OtherAccruedExpensesDisclosureTextBlock

Namespace Prefix: prtk_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Fixed Assets, Net
9 Months Ended

Sep. 30, 2019

Property Plant And Equipment [Abstract]

Fixed Assets, Net
6. Fixed Assets, Net

Fixed assets, net, consists of the following (in thousands):

September 30,

2019

December 31,

2018

Office equipment

$

866

$

866

Computer equipment

412

412

Computer software

798

798

Leasehold improvements

920

909

Construction in progress

184

—

Gross fixed assets

3,180

2,985

Less: Accumulated depreciation and amortization

(2,213

)

(1,812

)

Net fixed assets

$

967

$

1,173

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 59 0001564590-19-042902-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-042902-xbrl.zip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�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end XML 60 R54.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Number of Shares Outstanding, Beginning Balances 3,777,162

Number of Shares Outstanding, Granted 186,710

Number of Shares Outstanding, Cancelled or forfeited (670,770)

Number of Shares Outstanding, Ending Balances 3,293,102 3,777,162

Number of Shares Outstanding, Exercisable 2,768,725

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]

Weighted Average Exercise Price, Beginning Balances $ 16.65

Weighted Average Exercise Price, Ending Balances 15.57 $ 16.65

Weighted Average Exercise Price, Exercisable $ 16.13

Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted-Average Remaining Contractual Term (in Years)

Options Outstanding, Weighted-Average Remaining Contractual Term (in Years) 6 years 6 months 10 days 7 years 1 month 6 days

Options Exercisable, Weighted-Average Remaining Contractual Term (in Years) 6 years 1 month 28 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value

Options Outstanding, Aggregate Intrinsic Value $ 126 $ 506

Options Exercisable, Aggregate Intrinsic Value $ 12

X

- Definition
Share based compensation arrangement by share based payment award options aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: prtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract

Namespace Prefix: prtk_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options weighted average remaining contractual term.
+ References
No definition available.
+ Details

Name: prtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract

Namespace Prefix: prtk_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 61 R50.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Assets

Total Assets $ 120,730 $ 245,851

Total Assets 120,730 245,851

U.S. Treasury Securities [Member]

Assets

Total Assets 120,730 245,851

Quoted Prices in Active Markets (Level 1) [Member]

Assets

Total Assets 120,730 245,851

Quoted Prices in Active Markets (Level 1) [Member] | U.S. Treasury Securities [Member]

Assets

Total Assets $ 120,730 $ 245,851

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R58.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Debt - Schedule of Future Principal Payments (Detail) - Hercules Term Loan [Member] - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Debt Instrument [Line Items]

2021 $ 65,835

2022 4,165

Total $ 70,000 $ 70,000

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=prtk_HerculesTermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R30.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss Per Share (Tables)
9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share
The following outstanding shares subject to stock options and restricted stock units, warrants to purchase shares of common stock, common stock issuable upon conversion of convertible debt and shares issuable under the employee stock purchase plan were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation as of the three and nine months ended September 30, 2019 and 2018 as indicated below:

Nine Months Ended

September 30,

2019

2018

Excluded potentially dilutive securities ⁽¹⁾:

Common stock issuable under outstanding convertible

 notes

10,377,361

10,377,361

Shares subject to outstanding options to purchase

 common stock

3,293,102

3,762,912

Unvested restricted stock units

2,955,758

1,937,512

Shares subject to warrants to purchase common stock

104,455

104,455

Shares issuable under employee stock purchase plan

884,621

979,833

Totals

17,615,297

17,162,073

(1)

The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of September 30, 2019. Such amounts have not been adjusted for the treasury-stock method or weighted-average outstanding calculations as required if the securities were dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R34.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Debt (Tables)
9 Months Ended

Sep. 30, 2019

Schedule of Future Principal Payments
Future principal payments, which exclude the end of term charge, in connection with the Hercules Loan Agreement as of September 30, 2019 are as follows (in thousands):

Fiscal Year

2019

$

—

2020

—

2021

65,835

2022

4,165

Total

$

70,000

Royalty Backed Loan Agreement [Member]

Summary of Debt
The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):

September 30,

2019

December 31,

2018

Gross proceeds

$

32,500

$

—

Unamortized debt issuance costs

(1,905

)

—

Carrying value

$

30,595

$

—

4.75% Convertible Senior Subordinated Notes due 2024 [Member]

Summary of Debt
The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018:

September 30,

2019

December 31,

2018

Gross proceeds

$

165,000

$

165,000

Unamortized debt issuance costs

(4,762

)

(5,434

)

Carrying value

$

160,238

$

159,566

Hercules Term Loan [Member]

Summary of Debt
The following table summarizes the impact of the Hercules Loan Agreement on the Company’s consolidated balance sheets at September 30, 2019 and December 31, 2018 (in thousands):

September 30,

2019

December 31,

2018

Gross proceeds

$

70,000

$

70,000

Unamortized debt issuance costs

(423

)

(606

)

Carrying value

$

69,577

$

69,394

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CreditFacilityAxis=prtk_RoyaltyBackedLoanAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=prtk_FourPointSevenFivePercentConvertibleSeniorSubordinatedNotesDueTwoThousandTwentyFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=prtk_HerculesTermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R38.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies and Basis of Presentation - Summary of Product Revenue Allowance and Reserve Categories (Detail)
9 Months Ended

Sep. 30, 2019

USD ($)

Accounting Policies [Line Items]

Provision related to current period sales $ 1,907

Credit or payments made during the period (597)

Balance at September 30, 2019 1,310

Chargebacks, Discounts and Fees [Member]

Accounting Policies [Line Items]

Provision related to current period sales 514

Credit or payments made during the period (272)

Balance at September 30, 2019 242

Government and Other Rebates [Member]

Accounting Policies [Line Items]

Provision related to current period sales 995

Credit or payments made during the period (309)

Balance at September 30, 2019 686

Returns [Member]

Accounting Policies [Line Items]

Provision related to current period sales 149

Balance at September 30, 2019 149

Patient Assistance [Member]

Accounting Policies [Line Items]

Provision related to current period sales 249

Credit or payments made during the period (16)

Balance at September 30, 2019 $ 233

X

- Definition
Accounting policies.
+ References
No definition available.
+ Details

Name: prtk_AccountingPoliciesLineItems

Namespace Prefix: prtk_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Product revenue allowance and reserves balance.
+ References
No definition available.
+ Details

Name: prtk_ProductRevenueAllowanceAndReservesBalance

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Product revenue allowance and reserves credit or payments made during the period.
+ References
No definition available.
+ Details

Name: prtk_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Product revenue allowance and reserves provision related to current period sales.
+ References
No definition available.
+ Details

Name: prtk_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=prtk_ChargebacksDiscountsAndFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=prtk_GovernmentAndOtherRebatesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=prtk_SalesReturnsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=prtk_PatientAssistanceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements
9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements
11. Fair Value Measurements

Financial instruments, including cash, cash equivalents, restricted cash, money market funds, U.S. treasury securities, accounts receivable, accounts payable, and accrued expenses are carried on the condensed consolidated financial statements at amounts that approximate fair value. The fair value of the Company’s long-term debt is determined using current applicable rates for similar instruments as of the balance sheet date. The fair value of the Company’s debt (including the Notes as defined in Note 13, Long-Term Debt), is $187.5 million as of September 30, 2019. The fair value of the Company’s debt was determined using Level 3 inputs. Fair values are based on assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.

The following table presents information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2019 and December 31, 2018 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities or other inputs that are observable market data. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability (in thousands):

Description

Quoted

Prices in

Active

Markets

(Level 1)

Significant

Other

Observable

Inputs

(Level 2)

Significant

Unobservable

Inputs

(Level 3)

Total

September 30, 2019

Assets:

U.S. treasury securities

$

120,730

$

—

$

—

$

120,730

Total Assets

$

120,730

$

—

$

—

$

120,730

December 31, 2018

Assets:

U.S. treasury securities

$

245,851

$

—

$

—

$

245,851

Total Assets

$

245,851

$

—

$

—

$

245,851

Marketable Securities

U.S. treasury securities fair values can be obtained through quoted market prices in active exchange markets and are therefore classified as Level 1.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss Per Share
9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Net Loss Per Share
7. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method or the if-converted method, as applicable. For purposes of this calculation, shares of common stock issuable upon conversion of convertible debt, stock options, restricted stock units, warrants to purchase common stock, and shares issuable under the employee stock purchase plan are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following outstanding shares subject to stock options and restricted stock units, warrants to purchase shares of common stock, common stock issuable upon conversion of convertible debt and shares issuable under the employee stock purchase plan were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation as of the three and nine months ended September 30, 2019 and 2018 as indicated below:

Nine Months Ended

September 30,

2019

2018

Excluded potentially dilutive securities ⁽¹⁾:

Common stock issuable under outstanding convertible

 notes

10,377,361

10,377,361

Shares subject to outstanding options to purchase

 common stock

3,293,102

3,762,912

Unvested restricted stock units

2,955,758

1,937,512

Shares subject to warrants to purchase common stock

104,455

104,455

Shares issuable under employee stock purchase plan

884,621

979,833

Totals

17,615,297

17,162,073

(1)

The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of September 30, 2019. Such amounts have not been adjusted for the treasury-stock method or weighted-average outstanding calculations as required if the securities were dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 299 424 1 false 95 0 false 10 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.transcept.com/20190930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.transcept.com/20190930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) Sheet http://www.transcept.com/20190930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://www.transcept.com/20190930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.transcept.com/20190930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) Sheet http://www.transcept.com/20190930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Description of the Business Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureDescriptionOfBusiness Description of the Business Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of Significant Accounting Policies and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Cash and Cash Equivalents and Marketable Securities Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCashAndCashEquivalentsAndMarketableSecurities Cash and Cash Equivalents and Marketable Securities Notes 9 false false R10.htm 100090 - Disclosure - Restricted Cash Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureRestrictedCash Restricted Cash Notes 10 false false R11.htm 100100 - Disclosure - Inventories, Net Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureInventoriesNet Inventories, Net Notes 11 false false R12.htm 100110 - Disclosure - Fixed Assets, Net Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFixedAssetsNet Fixed Assets, Net Notes 12 false false R13.htm 100120 - Disclosure - Net Loss Per Share Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 13 false false R14.htm 100130 - Disclosure - License and Collaboration Agreements Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 14 false false R15.htm 100140 - Disclosure - Capital Stock Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCapitalStock Capital Stock Notes 15 false false R16.htm 100150 - Disclosure - Other Accrued Expenses Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureOtherAccruedExpenses Other Accrued Expenses Notes 16 false false R17.htm 100160 - Disclosure - Fair Value Measurements Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 100170 - Disclosure - Stock-Based and Incentive Compensation Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensation Stock-Based and Incentive Compensation Notes 18 false false R19.htm 100180 - Disclosure - Long-Term Debt Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLongTermDebt Long-Term Debt Notes 19 false false R20.htm 100190 - Disclosure - Leases Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLeases Leases Notes 20 false false R21.htm 100200 - Disclosure - Income Taxes Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 21 false false R22.htm 100210 - Disclosure - Commitments and Contingencies Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 100220 - Disclosure - Recent Accounting Pronouncements Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 23 false false R24.htm 100230 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of Significant Accounting Policies and Basis of Presentation (Policies) Policies http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 24 false false R25.htm 100240 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of Significant Accounting Policies and Basis of Presentation (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 25 false false R26.htm 100250 - Disclosure - Cash and Cash Equivalents and Marketable Securities (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables Cash and Cash Equivalents and Marketable Securities (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureCashAndCashEquivalentsAndMarketableSecurities 26 false false R27.htm 100260 - Disclosure - Restricted Cash (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureRestrictedCashTables Restricted Cash (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureRestrictedCash 27 false false R28.htm 100270 - Disclosure - Inventories, Net (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureInventoriesNetTables Inventories, Net (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureInventoriesNet 28 false false R29.htm 100280 - Disclosure - Fixed Assets, Net (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFixedAssetsNetTables Fixed Assets, Net (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureFixedAssetsNet 29 false false R30.htm 100290 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureNetLossPerShare 30 false false R31.htm 100300 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureOtherAccruedExpensesTables Other Accrued Expenses (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureOtherAccruedExpenses 31 false false R32.htm 100310 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureFairValueMeasurements 32 false false R33.htm 100320 - Disclosure - Stock-Based and Incentive Compensation (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensationTables Stock-Based and Incentive Compensation (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensation 33 false false R34.htm 100330 - Disclosure - Long-Term Debt (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLongTermDebtTables Long-Term Debt (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureLongTermDebt 34 false false R35.htm 100340 - Disclosure - Leases (Tables) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.transcept.com/20190930/taxonomy/role/DisclosureLeases 35 false false R36.htm 100350 - Disclosure - Description of the Business - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail Description of the Business - Additional Information (Detail) Details 36 false false R37.htm 100360 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAdditionalInformationDetail Summary of Significant Accounting Policies and Basis of Presentation - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Summary of Product Revenue Allowance and Reserve Categories (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail Summary of Significant Accounting Policies and Basis of Presentation - Summary of Product Revenue Allowance and Reserve Categories (Detail) Details 38 false false R39.htm 100380 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Summary of Available for Sale Securities (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetail Cash and Cash Equivalents and Marketable Securities - Summary of Available for Sale Securities (Detail) Details 39 false false R40.htm 100390 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail Cash and Cash Equivalents and Marketable Securities - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Condensed Consolidated Statement of Cash Flows (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureRestrictedCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinCondensedConsolidatedStatementOfCashFlowsDetail Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Condensed Consolidated Statement of Cash Flows (Detail) Details 41 false false R42.htm 100410 - Disclosure - Restricted Cash - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail Restricted Cash - Additional Information (Detail) Details 42 false false R43.htm 100420 - Disclosure - Inventories, Net - Schedule of Inventories (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureInventoriesNetScheduleOfInventoriesDetail Inventories, Net - Schedule of Inventories (Detail) Details 43 false false R44.htm 100430 - Disclosure - Fixed Assets, Net - Schedule of Fixed Assets, Net (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFixedAssetsNetScheduleOfFixedAssetsNetDetail Fixed Assets, Net - Schedule of Fixed Assets, Net (Detail) Details 44 false false R45.htm 100440 - Disclosure - Net Loss Per Share - Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedNetIncomeLossPerShareDetail Net Loss Per Share - Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) Details 45 false false R46.htm 100450 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail License and Collaboration Agreements - Additional Information (Detail) Details 46 false false R47.htm 100460 - Disclosure - Capital Stock - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureCapitalStockAdditionalInformationDetail Capital Stock - Additional Information (Detail) Details 47 false false R48.htm 100470 - Disclosure - Other Accrued Expenses - Schedule of Other Accrued Expenses (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureOtherAccruedExpensesScheduleOfOtherAccruedExpensesDetail Other Accrued Expenses - Schedule of Other Accrued Expenses (Detail) Details 48 false false R49.htm 100480 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 49 false false R50.htm 100490 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) Details 50 false false R51.htm 100500 - Disclosure - Stock-Based and Incentive Compensation - Summary of Stock-Based Compensation Expense Included in Company's Condensed Consolidated Statements of Operations and Comprehensive loss (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensationSummaryOfStockBasedCompensationExpenseIncludedInCompanySCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetail Stock-Based and Incentive Compensation - Summary of Stock-Based Compensation Expense Included in Company's Condensed Consolidated Statements of Operations and Comprehensive loss (Detail) Details 51 false false R52.htm 100510 - Disclosure - Stock-Based and Incentive Compensation - Schedule of Share-based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensationScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageValuationAssumptionsDetail Stock-Based and Incentive Compensation - Schedule of Share-based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail) Details 52 false false R53.htm 100520 - Disclosure - Stock-Based and Incentive Compensation - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensationAdditionalInformationDetail Stock-Based and Incentive Compensation - Additional Information (Detail) Details 53 false false R54.htm 100530 - Disclosure - Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensationScheduleOfShareBasedCompensationStockOptionsActivityDetail Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Detail) Details 54 false false R55.htm 100540 - Disclosure - Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, RSU, Activity (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureStockBasedAndIncentiveCompensationScheduleOfShareBasedCompensationRSUActivityDetail Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, RSU, Activity (Detail) Details 55 false false R56.htm 100550 - Disclosure - Long-Term Debt - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail Long-Term Debt - Additional Information (Detail) Details 56 false false R57.htm 100560 - Disclosure - Long-Term Debt - Summary of Debt (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLongTermDebtSummaryOfDebtDetail Long-Term Debt - Summary of Debt (Detail) Details 57 false false R58.htm 100570 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLongTermDebtScheduleOfFuturePrincipalPaymentsDetail Long-Term Debt - Schedule of Future Principal Payments (Detail) Details 58 false false R59.htm 100580 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 59 false false R60.htm 100590 - Disclosure - Leases - Summary of Lease Costs Recognized Under Topic 842 and Other Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsRecognizedUnderTopic842AndOtherInformationDetail Leases - Summary of Lease Costs Recognized Under Topic 842 and Other Information (Detail) Details 60 false false R61.htm 100600 - Disclosure - Leases - Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeaseObligationsUnderNonCancelableOperatingLeasesDetail Leases - Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases (Detail) Details 61 false false R62.htm 100620 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 62 false false R63.htm 100630 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) Sheet http://www.transcept.com/20190930/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetail Recent Accounting Pronouncements - Additional Information (Detail) Details 63 false false All Reports Book All Reports prtk-20190930.xml prtk-20190930.xsd prtk-20190930_cal.xml prtk-20190930_def.xml prtk-20190930_lab.xml prtk-20190930_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 69 R59.htm IDEA: XBRL DOCUMENT v3.19.3

Leases - Additional Information (Detail)
1 Months Ended 9 Months Ended

Apr. 30, 2015

Jan. 31, 2015

Sep. 30, 2019

USD ($)

Oct. 30, 2016

ft²

Jul. 31, 2016

USD ($)

ft²

Leases [Line Items]

Operating lease, liability, current $ 900,000

Operating lease liability, noncurrent $ 2,344,000

Boston [Member]

Leases [Line Items]

Lease expiration period 2021

Lease terms 4 years

Operating leases beginning date 2015-07 2016-07

Lease agreement rentable of office space | ft² 4,153

Option to extend, operating lease, term 2 years

Lessee operating lease agreement security deposit paid $ 100,000

Lease expense $ 49,000

King of Prussia [Member]

Leases [Line Items]

Lease expiration period 2024

Lease terms 6 years

Operating leases beginning date 2015-06 2016-10

Lease agreement rentable of office space | ft² 19,708

X

- Definition
Leases.
+ References
No definition available.
+ Details

Name: prtk_LeasesLineItems

Namespace Prefix: prtk_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating lease agreement of lessee, additional rented office space.
+ References
No definition available.
+ Details

Name: prtk_OperatingLeaseAgreementOfLesseeAdditionalRentedOfficeSpace

Namespace Prefix: prtk_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
Operating lease expiry period.
+ References
No definition available.
+ Details

Name: prtk_OperatingLeaseExpiryPeriod

Namespace Prefix: prtk_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating lease monthly rent expenses.
+ References
No definition available.
+ Details

Name: prtk_OperatingLeaseMonthlyRentExpenses

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Operating leases beginning date.
+ References
No definition available.
+ Details

Name: prtk_OperatingLeasesBeginningDate

Namespace Prefix: prtk_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8,17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_SecurityDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: srt_StatementGeographicalAxis=prtk_BostonMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=prtk_KingOfPrussiaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R55.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, RSU, Activity (Detail) - Restricted Stock Units [Member]
9 Months Ended

Sep. 30, 2019

$ / shares

shares

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Unvested Number of Shares, Beginning Balance | shares 1,470,237

Number of Shares, Granted | shares 2,269,340

Number of Shares, Released | shares (186,296)

Number of Shares, Forfeited | shares (597,523)

Unvested Number of Shares, Ending Balance | shares 2,955,758

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]

Unvested Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares $ 15.28

Weighted Average Grant Date Fair Value, Granted | $ / shares 6.01

Weighted Average Grant Date Fair Value, Released | $ / shares 14.06

Weighted Average Grant Date Fair Value, Forfeited | $ / shares 10.84

Unvested Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 9.14

X

- Definition
Share based compensation arrangement by share based payment award equity instruments other than options released in period.
+ References
No definition available.
+ Details

Name: prtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod

Namespace Prefix: prtk_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award equity instruments other than options released in period weighted average grant date fair value.
+ References
No definition available.
+ Details

Name: prtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: prtk_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R51.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based and Incentive Compensation - Summary of Stock-Based Compensation Expense Included in Company's Condensed Consolidated Statements of Operations and Comprehensive loss (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense $ 3,824 $ 4,084 $ 10,742 $ 12,955

Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense 560 1,442 2,868 4,456

Selling, General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock-based compensation expense $ 3,264 $ 2,642 $ 7,874 $ 8,499

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R3.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - $ / shares

Sep. 30, 2019

Dec. 31, 2018

Statement Of Financial Position [Abstract]

Undesignated preferred stock, par value $ 0.001 $ 0.001

Undesignated preferred stock, shares authorized 5,000,000 5,000,000

Undesignated preferred stock, shares issued 0 0

Undesignated preferred stock, shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 32,901,446 32,259,363

Common stock, shares outstanding 32,901,446 32,259,363

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 73 R63.htm IDEA: XBRL DOCUMENT v3.19.3

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Jan. 01, 2019

Dec. 31, 2018

New Accounting Pronouncements Or Change In Accounting Principle [Line Items]

Operating lease liabilities $ 3,275

Right-of-use asset $ 2,701 $ 0

ASU 2016-02 [Member]

New Accounting Pronouncements Or Change In Accounting Principle [Line Items]

Operating lease liabilities $ 3,700

Right-of-use asset $ 3,200

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R7.htm IDEA: XBRL DOCUMENT v3.19.3

Description of the Business
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Description of the Business
1. Description of the business

Paratek Pharmaceuticals, Inc., or the Company or Paratek, is a Delaware corporation with its corporate office in Boston, Massachusetts and an office in King of Prussia, Pennsylvania.

The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The Company’s United States Food and Drug Administration, or FDA, approved commercial product, NUZYRA^® (omadacycline) is a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, and acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible pathogens. The Company launched NUZYRA in the United States in February 2019. SEYSARA^® (sarecycline) is an FDA-approved product, with respect to which the Company has exclusively licensed development and commercialization rights in the United States to Almirall, LLC, or Almirall. SEYSARA was launched by Almirall in the United States in January 2019 as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Company retains development and commercialization rights with respect to sarecycline in the rest of the world.

The Company has incurred significant losses since inception in 1996. The Company has generated an accumulated deficit of $683.9 million through September 30, 2019 and will require substantial additional funding in connection with the Company’s continuing operations to support development and commercial activities associated with NUZYRA. Based upon the Company’s current operating plan, it anticipates that its cash, cash equivalents and available for sale marketable securities of $225.6 million as of September 30, 2019 will enable the Company to fund operating expenses and capital expenditure requirements through at least the next twelve months from the issuance of the financial statements included in this Quarterly Report on Form 10-Q. The Company expects to finance future cash needs primarily through a combination of product sales, royalties, public or private equity offerings, debt or other structured financings, strategic collaborations and grant funding. The Company is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain additional financing to fund the future development of the Company’s product candidates, the need to obtain compliant product from third party manufacturers, the need to obtain marketing approval for the Company’s product candidates, the need to successfully commercialize and gain market acceptance of product candidates, the risks of manufacturing product with an external supply chain, dependence on key personnel, and compliance with government regulations as well as the risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission, or the SEC, on March 6, 2019, and in the Company’s other filings with the SEC.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 75 R40.htm IDEA: XBRL DOCUMENT v3.19.3

Cash and Cash Equivalents and Marketable Securities - Additional Information (Detail) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Cash And Cash Equivalents [Abstract]

Available for sale securities have remaining maturities greater than fifteen months $ 0 $ 0

Available for sale securities have remaining maturities greater than twelve months $ 0 $ 0

X

- Definition
Available for sale securities debt maturities greater than fifteen months.
+ References
No definition available.
+ Details

Name: prtk_AvailableForSaleSecuritiesDebtMaturitiesGreaterThanFifteenMonths

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Available-for-sale securities, debt maturities, greater than twelve months.
+ References
No definition available.
+ Details

Name: prtk_AvailableForSaleSecuritiesDebtMaturitiesGreaterThanTwelveMonths

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 76 R44.htm IDEA: XBRL DOCUMENT v3.19.3

Fixed Assets, Net - Schedule of Fixed Assets, Net (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Property, Plant and Equipment [Line Items]

Gross fixed assets $ 3,180 $ 2,985

Less: Accumulated depreciation and amortization (2,213) (1,812)

Net fixed assets 967 1,173

Office Equipment [Member]

Property, Plant and Equipment [Line Items]

Gross fixed assets 866 866

Computer Equipment [Member]

Property, Plant and Equipment [Line Items]

Gross fixed assets 412 412

Computer Software [Member]

Property, Plant and Equipment [Line Items]

Gross fixed assets 798 798

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Gross fixed assets 920 $ 909

Construction In Progress [Member]

Property, Plant and Equipment [Line Items]

Gross fixed assets $ 184

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R48.htm IDEA: XBRL DOCUMENT v3.19.3

Other Accrued Expenses - Schedule of Other Accrued Expenses (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Payables And Accruals [Abstract]

Accrued legal costs $ 271 $ 366

Accrued other 54 809

Accrued professional fees 754 750

Accrued compensation 5,529 6,070

Accrued interest 4,199 1,813

Accrued contract research 3,514 1,747

Accrued commercial 2,330 1,280

Accrued manufacturing 1,408 2,784

Accrued sales allowances 1,310

Accrued inventory 673

Total $ 20,042 $ 15,619

X

- Definition
Accrued contract research current.
+ References
No definition available.
+ Details

Name: prtk_AccruedContractResearchCurrent

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued expenses other current.
+ References
No definition available.
+ Details

Name: prtk_AccruedExpensesOtherCurrent

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued inventory current.
+ References
No definition available.
+ Details

Name: prtk_AccruedInventoryCurrent

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued legal costs current.
+ References
No definition available.
+ Details

Name: prtk_AccruedLegalCostsCurrent

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued manufacturing current.
+ References
No definition available.
+ Details

Name: prtk_AccruedManufacturingCurrent

Namespace Prefix: prtk_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: us-gaap_AccruedMarketingCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedSalesCommissionCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R29.htm IDEA: XBRL DOCUMENT v3.19.3

Fixed Assets, Net (Tables)
9 Months Ended

Sep. 30, 2019

Property Plant And Equipment [Abstract]

Schedule of Fixed Assets, Net
Fixed assets, net, consists of the following (in thousands):

September 30,

2019

December 31,

2018

Office equipment

$

866

$

866

Computer equipment

412

412

Computer software

798

798

Leasehold improvements

920

909

Construction in progress

184

—

Gross fixed assets

3,180

2,985

Less: Accumulated depreciation and amortization

(2,213

)

(1,812

)

Net fixed assets

$

967

$

1,173

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 79 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies and Basis of Presentation (Tables)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Product Revenue Allowance and Reserve Categories
The following table summarizes balances and activity in each of the product revenue allowance and reserve categories:

Chargebacks,

discounts and

fees

Government

and other

rebates

Returns

Patient

assistance

Total

Balance at December 31, 2018

$

—

$

—

$

—

$

—

$

—

Provision related to current period sales

514

995

149

249

1,907

Adjustment related to prior period sales

—

—

—

—

—

Credit or payments made during the period

(272

)

(309

)

—

(16

)

(597

)

Balance at September 30, 2019

$

242

$

686

$

149

$

233

$

1,310

X

- Definition
Schedule of product revenue allowance and reserve categories.
+ References
No definition available.
+ Details

Name: prtk_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock

Namespace Prefix: prtk_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 80 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes
9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes
15. Income Taxes

The Company recorded no provision for income taxes for the three or nine months ended September 30, 2019 and September 30, 2018.

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax bases of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company’s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the Company’s otherwise recognizable net deferred tax assets.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Cash and Cash Equivalents and Marketable Securities - Summary of Available for Sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 120,582	$ 245,979
Unrealized Gains	155	65
Unrealized Losses	(7)	(193)
Fair Value	120,730	245,851
U.S. Treasury Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	120,582	245,979
Unrealized Gains	155	65
Unrealized Losses	(7)	(193)
Fair Value	$ 120,730	$ 245,851

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets
Total Assets	$ 120,730	$ 245,851
Total Assets	120,730	245,851
U.S. Treasury Securities [Member]
Assets
Total Assets	120,730	245,851
Quoted Prices in Active Markets (Level 1) [Member]
Assets
Total Assets	120,730	245,851
Quoted Prices in Active Markets (Level 1) [Member] \| U.S. Treasury Securities [Member]
Assets
Total Assets	$ 120,730	$ 245,851

Long-Term Debt - Schedule of Future Principal Payments (Detail) - Hercules Term Loan [Member] - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
2021	$ 65,835
2022	4,165
Total	$ 70,000	$ 70,000

Leases - Additional Information (Detail)	1 Months Ended		9 Months Ended
Leases - Additional Information (Detail)	Apr. 30, 2015	Jan. 31, 2015	Sep. 30, 2019 USD ($)	Oct. 30, 2016 ft²	Jul. 31, 2016 USD ($) ft²
Leases [Line Items]
Operating lease, liability, current			$ 900,000
Operating lease liability, noncurrent			$ 2,344,000
Boston [Member]
Leases [Line Items]
Lease expiration period			2021
Lease terms	4 years
Operating leases beginning date	2015-07		2016-07
Lease agreement rentable of office space \| ft²					4,153
Option to extend, operating lease, term					2 years
Lessee operating lease agreement security deposit paid					$ 100,000
Lease expense			$ 49,000
King of Prussia [Member]
Leases [Line Items]
Lease expiration period			2024
Lease terms		6 years
Operating leases beginning date		2015-06	2016-10
Lease agreement rentable of office space \| ft²				19,708

Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, RSU, Activity (Detail) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested Number of Shares, Beginning Balance \| shares	1,470,237
Number of Shares, Granted \| shares	2,269,340
Number of Shares, Released \| shares	(186,296)
Number of Shares, Forfeited \| shares	(597,523)
Unvested Number of Shares, Ending Balance \| shares	2,955,758
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 15.28
Weighted Average Grant Date Fair Value, Granted \| $ / shares	6.01
Weighted Average Grant Date Fair Value, Released \| $ / shares	14.06
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	10.84
Unvested Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 9.14

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.001	$ 0.001
Undesignated preferred stock, shares authorized	5,000,000	5,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,901,446	32,259,363
Common stock, shares outstanding	32,901,446	32,259,363

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Operating lease liabilities	$ 3,275
Right-of-use asset	$ 2,701		$ 0
ASU 2016-02 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Operating lease liabilities		$ 3,700
Right-of-use asset		$ 3,200

Cash and Cash Equivalents and Marketable Securities - Additional Information (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Cash And Cash Equivalents [Abstract]
Available for sale securities have remaining maturities greater than fifteen months	$ 0	$ 0
Available for sale securities have remaining maturities greater than twelve months	$ 0	$ 0

Fixed Assets, Net - Schedule of Fixed Assets, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 3,180	$ 2,985
Less: Accumulated depreciation and amortization	(2,213)	(1,812)
Net fixed assets	967	1,173
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	866	866
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	412	412
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	798	798
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	920	$ 909
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 184

Other Accrued Expenses - Schedule of Other Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accrued legal costs	$ 271	$ 366
Accrued other	54	809
Accrued professional fees	754	750
Accrued compensation	5,529	6,070
Accrued interest	4,199	1,813
Accrued contract research	3,514	1,747
Accrued commercial	2,330	1,280
Accrued manufacturing	1,408	2,784
Accrued sales allowances	1,310
Accrued inventory	673
Total	$ 20,042	$ 15,619